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RUNX1 is essential for definitive hematopoeisis and is frequently mutated in 
human leukemias. In the absence of Runx1, intra-aortic clusters which represent 
the first hematopoietic stem cells (HSC) generated from hemogenic endothelial 
cells (EC), fail to form. This complete block in the establishment of definitive 
hematopoiesis results in death in utero of Runx1-/- mouse embryos at embryonic 
day (E) 12.5. In contrast to the vast knowledge available on the role of Runx1 as 
a transcription factor (TF), regulating gene expression of downstream target 
genes, the precise transcriptional regulation of the Runx1 gene itself remains 
largely unknown due to the extremely large size of the mammalian Runx gene 
loci [which spans approximately 1.0-Megabase (Mb) in mammalian Runx 
genes] and the complex Runx1 gene structure. The search for regulatory regions 
outside the immediate promoters by traditional methods such as DNase 
hypersensitivity assay, proved to be a very daunting task.  
 A combinatorial in silico approach was first taken, involving 
comparative genomics and retroviral integration sites (RIS) mapping, to identify 
highly evolutionarily conserved non-coding elements (CNE) which are likely to 
have regulatory function. By defining RIS mapping within 2-kilobases (kb) of 
CNE to indicate the presence of elements which are more likely to have a 
functional regulatory role, the number of candidate regulatory elements was 
dramatically reduced, from more than one hundred (initially identified by 
comparative genomics) to a mere twelve. Using this innovative and simple in 
silico approach, RIS flanked-CNE (RIS-CNE) more likely to possess regulatory 
function were assigned high priority for validation of regulatory function by 
experimental means. 
 viii
These RIS-CNE were individually assessed for their in vivo ability to 
drive enhanced green fluorescence protein (EGFP) which corresponds to 
endogenous Runx1 expression pattern during different developmental stages in 
the zebrafish embryo. This led to the identification of a mouse CNE (+24.1 
mCNE) which drives the specific expression of EGFP in immature precursor 
cells in the intermediate cell mass (ICM) region, a known site of endogenous 
Runx1 expression and hematopoiesis, in 19-20 hours post-fertilization (hpf) 
zebrafish embryos. Interestingly, these Runx1 +24.1 enhancer activity-targeted 
precursor cells at 24 hpf are visualised as rare circulating cells. Quantitative 
chromatin immunoprecipitation (qChIP), using antibodies against modified 
histones which mark either open or close regions of chromatin, showed a tight 
correlation between the chromatin state at the +24.1 mCNE locus and the 
expression of Runx1.  
To further characterize this element in a more relevant in vivo system, 
+24.1 mCNE-EGFP transgenic (Tg) mouse lines were generated. Analyses of 
Tg mouse embryos show that this Runx1 +24.1 enhancer drives reporter gene 
expression in hemogenic sites where the de novo generation of HSC/progenitor 
cells occur. Significantly, this enhancer is preferentially active in hemogenic 
endothelial cells (EC) but not in non-hemogenic EC. Furthermore, 
transplantation assays reveal that long-term hematopoietic stem cells (LT-HSC) 
are enriched in Runx1 +24.1 enhancer activity-targeted adult bone marrow (BM) 
cells, even within the HSC-containing, c-Kit+Sca-1+Lin- (KSL) fraction. Taken 
together, these results obtained strongly support the role of the Runx1 +24.1 
mCNE as a HSC-specific enhancer.                       
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Chapter 1 – Introduction 
 
1.1 Hematopoiesis 
The hematopoietic system has developed through evolution to ensure oxygen supply 
and protection from immunological challenges in multicellular organisms. The 
constitution of this system is dependent on a process termed hematopoiesis which 
involves the formation and development of blood cells. In vertebrates, hematopoiesis 
occurs in two waves, namely the transient ‘primitive’ wave which is eventually 
replaced by the ‘definitive’ wave. Within each wave, distinct lineages of 
hematopoietic cells differing in differentiation potential are generated in embryonic 
sites that are divergent among vertebrate species. Primitive hematopoiesis gives rise 
to transient populations of erythrocytes and macrophages, primarily to facilitate tissue 
oxygenation to the rapidly developing embryo and to enable the clearance of dead 
cells (Godin and Cumano, 2002). Primitive hematopoiesis is characterized by the 
presence of nucleated erythrocytes expressing embryonic isoforms of hemoglobin 
(βH1 and ε) which are absent in definitive hematopoiesis. In contrast, adult-type, 
definitive hematopoiesis persists throughout the lifespan of an organism to constantly 
replenish blood, which is composed of a large variety of mature cell types with a 
limited life span. This replenishment involves cell differentiation from a pool of self-
renewing, multipotent precursors – the hematopoietic stem cells (HSC). 
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1.1.1 Hematopoiesis during development in mammals 
Although the earliest studies on blood development were carried out in birds and 
amphibians, the mouse ultimately became the main model organism in this field. The 
process of blood cell development in the mammalian conceptus is particularly 
complex, as it occurs in many sites that are separated both temporally and spatially 
(Figure 1.1). As such, it remains unclear to date precisely when and where the very 















Figure 1.1: Hematopoietic development in mouse. Using Runx1 as a surrogate 
marker for hematopoietic cells, the sites of hematopoiesis during early embryonic 
stages are visualised as blue stains. AGM, Aorta-gonad-mesonephros; bi, yolk sac 
blood island; FL, fetal liver; P-Sp, Para-aortic splanchnopleura; U,  umbilical artery; 
V, vitelline artery (modified from Dzierzak and Speck, 2008; Samokhvalov et al., 




The first hematopoietic organ in both mouse and human is the extra-
embryonic yolk sac (YS) where the first blood cells in the vertebrate conceptus 
appear concomitant with the developing vasculature. Mouse hematopoiesis first 
becomes evident in the YS just after gastrulation at embryonic day (E)7.5  with the 
development of clusters of red cell aggregates initially identical in shape, termed the 
blood islands (Figure 1.2) (Moore and Metcalf, 1970). As development proceeds, the 
cells bordering these aggregates flatten and adopt the morphology of endothelial cells 
(EC), whereas the inner cells progressively lose their connections and evolve into 
nucleated erythrocytes, leading to the formation of a lumen (Godin and Cumano, 
2002; Godin and Cumano, 2005) (Figure 1.2). The close physical association of 
primitive erythrocytes (EryP) and their synchronous appearance with EC led to the 







Figure 1.2: Mechanism of yolk sac blood island formation. Schematic 
representation of the progressive evolution of blood island mesodermal cells to a 
functional vascular network and primitive erythroid cells. (Cumano and Godin, 2007) 
 
The YS has a well-established role in the generation of transient hematopoietic 
populations for the immediate needs of the embryo, including EryP required for 
oxygen transport (Palis et al., 1999) and macrophages for clearance of dead cells as 
part of tissue remodelling and defense (Bertrand et al., 2005c). Recently, unique 
megakaryoctes have also been shown to be generated in primitive hematopoiesis 
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(Tober et al., 2007), and are postulated to be required for protection from bleeding of 
the newly formed blood vessels during early organogenesis (Godin and Cumano, 
2002). Notably, some of the YS vasculature is derived from hemangioblasts while the 
remainder is derived from angioblasts that do not contribute to blood.  
The embryo proper has been considered to be the major source of HSC in 
mammals (Dzierzak, 2002). Production of hematopoietic precursors occurs 
independently in mesodermal cells from the caudal part of the intra-embryonic 
compartment, which is known as the splanchnopleura (Sp), beginning at E7.5-8 in 
mouse and E19-23 in human embryos. As the Sp develops, it is referred to as the 
para-aortic splanchnopleura (P-Sp) at E8.5-10 in mouse and E25-30 in human 
embryos. Coincidentally, the P-Sp is the region homologous to early avian aorta 
previously shown to harbour intra-embryonic HSC (Godin and Cumano, 2005).  
By E10-11.5 in mouse and E30-40 in human, the aorta-gonad-mesonephros 
(AGM) region (derivative of the P-Sp) contains the aorta and developing urogenital 
system, and is the primary intraembryonic hemogenic territory. The AGM transiently 
harbours the first multipotential hematopoietic precursors that are capable of long-
term repopulating activity when transplanted into irradiated adult recipient mice. 
Notably, whereas terminal differentiation into functional erythroid cells occurs in the 
YS, no such differentiation takes place in the AGM (Godin and Cumano, 2002). 
During this time, clusters of presumptive hematopoietic precursors can be visualized 
budding into the lumen from the ventral side of the dorsal aorta (DA) (Figure 1.3), 
suggesting that they originate in situ (Jaffredo et al., 2005a; Jaffredo et al., 2005b). 
These intra-aortic clusters are similar to those previously detected in birds (Dieterlen-
Lievre and Martin, 1981; Jaffredo et al., 1998; Pardanaud et al., 1989), in human 
embryos (Tavian et al., 1996), and more recently in zebrafish (Pardanaud et al., 1989; 
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Thompson et al., 1998) and amphibian embryos (Ciau-Uitz et al., 2000). Their 
combined expression of immature hematopoietic cell-surface markers established 
further that these clusters consist of hematopoietic cells (Godin and Cumano, 2002). 
In contrast to the strict ventral localization of hematopoietic clusters in the chick 
aorta, studies of mice have identified hematopoietic clusters on both the ventral and 
dorsal aspects of the DA. Functional studies indicate that definitive hematopoietic 
progenitors reside on both aspects of the DA, but only the ventral aspect contains 
fully potent HSC (Taoudi and Medvinsky, 2007). 
Of note, the DA is not the only hemogenic artery; the emergence of definitive 
HSC which contribute to adult hematopoiesis has also been documented from 
vitelline and umbilical arteries (VU) that connect the DA to the YS and placenta, 
respectively (de Bruijn et al., 2000). In contrast, umbilical veins lack hematopoietic 
potential, suggesting that a hierarchy exists during definitive hematopoiesis in which 
HSC arise predominantly during artery specification (Orkin and Zon, 2008). The 
intimate association of HSC generation and arterial vasculature suggests an 
endothelial origin for definitive hematopoietic cells wherein definitive HSC are 
specified directly from discrete subsets of vascular EC, termed hemogenic EC – the 
hemogenic endothelium model. An alternative model suggests that HSC arise from a 
mesodermal/hemangioblast precursor that is specified to a hematopoietic fate in the 
subvascular mesenchyme and migrates through the vascular wall to enter circulation 
(Bertrand et al., 2005c). 
While the AGM and the VU are the first source of fully competent adult-type 
HSC which can reconstitute adult BM, other in vivo transplantation strategies 
(injection into the placenta or YS cavity of embryos, injection into the liver of 
conditioned neonatal recipients, or intravenous injection into immunodeficient 
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recipients) have revealed long-term repopulating cells with multipotential 
hematopoietic properties at earlier embryonic stages (Cumano et al., 2001; 
Medvinsky and Dzierzak, 1996; Toles et al., 1989; Weissman et al., 1978; Yoder et 
al., 1997a; Yoder et al., 1997b). Such multipotential cells were found in the YS and 
P-Sp at E8, E9, and E10. In a recent review, these developmental hematopoietic cells 
were divided into five broad classes as defined by their activity in in vitro clonogenic 
or transplantation assays: primitive, pro-definitive (myeloid progenitors), meso-
definitive (lymphoid-myeloid progenitors), meta-definitive (neonatal repopulating 

























































Figure 1.3: Location of intra-embryonic HSC generation. (A) The general 
structure of an E10.5–11 mouse embryo, showing the location of the aorta, gonads 
and mesonephros, as well as the area that has hemogenic activity (red outline). (B) A 
schematic of a transverse section through the embryo, showing the internal structure 
of the embryo at the level of the truncal AGM. (C) An enlargement of the aortic 
region, schematically showing the intra-aortic clusters, which are restricted to the 
ventral part (floor) of the vessel, and the sub-aortic patches. The area that has 
hemogenic activity is shown in a red box. AGM, aorta–gonad–mesonephros; ED, 




In addition to the AGM and YS, other hematopoietic sites in vertebrate 
embryos were first identified in birds. Initial studies using the quail-chick chimera 
assay first described the presence of definitive hematopoietic cells that contribute to 
hematopoiesis within the allantois region (Caprioli et al., 1998). In mammals, the 
allantois gives rise to the mesodermal components of the placenta. Recent 
experiments have demonstrated multilineage hematopoietic activity in the murine 
allantois and chorion before circulation and before these tissues fuse to become the 
placenta (Zeigler et al., 2006). The placenta has become recognized as a prolific 
source of HSC in the developing mouse embryo (Gekas et al., 2005; Ottersbach and 
Dzierzak, 2005). HSC activity in the placenta starts concomitantly with the AGM and 
the YS, but exceeds in numbers (15-fold more HSC) and duration as compared to the 
other two sites (Martinez-Agosto et al., 2007). Placental HSC could arise through de 
novo generation or colonization upon circulation, or both (Corbel et al., 2007; Rhodes 
et al., 2008). Furthermore, the placenta vascular labyrinth may provide a unique 
microenvironment for HSC maturation and expansion without promoting immediate 
lineage differentiation. HSC from the AGM and VU may circulate through the 
placenta prior to colonizing the fetal liver (FL), and since the placenta is directly 
upstream of the FL in fetal circulation, the placenta could potentially be a major 
source of HSC that seed the FL.  
Once the various hematopoietic progenitors and HSC emerge from their 
anatomically distinct sites, they enter the circulation and colonize the FL beginning at 
late E9-E10 of mouse development (Cumano and Godin, 2007; Dzierzak and Speck, 
2008; Johnson and Moore, 1975). The FL is a site of hematopoietic colonization and 
is not an intrinsic source of hematopoietic cells (Houssaint, 1981). From E11.5–12.5 
in mice, the FL serves as the main hematopoietic organ for rapid HSC expansion and 
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differentiation to pools of various blood progenitors for the next 5–6 days, during 
mid-late gestation (Martinez-Agosto et al., 2007). In mice, the liver is first seeded by 
YS-derived progenitors, followed by HSC seeding from the AGM, the placenta and 
perhaps the YS (Cumano and Godin, 2007). The cumulative production of HSC by 
the AGM, YS and placenta, in addition to the expansion of these cell populations by 
the FL itself, is most likely responsible for the large numbers of FL HSC (Dzierzak 
and Speck, 2008).  In addition to supporting HSC expansion, the liver is also the main 
site for hematopoietic differentiation in the fetus, providing a microenvironment both 
for myelo-erythroid and B-lymphoid differentiation (Mikkola and Orkin, 2006). 
Although the exact cellular niches that support HSC self-renewal or differentiation in 
FL have not been defined, both endothelial and stromal cells, and perhaps developing 
hepatocytes, likely provide cues into the hematopoietic microenvironment (Martinez-
Agosto et al., 2007). 
Subsequent definitive hematopoiesis involves the colonization of the thymus, 
spleen and ultimately the bone marrow (BM), which occurs just 1-2 days before 
birth (Christensen et al., 2004; Orkin and Zon, 2008). These sites are believed to be 
incapable of de novo HSC generation and instead, like the FL, provide niches which 
support the expansion of HSC. Interestingly, soon after their arrival at the BM, the 
site of continued adult hematopoiesis, fetal mouse HSC curb their proliferative 
activities and enter a state of relative quiescence (Bowie et al., 2006). This transition 
is shown to be intrinsically programmed and occurs at a precise time point between 3 
and 4 weeks of postnatal life in mice (Bowie et al., 2006). Supportive evidence comes 
from the identification of Sox17 as a factor that is important for the self-renewal of 
fetal and early postnatal HSC in the BM but becomes unimportant after the first few 
weeks of life (Kim et al., 2007). Yet, HSC migration is hardly finished. Indeed, HSC 
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migration persists throughout adulthood with a continuous recirculation throughout 
the blood, tissues, and lymphatic system (Abkowitz et al., 2003; Massberg et al., 
2007; Wright et al., 2001). 
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1.1.2 Hematopoiesis in zebrafish 
The zebrafish has only recently become a standard model for studying hematopoiesis 
and HSC development. The molecular pathways governing hematopoiesis are largely 
conserved between mammals and zebrafish, and several zebrafish orthologs of key 
mammalian hematopoietic factors have been identified. As with higher vertebrates, 
zebrafish blood lineages are believed to derive from a small population of self-
renewing, pluripotent HSC. Moreover, the counterparts for the various different blood 
cell types (erythroid, myeloid and lymphoid) in the mammalian system are also 
present in the zebrafish (Figure 1.4). While the transcriptional mechanisms of 
hematopoiesis are evolutionarily well conserved among vertebrates, there are distinct 
spatial differences in the sites of hematopoiesis between mammals and zebrafish 















Figure 1.4 : Comparison of human and zebrafish mature peripheral blood cells 
stained with Wright Giemsa. (Davidson and Zon, 2004) 
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 Figure 1.5: Hematopoietic development in zebrafish. (A) In situ hybridisation 
results depicting sites of hematopoiesis in zebrafish. (B) Developmental time 
windows for hematopoietic sites in the zebrafish. (Orkin and Zon, 2008) 
 
Embryonic hematopoiesis in zebrafish appears to occur through four 
independent waves of precursor production (Bertrand et al., 2007) (Figure 1.6). The 
first two of these waves is collectively known as primitive hematopoiesis. Primitive 
hematopoiesis in the zebrafish, which lack the mammalian extraembryonic blood 
island, occur concurrently in two intraembryonic locations, namely the rostral blood 
island (RBI) arising from the cephalic mesoderm and the intermediate cell mass 
(ICM), which is the zebrafish equivalent of the YS blood island, located above the 
yolk tube in the trunk ventral to the notochord (Al-Adhami and Kunz, 1977; Davidson 
and Zon, 2004). The RBI and ICM share the similar ability to form vasculature, but 
show contrasting potentials to differentiate into myeloid and erythroid cells, 
respectively. The first embryonic wave involves the migration of primitive 
macrophages arising from the anterior, cephalic mesoderm onto the yolk syncitial 
 12
layer before colonizing embryonic tissues (Herbomel et al., 1999), while the second 
wave involves the entering into circulation of around 300 proerythroblasts expressing 
embryonic globins, developed from the ICM (Detrich et al., 1995; Thompson et al., 
1998), upon initiation of heart contractions at approximately 24 hpf. Interestingly, 
cross-section of the endothelium of the axial vein encapsulating the converged mass 
of erythroid cells resembles the cellular architecture of the mammalian YS blood 
island (Al-Adhami and Kunz, 1977; Davidson and Zon, 2004; Willett et al., 1999). 
Furthermore, this nomenclature of ‘primitive hematopoiesis’ is consistent with 
findings in mammals, where both primitive macrophages and erythrocytes develop in 
the YS without passing through a multipotent progenitor (MPP) stage (Bertrand et al., 
2005a; Bertrand et al., 2005c; Keller et al., 1999; Palis et al., 1999).  
 
 
Figure 1.6: Model of hematopoietic ontogeny in the zebrafish embryo. (A) 
Different regions of lateral plate mesoderm (LPM) give rise to anatomically distinct 
regions of blood cell precursors. Drawing depicts a dorsal view of a five-somite-stage 
embryo. (B) Embryonic hematopoiesis appears to occur through four independent 
waves of precursor production. Each wave is numbered based on the temporal 
appearance of functional cells from each subset. (Bertrand et al., 2007) 
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Definitive hematopoiesis was recently shown by lineage tracing to initiate 
with the formation of committed erythromyeloid progenitors (EMP) in the posterior 
blood island (PBI) of the zebrafish embryo between 24 and 30  hpf (Bertrand et al., 
2007), constituting the third wave of embryonic hematopoiesis. EMP exist only 
transiently, probably disappearing by 48 hpf. These precursors, with limited potential, 
generate the first definitive myeloid cells and a new wave of erythroid cells, and like 
their counterparts described in the murine YS (Bertrand et al., 2005b; Cumano et al., 
2001; Palis et al., 1999; Yokota et al., 2006), EMP lack lymphoid and self-renewal 
potential.  
Finally, embryonic hematopoiesis culminates with the formation of HSC, the 
first multipotent precursors endowed with lymphoid and self renewal potentials 
(Bertrand et al., 2005b; Cumano et al., 1996; Delassus and Cumano, 1996). Similar to 
mammalian definitive hematopoiesis, the site of formation of the first definitive 
multipotential HSC in zebrafish is the AGM (Figure 1.7). The AGM in zebrafish is 
defined as the region dorsal to the yolk-tube extension that is bounded by the 
evolutionarily conserved axial blood vessels [comprising the DA and the posterior 
cardinal vein (PCV); (Figure 1.7)] and pronephric tubules, initiated from ~30-36 hpf 
(Bertrand et al., 2008). 
The hemangiopoietic capacity of the ICM switches to the AGM within the 
first few days of development as reflected by decreasing expression of gata1 in the 
ICM while expression of c-myb and runx1 increases in the AGM. In the zebrafish 
embryo, cells expressing the HSC-associated genes c-myb and runx1 have been 
observed between the ventral wall of the DA and the cardinal vein between 26 and 48 
hpf (Burns et al., 2002; Kalev-Zylinska et al., 2002; Thompson et al., 1998). As 
suggested by the expression of c-myb and runx1, zebrafish definitive hematopoiesis 
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initiates at ~26 hpf from the ventral wall of DA (Burns et al., 2005; Gering and 
Patient, 2005). In support of this, loss of runx1 function causes elimination of the 
trunk hematopoietic clusters (Burns et al., 2005; Kalev-Zylinska et al., 2002; 
Murayama et al., 2006). Based on the similarities to other vertebrate AGM regions, 
these cells have been presumed to be the first HSC to arise in the zebrafish. However, 
functional data was lacking until recent lineage tracing studies demonstrated that the 
ventral aortic region contained cells with hematopoietic potential, the progeny of 
which colonized the thymus and the pronephros, major definitive hematopoietic 
organs in the adult zebrafish (Jin et al., 2007; Murayama et al., 2006). Together, these 
studies confirm that the cells located in the ventral wall of the DA represent the 









































Figure 1.7: AGM region in zebrafish. (A) 27 hpf zebrafish embryo. Purple region 
denotes left thymic lobe, blue region the left pronephric tubule and red region the 
AGM (space between axial vessels) (Bertrand et al., 2007) (Bi) camera lucida 
drawings of a lateral view of zebrafish embryos at 24-30 hpf. (Bii) A lateral view of a 
24-hpf embryo after whole-mount in situ hybridization with a fli1 probe, showing the 
DA and PCV. (Biii) A cross-section through the trunk of a 30-hpf embryo, in which 
the lumens have already formed in the single DA and posterior cardinal vein. Also 
shown are adjacent structures, such as the notochord and somites. (Lawson and 
Weinstein, 2002) 
 
Similar lineage tracing studies showed that CD41+ cells targeted along the 
ventral aortic wall displayed robust thymic colonization (Bertrand et al., 2007). 
Subsequent studies confirmed that CD41+ cells from the zebrafish AGM first 
colonized the developing thymus (Kissa et al., 2008), a hallmark of embryonic HSC 
in other vertebrate species (Delassus and Cumano, 1996; Jaffredo et al., 2003; 
Jotereau et al., 1980; Jotereau and Le Douarin, 1982; Moore and Owen, 1967; Owen 
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and Ritter, 1969). These findings reiterate that HSC are indeed present in the 
zebrafish AGM and, like murine AGM HSC (Bertrand et al., 2005b; Ferkowicz et al., 
2003; Mikkola et al., 2003), can be identified by expression of CD41 even though 
CD41 is better known as a megakaryocyte marker. 
Until recently, it was thought that the HSC that formed de novo in the 
zebrafish AGM colonized the pronephros to initiate definitive hematopoiesis (Hsia 
and Zon, 2005). This view has since been altered by lineage tracing studies showing 
that presumptive HSC targeted along the aorta first migrate to a region in the tail, 
located between the caudal artery and caudal vein, termed the PBI, also known as the 
caudal hematopoietic tissue (CHT) (Jin et al., 2007; Murayama et al., 2006). At 
earlier stages, before 36 hpf, this region has also been referred to as the posterior ICM 
(Detrich et al., 1995; Thompson et al., 1998) and ventral vein region (Liao et al., 
2002; Willett et al., 1999), based on localization of hematopoietic markers to the 
ventral portion of the tail immediately caudal to the yolk tube extension. Electron 
microscopy studies showed that definitive myeloid cells, such as neutrophilic 
granulocytes, are first detected in this region at 34 hpf (Willett et al., 1999). It is not 
clear whether these cells migrate here from other hematopoietic sites, or whether they 
arise in situ from resident stem or progenitor cells, though it has been hypothesized 
that the PBI is generated by migration of HSC from the zebrafish AGM to provide a 
transitional niche to support definitive HSC expansion and maturation until the 
pronephros becomes the final hematopoietic site (Jin et al., 2007; Murayama et al., 
2006). Furthermore, the PBI is found to be capable of not only sustaining the growth 
of definitive HSC/progenitor cells emigrating from the ventral wall of the DA but also 
promoting their myeloid/erythroid differentiation (Jin et al., 2007), suggesting that the 
PBI is more likely to represent an equivalent of the mouse FL rather than the placenta 
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which mainly supports expansion of immature definitive HSC/progenitor cells  
without promoting myeloid/erythroid differentiation (Jin et al., 2007). 
Around 4–5 days post fertilization (dpf), the location of blood formation shifts 
to the kidney in the zebrafish embryo as lifelong definitive hematopoiesis is 
established (Galloway and Zon, 2003; Willett et al., 1999). In the adult zebrafish, the 
entire kidney is hematopoietically active and all blood cell lineages and their 
precursors are found as a heterogeneous population intercalated between the renal 
tubules and the blood vessels, much like mammalian adult hematopoiesis that takes 
place in and around the fat and stroma of the BM. 
 
 
1.1.3 Adult hematopoiesis 
The blood is composed of a large array of cell types that circulate through the blood 
vessels to reach different tissues. Erythrocytes provide oxygen and myeloid cells such 
as megakaryocytes produce platelets that are essential for clotting processes while 
macrophages and neutrophils provide the first barrier of defence against 
environmental pathogens and clear exogenous particles and cellular debris. In 
addition, cells of the lymphoid lineage [T-cells, B-cells and natural killer (NK)-cells] 
mediate specific defences against pathogens and the elimination of abnormal cells 
(tumours). Erythrocytes and myeloid cells have a constant half-life (estimated to be 
two days for neutrophils and 30 days for erythrocytes), whereas the life span of 
lymphocytes can vary widely. Every functionally-specialized, mature blood cell is 
derived from a rare population of cells in the BM known as the HSC. These stem cells 
represent a self-renewing population of cells that have the potential to generate 
progenitor cells that differentiate and become committed to a particular blood cell 
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lineage. A single HSC is capable of completely restoring the hematopoietic process. 
Two properties define these cells. First, they can generate more HSC through a 
process of self-renewal. Second, they have the potential to differentiate into various 
progenitor cells that eventually commit to further maturation along specific pathways. 
The end result of these events is the continuous production of sufficient, but not 
excessive, numbers of hematopoietic cells of all lineages. The pluripotent HSC can 
undergo a decision to either self renew or differentiate into committed progenitor cells. 
Once the process of differentiation is triggered, HSC generate progenitor cells, 
namely common lymphoid progenitor (CLP) and common myeloid progenitor (CMP) 
cells (Akashi et al., 2000; Kondo et al., 2003; Ling and Dzierzak, 2002; Ogawa, 1993; 
Orkin, 2000). These cells are committed to a given cell lineage; nevertheless, they are 
highly proliferative and undergo several successive stages of differentiation until they 
terminally differentiate into mature, usually non-dividing progeny that make up 
specific blood cell types. The CMP gives rise to myeloid and erythroid lineage 
through granulocyte/macrophage progenitors (GMP) and megakaryocyte/erythroid 
progenitors (MEP). GMP differentiate into granulocytes including neutrophils, 
eosinophils, basophils and monocytes, which further differentiate into macrophages. 
MEP differentiate into megakaryocytes/platelets and erythrocytes (Figure 1.8). The 
myeloid lineage is involved in various functions such as innate immunity, adaptive 































Figure 1.8: Hematopoiesis differentiation chart showing the transcription factors 
required for the respective lineage specification. Maturation patterns of myeloid 
and lymphoid cells into their respective lineage. HSC, hematopoietic stem cell; LT, 
long term; ST, short term; MPP, multipotent progenitor; CMP, common myeloid 
progenitor; CLP, common lymphoid progenitor; MEP, megakaryocyte erythrocyte 







The CLP gives rise to the lymphoid lineage, namely T-, B- and NK-cells, 
which form the cornerstone of the adaptive immune system. Lymphocyte progenitors 
leave the BM and mature in lymphoid organs, including the thymus, lymph nodes, 
and spleen - these organs provide specialized microenvironments for the expression of 
factors that move lymphocytes along their distinctive pathways of differentiation. B-
cell development to the stage of the mature B lymphocyte is completed within the BM. 
Further differentiation into plasma cells or memory B-cells does not occur until the 
mature (but naïve) B lymphocyte encounters specific antigen. T-cell development to 
the stage of precursor T lymphocyte occurs within the BM. The precursor T 
lymphocytes then migrate to the thymus to complete maturation. When mature T 
lymphocytes leave the thymus, they are mature, (but naïve) Tc (T cytotoxic 
lymphocytes) or Th (T helper lymphocytes). Further differentiation does not occur 
until the mature T-cells encounter antigens (presented to the T-cell in association with 
major histocompatibility complex (MHC) proteins on 3 types of antigen presenting 
cells: macrophages, B-cells and dendritic cells) (Schwarz and Bhandoola, 2006). 
 
 
1.1.4  Genes in hematopoiesis 
1.1.4.1 Genes that affect hematopoiesis during embryonic development 
Gene-targeting experiments have provided important information about the function 
of various genes in the generation and maintenance of hematopoietic lineages. Table 
1.1 lists some of the published mutations that differentially affect primitive versus 














Genes that affect both primitive and definitive hematopoiesis 
TAL1/SCL* 9-10.5 Markedly reduced Absent Lack of precursor determination or 
maintenance 
LMO2* 9-10.5 Markedly reduced Absent Lack of precursor determination or 
maintenance 
GATA1* 10.5-11.5 Markedly reduced Absent Erythrocytes arrested at the 
proerythroblast stage 
FLK1 8.5-9.5 Markedly reduced Absent Defect of precursor migration during 
gastrulation 
TIE2 8.5-9.5 Markedly reduced Absent Defects in EC production 
CBP 8.5-10.5 Reduced Absent Defects in angiogenesis 
Genes that affect definitive hematopoiesis only 
RUNX1/AML1* 11.5-12.5 Slightly reduced Absent Defective HSC generation and/or 
proliferation of immature precursors 
PEBP2β/CBFβ* 11.5-14 Normal Absent Proliferative defect of immature 
precursors 
GATA2* 10.5-11.5 Reduced Markedly reduced Reduced expansion of the various 
lineages 
c-MYB* 15 Normal Decreased Proliferative defect of immature 
precursors 















Pu.1* 18.5 Normal Reduced Multiple defects in the development of 
lymphoid and myeloid cells 
Ikaros* Viable Normal Reduced Decreased generation and/or 
proliferation of HSC. Multiple 
lymphocyte defects 
LHX2 (LIM)* 15.5 Normal Reduced 
erythropoiesis 
Affects definitive-erythrocyte production 
Jumonji* 10.5-15.5 Normal Reduced Reduced number of multipotent 
precursors due to defective hepatic 
environment 
N-CoR 15.5 Normal Reduced Affects erythrocyte and T-cell 
differentiation 
SOCS3 12-16 Normal Increased Erythrocytosis. Increased precursor 
proliferation 
REL/RELA 13.5 Normal Reduced Decreased CFU-S and erythromyeloid-
precursor expansion 








1.1.4.2 Hematopoietic transcription factors 
Many of the genes listed in Table 1.1 have come to be known as important 
hematopoietic TF for both developmental hematopoiesis and adult hematopoiesis. 
These TF can be divided into two main groups, (i) factors such as Runx1, Scl and 
Gata2, which are involved in formation of almost all blood cell lineages, and (ii) 
differentiation factors such as GATA1, PU.1 and CCAAT/enhancer binding protein-α 
(C/EBPα), which usually affects only a single or small number of related lineages. 
Not surprisingly, disruption of TF such as Runx1 or scl during embryonic 
development results in embryonic lethality since the formation of entire blood cell 
lineages is affected.  
Many of these TF which are important in developmental hematopoiesis 
continue to play important roles in adult hematopoiesis. However, gene targeting 
experiments involving critical factors, such as Runx1 and Scl, which result in 
embryonic lethality do not allow for understanding the role of these factors in adult 
hematopoiesis. This problem is circumvented by the use of conditional knockout mice. 
Table 1.2 summarizes the results obtained from studies of selected TF (illustrated in 
Figure 1.8) which are involved in normal adult hematopoiesis. 
The RUNX1/AML1 gene is a key regulator of hematopoiesis involved in 
definitive hematopoiesis during development and in differentiation of adult HSC. It is 
also the most frequently mutated gene in human leukemia. The role of Runx1 in 





Table 1.2: Transcription factors involved in normal adult hematopoiesis 
expression, and knockout phenotypes.  
Transcription 
factor 
Site of expression Hematopoietic phenotype in knockout mice and 
conditional knockout mice 
RUNX1 
Hematopoietic cells, nervous 
tissue, skeletal muscle, 
reproductive tissue 
Knockout: lack of all definitive hematopoiesis; 
embryonic lethal 
Conditional knockout: impaired megakaryocytic 
maturation, defective B-cell and T-cell development, 





MPPs, erythrocytes and 
megakaryocytes), EC, brain 
tissue 
Knockout: complete absence of YS hematopoiesis, 
lack of angiogenesis; embryonic lethal 
Conditional knockout: decreased erythrocytes and 
megakaryocytes, impaired ST-HSC, normal LT-HSC 
PU.1 
Hematopoietic cells (HSC, 
CMP, CLP, GMP, 
monocytes, granulocytes and 
B-cells) 
Knockout: lack of mature myeloid and B-cells 
Conditional knockout: block prior to CMP and CLP 
stages, increased granulopoiesis, defective HSC 
C/EBPα 
Hematopoietic cells (HSC, 
CMP, GMP, granulocytes), 
liver, adipose tissue 
Knockout: lack of GMP and granulocytes, impaired 
monocytes, increased immature myeloid cells 
Conditional knockout: same as knockout mice, plus 
increased HSC self-renewal 
GFI1 
Sensory epithelial cells in the 
inner ear, neuroendocrine 
cells of the lungs, 
neutrophils, B and T-cells, 
HSC 
Knockout: reduction in earliest lymphoid progenitors, 
complete block in late neutrophil maturation, 
defective HSC 
C/EBPε Preferentially in myeloid and lymphoid cells 
Knockout: abnormal late neutrophil maturation, block 
in eosinophil development, defective macrophage 
function 
C/EBP, CCAAT/enhancer binding protein; CLP, common lymphoid progenitor; CML, chronic 
myeloid leukemia; CMP, common myeloid progenitor; GFI1, growth factor independent 1; 
GMP, granulocyte/monocyte progenitor; LT-HSC, long-term hematopoietic stem cell; MPP, 
multipotential progenitor; PU.1, transcription factor encoded by SPI1; RUNX1, Runt-related 
transcription factor 1; SCL, stem-cell leukemia factor; ST-HSC, short-term hematopoietic stem 
cell. *(Motoda et al., 2007). (Rosenbauer and Tenen, 2007)  
 
GATA1 was the first 'lineage-specific' TF to be described, and its role in the 
development of erythroid and megakaryocytic lineages has been elucidated in a 
number of studies (Orkin, 2000; Shivdasani and Orkin, 1996). GATA1 participates in 
the differentiation of CMP to MEP and not GMP. This role is supported by studies 
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involving targeted disruption of regulatory elements that resulted in selective loss of 
erythroid development (Shivdasani et al., 1997). The relative expression levels of 
GATA1 is critical for normal differentiation and a study reported that every pediatric 
patient that was analysed — with acute megakaryoblastic leukemia associated with 
Down's syndrome — harbored mutations in GATA1, whereas other M7 acute myeloid 
leukemia (AML) samples did not (Wechsler et al., 2002) (Table 1.3). 
PU.1 and C/EBPα are both important in myeloid lineage development. In 
normal myelopoiesis, PU.1 seems to have two well-defined functions. The first is to 
mediate an early role in the development of a multipotential myeloid precursor, by 
promoting HSC differentiation. The second is a later role in the development of 
monocytes/macrophages (Anderson et al., 1999; DeKoter et al., 1998). In mice, Pu.1 
is absolutely required for the development of macrophages and B-cells, and disruption 
of Pu.1 also leads to delayed development of granulocytes and T-cells (McKercher et 
al., 1996; Scott et al., 1994). PU.1 regulates almost all myeloid genes, including the 
receptors for GM-CSF, M-CSF and G-CSF. PU.1 mutations have been detected in 7% 
of 126 AML patients (Mueller et al., 2002). In general, the mutations were found in 
either the most immature FAB subtype (M0), myelomonocytic or monocytic (M4 or 
M5), or erythroleukemia (M6) — consistent with the normal role of PU.1 in 
hematopoiesis (Table 1.3). 
In contrast to PU.1, C/EBPα has a more specific function in granulopoiesis 
and is required for development of granulocytes. Non-conditional targeted disruption 
of C/EBPα results in a selective early block in granulocyte maturation, without 
affecting other hematopoietic lineages, including monocytes (Zhang et al., 1997a). 
Analysis of adult hematopoiesis in conditional C/EBPα knockout models shows a 
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block at the CMP to GMP stage. Loss of C/EBPα affects expression of the G–CSF 
receptor, but not the receptors for GM–CSF or M–CSF (Iwama et al., 1998). 
Mutations in C/EBPα gene have been found with an approximate frequency of  7–9% 
in all AML patients (Table 1.3) (Gombart et al., 2002; Pabst et al., 2001; 
Preudhomme et al., 2002). 
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Table 1.3: Hematopoietic transcription factors altered in AML                  
Transcription 
Factor Mutations and effects 
Frequency 
in AML FAB Subtype 
RUNX1–ETO 
t(8;21) 
RUNX1 DNA-binding domain fused to the 
transcriptional corepressor ETO; downregulates 






Inversion of breaks in chromosome 16; joins 





PML fused to RARα; blocks myeloid 





MLL fused with one of 30 distinct partner 
proteins; believed to dysregulate HOX genes 
 
4-7% 





Missense, nonsense or frameshift mutations 
(often biallelic); clustered within the Runt 
domain 
 
9% M0 (most) 
PU.1 
Mutations decrease heterodimer formation and 
DNA binding*; PU.1 activity downregulated by 
RUNX1–ETO, P ML–RARα and FLT3–ITD 
 
<7% M0, M4, M5, M6 
C/EBPα 
Amino-terminal dominant negative; 
carboxyterminal loss of DNA binding 
 
7-9% M1, M2 (most), M4  






M7 with Down’s 
syndrome 
 
*Japanese cohort only. AML, Acute Myeloid Leukemia; AMKL, acute megakaryoblastic 
leukemia; CBFβ, core-binding factor-β; C/EBPα, CCAAT/enhancer binding protein-α; 
FAB, French–American–British; FLT3, FMS-related tyrosine kinase 3; GATA1, GATA-
binding protein 1; HOX, homeobox; ITD, internal tandem duplication; MLL, mixed lineage 
leukemia; MYH11, myosin heavy chain 11; PML, promyelocytic leukemia; PU.1, TF 
encoded by SPI1; RARα, retinoic acid receptor-α; RUNX1, Runt-related TF (Rosenbauer 
and Tenen, 2007). 
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1.1.5 Hematopoietic stem cells (HSC) defined 
HSC have tremendous therapeutic potential and have been harnessed in the clinic for 
more than 40 years in the context of bone marrow transplantation (BMT). The success 
of this work was further highlighted in 1990 when the Nobel Prize was awarded to Dr. 
Joseph Murray and Dr. E Donnall Thomas for their pioneering work in kidney and 
BM transplantation, respectively. The mouse is the most widely used animal model 
for studying mammalian disease and many molecules show a high degree of 
conservation between the mouse and human. Although many aspects of HSC biology 
are shared between mouse and man, the purification strategies used differ slightly for 
experimental isolation of mouse HSC and purification of human HSC for therapeutic 
applications. The rest of this section will focus on how HSC and their derivative 
populations of progenitors in mice are defined and purified in the laboratory setting. 
 HSC/progenitor cells are defined immunophenotypically and functionally. The 
immunophenotypic identification and purification of HSC relies on the unique cell 
surface molecule expression found on these cells compared with the remainder of BM 
cells, including the closely-related hematopoietic progenitor cell counterparts. Aided 
by advances in flow cytometric techniques and monoclonal antibody availability, 
several different antibody combination schemes have been developed to enrich and 
purify long-term, multilineage reconstituting HSC. Concurrently, antibody 
combinations for the identification of different populations of hematopoietic 
progenitor cells were also identified. Functional analysis of progenitors and HSC 
involves both in vitro and in vivo assays. Briefly, in vitro and short-term in vivo 
assays are often used for measuring HSC and progenitor cell content, but are 
generally a reflection of the more mature progenitor cells as opposed to the immature 
HSC. In contrast, in vivo long-term repopulating assays remain the gold standard for 
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measuring HSC. Combinations of antibody-based subselection of cells with in vitro 
and in vivo assays have proven to be extremely powerful in the identification of 
progenitors and HSC. 
1.1.5.1 Immunophenotypic identification of HSC / progenitors 
In the last 20 years, a number of different methods for identifying HSC and progenitor 
cells have emerged (Goldschneider et al., 1978; Spangrude et al., 1988; Visser and 
Bol, 1982; Visser et al., 1981). All rely on fluorescence-activated cell sorting 
(FACS)-based methods. In general, almost all HSC purification strategies revolve 
around at least one of the following: (i) positive selection for the markers c-Kit and 
Sca-1, and negative selection for markers of mature hematopoietic cell lineages 
(typically B220, CD3, CD4, CD8, Gr-1, Mac-1, and Ter-119) – KSL cells; (ii) 
Hoechst-effluxing side population (SP) and (iii) the staining scheme based on the 
signaling lymphocytic activation molecule (SLAM) family of cell surface 
glycoproteins. Although the c-Kit+Sca-1+Lin- (KSL) phenotype greatly enriches for 
hematopoietic reconstituting activity, this BM compartment contains progenitor cells 
in addition to long-term HSC (LT-HSC). In fact only ~10% of KLS cells are bona 
fide LT-HSC and, as such, the KLS compartment merely enriches for HSC. 
Consequently, a variety of strategies have been used to further enrich BM for HSC, 
using the KSL as a foundation (Table 1.4). Several studies have shown that the SP 
alone is remarkably enriched for HSC activity, and virtually all of the LT-HSC 
activity is contained within the SP fraction (Adolfsson et al., 2001). Moreover, most 
cells from the SP fraction were found to be highly homogeneous for other surface 
markers of HSC, such as Sca-1+, c-Kit+, EPCR, CD34-/lo and Fetal liver kinase (Flk)-
2- (Balazs et al., 2006; Camargo et al., 2006; Goodell et al., 1996; Goodell et al., 
1997). However, one drawback of SP staining is that it is highly sensitive to slight 
 29
modifications in preparation techniques, so much so that KSL antibody staining is 
often used to complement SP staining, and leads to the exclusion of approximately 
15% of SP cells that are not HSC (Weksberg et al., 2008). This ensures a highly pure 
HSC population is obtained by the phenotype of SP+c-Kit+Sca-1+Lineage-, which is 
termed SPKSL (Challen et al., 2009). Multiple SLAM markers, a family of cell-surface 
proteins originally characterized in lymphocyte signalling (Veillette and Latour, 
2003), can be used in combination to fractionate the HSC potential of adult murine 
BM wherein LT-HSC were highly purified as CD150+CD244−CD48− cells while 
MPPs were CD150−CD244+CD48− and most restricted progenitors were 
CD150−CD244+CD48+ (Kiel et al., 2005b). Further exclusion of CD41 (a non-SLAM 
family protein) expressing megakaryocytic lineage cells identifies a population of 
CD150+ CD48-CD244-CD41- cells which gives 45%  long-term multilineage 
reconstitution if transplanted as single cells (Table 1.4). 
 
Table 1.4: Summary of single-cell BM reconstitution data. 
KSL, c-Kit+ Sca1+Lin–; SP, side population (can efflux Hoechst 33342); SPlo, TIP of 
SP; Rho, Rhodamine. (Wilson et al., 2007) 
Immunophenotype of donor cells Frequency of reconstitution (%) 
KSL, CD150+CD48− 47 
CD150+CD41− CD48− 45 
KSL, SPlo, Thy1.1lo, CD34−, CD135− 35 
Lin-, SP, Rholo 33 
KSL, CD34lo/− 22 
CD150+CD48− 21 
KSL, Thy1.1lo 18 
 
 
Various cell staining combinations involving KSL, SLAM and SP are able to 
discern dormant HSC from actively self-renewing HSC. Based on BrdU label 
retaining assays, the CD34−CD48−CD150+KSL population, comprising only 
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0.00125% (12 cells/million) of total BM, are proposed to represent the most dormant 
HSC population, hypothesized not to contribute to the day-to-day production of 
progenitors, but rather serves as a reserve pool of stem cells that are only activated on 
injury (Wilson et al., 2007). In contrast, the CD34+CD48−CD150+KSL population 
defines actively self-renewing HSC from which progenitors arise during normal 
homeostasis (Wilson et al., 2007), consistent with the reports that actively expanding 
HSC, such as the earliest definitive HSC generated in the embryo and later on present 
in the FL as well as G-CSF mobilized adult HSC, are all CD34+ (Furness and 
McNagny, 2006; Ogawa et al., 2001; Sanchez et al., 1996). In addition, both 
CD150+SPKSL and CD150-SPKSL populations of cells have been found to contain LT-
HSC (Weksberg et al., 2008), of which the latter finding contradicts previous report 
that CD150- cells do not possess long-term multilineage reconstitution ability (Kiel et 
al., 2005b). Interestingly, CD150-SPKSL were found to be substantially more 
proliferative in vivo than their CD150+SPKSL counterparts, and despite their ability for 
multilineage reconstitution, appeared to have a lymphoid-biase (Weksberg et al., 
2008). Conversely, CD150+SPKSL appears to mark a population of more quiescent 










Table 1.5: Summary of cell surface phenotypes of various hematopoietic stem 
and progenitor cell populations. 
Marker Phenotype Cell type 
KSL Hematopoietic stem and progenitor cells 






CD150+SPKSL quiescent LT-HSC 
CD34−CD48−CD135−CD150+KSL quiescent LT-HSC 
CD150-SPKSL Activated, self-renewing LT-HSC 
CD34+CD48−CD135−CD150+KSL Activated, self-renewing LT-HSC 
Mac-1loKTLS ST-HSC 











BM, bone marrow; CLP, common lymphoid progenitors; CMP, common myeloid 
progenitors; GMP, granulocyte-macrophage progenitors; HSC, hematopoietic stem 
cell; LT-HSC, long-term HSC; MEP, megakaryocyte-erythrocyte progenitor; MPP, 
multipotent progenitor; KSL, c-Kit+ Sca1+Lin–; SP, side population (can efflux 
Hoechst 33342); SPlo, tip of SP; ST-HSC, short-term HSC; Rho, Rhodamine. 
(compiled from Challen et al., 2009; Kiel et al., 2005b; Morrison and Weissman, 
1994; Weksberg et al., 2008; Wilson et al., 2007) 
 
Evidently, there exist many different immunophenotypic strategies to 
fractionate BM cells into progenitors and HSC, the latter of which can be further 
subfractioned into quiescent and actively proliferating cells (Table 1.5). 
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1.1.5.2 In Vitro and Short-Term In Vivo Assays for Detecting Functional Potential of 
HSC and Progenitors 
As mentioned before, in vitro and short-term in vivo assays are often used for 
measuring HSC and progenitor cell content but are generally a reflection of the more 
mature progenitor cells as opposed to the immature HSC. The colony-forming cell 
(CFC) assays measure progenitor cells in a given population using semisolid agar-
based or, more commonly, well-defined methylcellulose-based culture media, which 
are commercially available whilst the cobblestone area-forming cells (CAFC) and 
long-term culture-initiating cell (LTC-IC) assays are coculture systems used to predict 
HSC frequencies (Purton and Scadden, 2007). The reliability of the use of the latter 
co-culture assays to measure HSC remains controversial, although they reflect a more 
immature or primitive population than the CFC.  
In vitro culture of HSC and progenitor cells requires the presence of 
combinations of synergistic hematopoietic growth factors, a family of cytokines that 
interact with specific receptors on hematopoietic cells (Clark and Kamen, 1987; 
Nicola, 1989). These molecules regulate the functional activation of the specific cells 
with which they interact and are required for the survival, proliferation, and 
differentiation of hematopoietic progenitors (Clark and Kamen, 1987). Numerous 
cytokines have been identified as important extracellular regulators of hematopoiesis, 
and have become useful reagents to promote HSC maintenance in vitro. These include 
stem cell factor [SCF, also known as steel factor (SF)]; a ligand to the tyrosine kinase 
receptor encoded by the protooncogene c-kit. SCF supports early hematopoiesis 
directly as well as in synergy with a variety of cytokines including interleukin (IL)-3, 
GM-CSF, G-CSF, erythropoietin, IL-1, IL-6, and IL-7 (Inatomi et al., 1994). 
Importantly, individual cytokines, when used alone, have only submaximal or no 
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effect on highly enriched HSC but strongly stimulate their growth and differentiation 
in the presence of SCF (Migliaccio et al., 1991). Of note, changes occur during 
ontogeny in the cytokine dependence of proliferative and differentiative responses as 
exemplified by the inability of cytokine combinations able to maintain or expand 
adult murine stem cell populations to sustain the long-term repopulating ability of 
their counterparts in E14.5 FL (Miller and Eaves, 1997).  
Short-term in vivo colony-forming unit-spleen (CFU-S) assay detects the 
ability of cells that, once injected into an irradiated recipient, home to the spleen and 
form macroscopic colonies that provide very short-term (usually 1–3 weeks) in vivo 
repopulation in the mouse (Till and McCullough, 1961). The CFU-S are therefore 
early engrafting cells, providing radioprotection to the mouse and allowing it to 
survive more readily in the first 2–3 weeks posttransplantation when pancytopenia 
usually occurs (Purton and Scadden, 2007). Although originally believed to be 
derived from HSC, it is noteworthy that the CFU-S described (Till and McCullough, 
1961) were later found to be derived from more committed progenitor cells 
(Schofield, 1978); these progenitors, while more immature than CFCs, they are more 
mature than HSC (Purton and Scadden, 2007). It is hence apparent that these studies, 
while informative, are unable to define true HSC which have the ability to provide 
long-term, multilineage reconstitution.  
 
1.1.5.3  In vivo long-term repopulating assay 
The gold standard for measuring HSC activity is the long-term repopulation assay as 
it requires donor cells to fulfill the two criteria that define HSC (Li and Johnson, 
1992; Ploemacher and Brons, 1988; Uchida and Weissman, 1992). Donor cells 
indicate that they are multipotent by contributing to B and T lymphoid as well as 
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myeloid lineages. In addition, these lineages are produced indefinitely post-transplant, 
demonstrating the ability of donor cells to self-renew.  
There are various types of long-term repopulating assays, the most common of 
which is the competitive repopulation assay (Harrison, 1980). This assay measures the 
functional potential of the unknown source of HSC against a set known number of 
HSC [usually whole bone marrow (WBM) cells from congenic wild-type (WT) mice; 
capable of providing short-term radioprotection]. While providing information about 
the function of HSC in their capacity to repopulate compared to the competing BM, 
this study provides qualitative or at best semiquantitative information about the HSC 
within a given population—it cannot distinguish between the number of HSC or their 
quality (progeny produced per HSC) (Purton and Scadden, 2007). The frequency of 
HSC (from which the number of HSC can be calculated) is commonly measured 
using the limiting dilution assay, which is a variation of the competitive repopulation 
assay. In this assay, a series of dilutions of the unknown source (donor ‘‘test’’ cells) 
are competed against a set number of competing BM cells. For both assays, a 
minimum of 16 weeks is required and an optimal 6 months is suggested, for 
monitoring long-term reconstitution post-transplant (Purton and Scadden, 2007).  
The most stringent test of HSC potential is the serial transplant assay. The 
HSC compartment has been shown to be heterogeneous, comprising a hierarchy of 
HSC that can be identified by their functional capacity. The most immature HSC in 
this hierarchy is capable of sustaining hematopoiesis throughout serial transplantation 
(Lemischka et al., 1986; Purton et al., 2006; Rosendaal et al., 1979). Hence, in this 
assay, the source of HSC is transplanted into sequential serial transplant recipients, 
and the ability of this population to sustain hematopoiesis by presumptive self-
renewing divisions is determined.  
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1.1.6 Hematopoietic stem cell niche 
HSC usually reside in a highly specialized microenvironment called the “stem cell 
niche” which produces essential factors to maintain a pool of HSC that provides the 
appropriate numbers of mature blood cells throughout life.  Most primitive HSC are 
thought to be in a quiescent state in these niches and regulation of HSC is largely 
dependant on their interaction with the niche. The niche serves as both a means of 
preserving and protecting stem cells from potentially depleting stimuli, such as 
apoptotic and differentiation stimuli, and as a means of protecting the host from the 
potential adverse effects of excessive stem cell activity. However, HSC must be 
periodically activated to produce progenitor cells that are committed to produce 
mature cell lineages. Thus, maintaining a balance of stem cell quiescence and activity 
is the hallmark of a functional niche. The niche therefore produces signals for the 
localization, expansion and constraint of stem cells (Moore and Lemischka, 2006; 











Figure 1.9: Bone marrow HSC niche. (Wilson et al., 2007) CAR cell, CXCL12-
abundant reticular cell; ECM, extracellular matrix; HSC, hematopoietic stem cell; 
MPP, multipotential progenitor.  
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HSC reside primarily within the BM during adulthood, mainly located in the 
trabecular part of the long bones (Kiel and Morrison, 2008; Wilson and Trumpp, 
2006). HSC have a defined spatial organization in the BM cavity, with the most 
primitive/dormant cells in direct contact with osteoblasts lining the endosteal surface 
of the bone (Figure 1.9). These specialized osteoblasts are thought to secrete or 
activate a variety of factors such as angiopoietin-1 and CXC chemokine ligand 12 
(CXCL12) that regulate the maintenance or numbers of HSC in the BM (Arai et al., 
2004; Calvi et al., 2003; Zhang et al., 2003). Especially, spindle shaped, N-cadherin+, 
osteoblast (SNO) cells fulfill the function of niche cells on the endosteum of BM 
(Zhang et al., 2003).  In the “endosteal niche” or “dormant niche,” CXCL12-
abundant reticular (CAR) cells and osteoblasts together with stromal fibroblasts and 
potentially other cell types such as osteoclasts generate a hypoxic (O2 low) 
environment with a dense extracellular matrix (ECM) that retains the dormancy of 
HSC. The second niche for HSC is the vascular niche located in the vascular network 
(the sinusoids; specialized venuoles that form a reticular network of fenestrated 
vessels that allow cells to pass in and out of circulation) of the BM and spleen, with 
two-thirds of the HSC localized here (Kiel et al., 2005a), particularly attached to CAR 
cells. Notably, dormant HSC in contact with CAR cells found at the endosteum, are 
more frequently associated with sinusoids. These dormant HSC are activated 
stochastically or in response to injury signals. Activated self-renewing HSC, however, 
are located adjacent to perivascular CAR cells near sinusoids forming the vascular 
niche. On a self-renewing division, asymmetry is generated, which leads to the 
generation of two daughter cells: a MPP and an activated HSC. MPPs and/or their 
progeny enter the circulation through the fenestrated endothelium of sinusoidal 
microvasculature. 
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CXCL12  is also known as SDF-1 (stromal cell derived factor), predominantly 
interacts with the chemokine (C-X-C motif) receptor 4 (CXCR4) receptor found on 
HSC (Peled et al., 1999; Sugiyama et al., 2006). High amounts of SDF-1 is secreted 
by both the CAR cells in the sinusoidal niche and the osteoblast cells lining the 
endosteal niche to which most of the HSC are attached. Thus, interaction of SDF-1 
with its receptor CXCR4 is essential for the interaction of the HSC with its niche, 
both endosteal and sinusoidal (Kollet et al., 2006; Sugiyama et al., 2006). Interrupting 
this localization of stem cells to the niche impairs engraftment or retention of normal 
HSC in the BM, preventing these cells from self-renewing and contributing to blood 
formation (Sugiyama et al., 2006). Collectively, all the genetic and functional data 
indicate that the SDF-1–CXCR4 axis is crucial and probably most important for 
retention and maintenance of adult HSC. In addition to CXCR4, other cell-surface 
receptors expressed on HSC  and several cell-surface adhesion molecules, including 
selectins and integrins, are involved in stem cell homing, localization and retention in 
the niche (Lapidot et al., 2005; Lapidot and Petit, 2002).  For example, β1-integrin-
deficient HSC fail to migrate to the BM after transplantation (Potocnik, 2000; 
Potocnik et al., 2000). 
HSC behave in a dynamic manner and often leave the BM (mobilization), 
circulate in the blood and return to either the endosteal niche or sinusoidal niche 
(homing). The egress of HSC from their niche is observed during homeostasis, when 
a small number of HSC are constantly released into the circulation (Wright et al., 
2001). Although their precise physiological role remains unclear, they might provide 
a rapidly accessible source of HSC to repopulate areas of injured BM (Lapidot and 
Petit, 2002). Alternatively, circulating HSC might be a secondary consequence of 
permanent bone remodeling that causes constant destruction and formation of HSC 
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niches, therefore requiring frequent re-localization of HSC which are on the lookout 
for an empty niche. Transplanted HSC also have the capacity to home back to and 
lodge in the stem cell niche of recipients. The stem cell pool is tightly controlled in 
the body and it is essential that the circulating stem cells or transplanted stem cells 
have their homing and niche interacting machinery intact so as to find a new niche 
and maintain their stem cell properties. Defects in this machinery could lead to loss of 
stem cells which leads to stem cell exhaustion as is seen in CXCR4 conditional 




1.2 Transcription factor RUNX1/AML1 
 
1.2.1 Runt domain transcription factors 
The Runt domain TF is known as polyomavirus enhancer-binding protein 2 
(PEBP2)/core-binding factor (CBF) and is a heterodimer of α and β subunits (Ito, 
2004; Speck and Gilliland, 2002).  Drosophila has 4 genes (Runt, Lozenge, CG1397 
and CG15445) (Rennert et al., 2003) coding for the α subunit and 2 genes (Brother 
and Big Brother) for the β subunit. In contrast, mammals have three distinct genes, 
Runx1, Runx2 and Runx3, localized on human chromosomes 21q22, 6p21 and 1p36.1 
and on mouse chromosomes 16, 17 and 4, respectively (Avraham et al., 1995; Bae et 
al., 1994; Bae et al., 1995; Calabi et al., 1995; Levanon et al., 1994; Zhang et al., 
1997b), which encode the DNA-binding α subunits, while the single CBFB gene 
encodes the shared, non-DNA binding β subunit, PEBP2β/CBFβ (Figure 1.10). The α 
subunits share an evolutionarily conserved 128 amino acid region called the Runt 
domain which is responsible for DNA binding at consensus binding sites 
(PuACCPuCA) and heterodimerisation (Figure 1.11). The binding affinity of Runx 
proteins is increased markedly in the presence of Pebp2β (Ogawa et al., 1993; Wang 
et al., 1993) and other binding cofactors. Furthermore, Pebp2β regulates turnover of 
Runx proteins by protecting them from ubiquitin–proteasome-mediated degradation 
(Huang et al., 2001). (RUNX is used when description applies only to human, 
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Figure 1.10: Illustration of Runx α-subunit heterodimerized with the Pebpb2β, 
bound to DNA. 
 
The human genes coding for α subunits have a number of alternative names 
(Table 1.6). Since RUNX1 was first identified in chromosomal rearrangements 
observed in patients with leukemia, it was also called AML1(Miyoshi et al., 1991). At 
the same time, RUNX2 gene was identified as the gene that codes for a protein that 
regulates the replication of mouse polyomavirus and thus was called Polyomavirus 
enhancer binding protein 2 (PEBP2α) (Satake et al., 1989). It was also called CBFα 
because it was identified from the core binding factor (CBF) complex that binds to the 
core site of murine leukemia viruses (Wang et al., 1993). The official nomenclature 
from the Human Gene Nomenclature Committee 
(http;//www.gene.ucl.ac.uk/nomenclature/) renamed the genes RUNX1-3 and these 
names will be used throughout this thesis (van Wijnen et al., 2004). 
 
   Table 1.6: Alternative names of RUNX transcription factors 
RUNX1 AML1 CBFα2 PEBP2αB 
RUNX2 AML3 CBFα1 PEBP2αA 





















Figure 1.11: Runx α-subunit proteins. (A) Schematic representation of Runx α-subunit 
proteins. The characteristic domains found in all Runx proteins are indicated to show their 
relative positions along the protein. (B) Multiple sequence alignment of fugu and human 
Runx α-subunit proteins. The Runx amino acid sequences were aligned by using ClustalW. fr, 
Fugu rubripes; hs, Homo sapiens. Amino acids that match the consensus are shaded in grey. 
The first line shows the amino-terminal part of the protein derived from the P1 promoter 
[MAS(N/D)S] that differs from the P2 promoter-derived form. Yellow highlighted amino 
acids indicate the start of the common protein sequences for both the P1 and P2 forms of 
Runx. The highly conserved Runt domain is boxed with a green solid line. NLS is been 
demarcated by a pink dashlined box. The PY domain and VWRPY motifs are indicated by 
solid line blue and orange boxes, respectively. The TAD is highlighted in red and the 
inhibitory domain (ID) is boxed by purple dotted-lines. Minimal consensus sequences for 
phosphorylation by Erk or cdc2 are boxed by dashed or solid black lines, respectively. The 
residue targeted for phosphorylation is indicated by Ⓟ. 
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Runx genes are found in phylogenetically diverse organisms (Bae and Lee, 
2000; Eggers et al., 2002; Kalev-Zylinska et al., 2002; Kataoka et al., 2000; Levanon 
and Groner, 2004; Ng et al., 2007; Rennert et al., 2003; Stricker et al., 2002; Sullivan 
et al., 2008) (Figure 1.12a). Lower organisms contain a single Runx gene, but 
climbing the phylogenetic ladder to arthropods and vertebrates is accompanied by 
multiplicity of Runx genes that occurred through gene duplication (Rennert et al., 
2003). The three vertebrate Runx genes maintained extensive structural similarities 
(Bangsow et al., 2001; Geoffroy et al., 1998; Ghozi et al., 1996; Levanon et al., 2001; 
Rennert et al., 2003; Xiao et al., 2001), which extend beyond the RUNX locus itself to 
include the neighboring paralogous genes, CLIC and DSCR (Eggers et al., 2002; 
Glusman et al., 2004; Levanon et al., 2001; Levanon and Groner, 2004) (Figure 
1.12).  
The structural similarities between the mammalian Runx genes include 
genomic elements that are involved in expression regulation. Each of the three genes 
is transcriptionally regulated by two distantly located promoter regions, P1 (distal) 
and P2 (proximal) (Figure 1.12b) (Bangsow et al., 2001; Drissi et al., 2000; Fujiwara 
et al., 1999; Ghozi et al., 1996; Rini and Calabi, 2001; Stewart et al., 1997; Telfer and 
Rothenberg, 2001; Xiao et al., 2001). The P2 promoter is nested within a particularly 
large CpG island (Bangsow et al., 2001; Levanon et al., 2001). The presence of CpG 
islands in mammalian Runx genes suggests possible regulation by promoter 
methylation. Consistent with this hypothesis, aberrant methylation of the Runx3 
promoter has been associated with human cancers (Kim et al., 2005; Lau et al., 2006; 
Li et al., 2002; Oshimo et al., 2004; Subramaniam et al., 2009; Tan et al., 2006; Tan 
et al., 2007). No such CpG rich region is found in the P1 promoter. Instead, Runx-
binding sites, conserved from fugu to human, are found in the P1 promoters, 
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suggesting either transcriptional auto-regulation or cross-regulation among the Runx 
family genes. Functional analyses using transfection assays have demonstrated that 
the P1 and P2 regions of the three genes possess promoter activity (Bangsow et al., 
2001; Drissi et al., 2000; Fujiwara et al., 1999; Ghozi et al., 1996; Rini and Calabi, 
2001; Xiao et al., 2001; Zambotti et al., 2002). In most cases, the activity was cell-
type specific, with higher promoter–reporter readouts in cells that normally express 
the genes. However, detailed information about the positive and negative elements 
that regulate tissue-specific expression of Runx genes in vivo remained largely 


























Figure 1.12: Runx gene phylogeny and gene structure. (a) Phylogenetic illustration of 
RUNX genes showing the gene number and promoter usage in different animals. The three 
lower nondesignated branches in the phylogenetic tree represent the animal groups (from 
bottom up) sponges, cnidarians (e.g. jellyfish) and acoelomates (e.g. flatworms). (b) Common 
exons are shown in similar colors. Exons in the RUNT domain are shown in green. 5’UTR 
are in yellow for the P1 promoter and in orange for the P2 promoter. 3’UTR are in blue. 
Neighboring genes are indicated. (Modified from Levanon & Groner, 2004). 
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The structure, key functional domains and phosphorylation sites of Runx 
proteins are highly conserved (Figure 1.11). As expected, the 128 amino acid Runt 
domain, that is critical for DNA-binding and heterodimerisation with the β subunit, is 
highly conserved throughout all α-subunit Runx proteins, regardless of whether they 
are from fugu or human. The nuclear localization signal (NLS) is also highly 
conserved. However, regions outside the Runt domain are less conserved apart from 
the VWRPY, PY motif and phosphorylation sites of extracellular signal-regulated 
kinase (Erk)/cell division cycle 2 protein (cdc2) (Figure 1.11). With regard to these 
sequences, the PY and VWRPY motifs are known to modulate the transcriptional 
activities of the Runx proteins by recruiting different interacting proteins. The PY 
motif mediates the binding of Runx proteins to WW domain-containing proteins, such 
as Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding 
motif (TAZ) (Kanai et al., 2000; Yagi et al., 1999), and has also been shown recently 
to mediate Runx1 phosphorylation by homeodomain interacting kinase 2 (HIPK2) 
(Wee et al., 2008); while the VWRPY motif binds a transcriptional repressor called 
Transducin-like enhancer (TLE) (Imai et al., 1998; Javed et al., 2000; Levanon et al., 
1998), the mammalian homolog of Groucho in Drosophila, which recruits histone 
deacetylases (HDAC) to repress transcription. 
 Despite their structural similarity, the Runx genes have divergent biological 
roles as evidenced by the disruption of the individual Runx genes in mouse models 
and in human diseases. Runx1 is essential for definitive hematopoeisis and is 
frequently mutated in human leukemias (Blyth et al., 2005; Miyoshi et al., 1991; 
Osato, 2004; Speck and Gilliland, 2002). RUNX1 haploinsufficiency causes familial 
platelet disorder with a predisposition to develop acute myeloid leukemia (FPD/ 
AML) (Michaud et al., 2002; Osato, 2004; Song et al., 1999). The β subunit is also 
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involved in the development of leukemias due to the inv(16), which generates the 
CBFB-MYH11 chimeric gene (Liu et al., 1993). Moreover, in mice, Runx1 is required 
for neuronal development (Kalev-Zylinska et al., 2002; Theriault et al., 2004). Runx2 
is indispensable for bone formation as shown by Runx2-deficient mice (Ducy et al., 
1997; Komori et al., 1997; Otto et al., 1997). Furthermore, haploinsufficiency of 
RUNX2 is associated with the human autosomal dominant skeletal disorder 
cleidocranial dysplasia (CCD) (Mundlos et al., 1997; Otto et al., 2002; Otto et al., 
1997). Runx3 plays roles in the proliferation and apoptosis of gastric and intestinal 
epithelial cells (Ito et al., 2008; Li et al., 2002), T cell development (Egawa and 
Littman, 2008; Ehlers et al., 2003; Grueter et al., 2005; Naoe et al., 2007; Taniuchi et 
al., 2002), and neuronal development (Inoue et al., 2007; Inoue et al., 2003; Inoue et 
al., 2002; Levanon et al., 2002). In addition, both Runx1 and Runx3 have recently 
been shown to play roles in T cell development (Egawa et al., 2007; Setoguchi et al., 
2008) and dorsal root ganglion sensory neuron diversification (Inoue et al., 2008; 
Kramer et al., 2006). 
 
1.2.2 Genomic structure of the Runx1 gene 
Like other members of the Runx family, Runx1 has a complex gene structure which 
through alternative promoter (distal P1 versus proximal P2) usage in combination 
with exon skipping and alternative 3’ exon usage, generates a diversity of potential 
Runx1 alternatively spliced mRNAs (Figure 1.13) and their proteins (Levanon et al., 
2001). Notably, some of the splice variants generated from P2 promoter lack the 
transactivation domain and are thought to have dominant-negative functions in 
inhibiting myeloid differentiation (Ghozi et al., 1996). Of the isoforms generated by 
Runx1/AML1, three occur in particular abundance, namely Runx1/p27 (AML1a), 
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Runx1/p49 (AML1b), and Runx1/p52 (AML1c). Interestingly, high expression levels 
of the P1 isoform have been found in murine HSC and T-cells, suggesting preferential 
































Figure 1.13: Genomic organization of the human RUNX1 gene and the structure 
of alternatively spliced mRNAs. Striped boxes represent UTRs. RUNX1/p29 and 
RUNX1/p24 are incomplete coding regions. The translocation breakpoints are marked 
by arrows beneath the gene map. (Levanon et al., 2001) 
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1.2.3 Transcriptional regulation mediated by Runx1 
RUNX1 binds to the promoters and enhancers of its target genes, where it 
recruits and synergizes with other proteins, including TF, to regulate the 
transcriptional activation or repression of downstream target genes (Bruhn et al., 
1997; Mao et al., 1999; Petrovick et al., 1998). Runx1 function is context dependent 
based on the level of expression of cell-specific Runx1 isoforms, the availability of 
co-factors and the signals triggering posttranslational modifications. Given the 
important role of Runx1 in hematopoiesis and leukemia, it is no surprise that the 
majority of proteins that interact with Runx1 are involved in the hematopoietic system 
(Table 1.7). In addition, the function of Runx1 is also promoter-specific as Runx1 
depends on other binding sites present in the regulatory regions of its target genes. 
Consequently, various combinations of these factors dictate the role of Runx1 in the 
transcriptional regulation of target genes (Table 1.8). The majority of these studies 
focused on specific genes known to be involved in the hematopoietic system. 
However, they are mainly based on in vitro studies, and whether their expression is 




















Table 1.7: RUNX1 interacting proteins.  
Interacting 
proteins  Description  Clinical leukemia association 
Activation   
ETS1  TF; ETS family  
ELF4 (MEF) TF; ETS family  
SPI1 (PU.1) TF; ETS family Point mutation in 7% of AML  
ELF2 
(NERF2) TF; ETS family  
CEBPA TF Point mutation in AML 
Pax5 TF; paired box gene t(9;12) Pax5-ETV6/TEL (ALL) 
MITF TF; bHLH-Zip family  
ZNFN1A1 
(Ikaros) TF; zinc finger 
t(3;7) Bcl6-Ikaros; high-level expression in ALL 
infants 
JUN (AP1) TF  
GATA1 TF Point mutations in DS - AMKL 
ATF2 
(CREBP1) Cyclic AMP   
LEF1 Architectural protein  
THOC4 




HAT t(8;16) CBP-MOZ 
SMAD3  Signaling molecule  
MYST3 
(MOZ) 
Histone acetyl transferase 
(HAT) t(8;16) CBP-MOZ 
Repression   
TLE1,2 
(Groucho) Protein interaction  
Sin3A Histone deacetylase  
NR2F6 (Ear2) Nuclear hormone receptor family  
ELF2 (NERF 
1a) TF; ETS family  
HDAC1,3,9 Histone deacetylases  
SUV39H1 Histone methyltransferase  





Table 1.8: Targets of Runx1 regulation 
Gene Description Affected cell type 
Growth factors   
GM-CSF Granulocyte-macrophage colony stimulating factor 
granulocytes, macrophages, 
eosinophils  & progenitors 
IL-3 Interleukin-3 mature/immature myeloid / lymphoid 
Receptors   
M-CSFR Macrophage colony stimulating factor receptor  
macrophages, monocytes / 
progenitors 
TCR α, β, γ, δ  T-cell receptors α, β, γ, δ chain  T-cell 
Surface molecules   
CD11a CD11a integrin T-cells, macrophages, neutrophils 
CD36  CD36 antigen; cell surface glycoprotein macrophages, monocytes 
Signal molecules   
BLK  B-lymphocyte specific tyrosine kinase B-cells 
p21CIP1 Cyclin dependent kinase inhibitor 1A myeloid / lymphoid 
Bcl-2 B- cell CLL/Lymphoma 2; prevent 
apoptosis 
myeloid / lymphoid 
p14ARF  Cyclin dependent kinase inhibitor 2A  myeloid / lymphoid 
CCND3  Cyclin D3  myeloid / lymphoid 
Transcription activators   
Fos Osteosarcoma viral oncogene homologue; AP-1 component  
Others   
MPO Myeloperoxidase Myeloid 
MMCP6  Mast cell protease 6  mast cells 
ELA2 Neutrophil elastase Myeloid 
GZMB  Granzyme B NK cells, cytotoxic T-cells, HSC 





1.2.3.1 Post-translational modification of Runx1 regulates its function 
The activity of Runx1 proteins are modulated by post-translational 
modifications such as phosphorylation and acetylation. ERK, a member of the MAPK 
family, phosphorylates RUNX1 on two serine residues at the beginning of the 
transactivation domain (TAD) (Figure 1.11) (Tanaka et al., 1996). This 
phosphorylation enhances the transactivation ability of RUNX1, but does not seem to 
affect its DNA-binding affinity. Phosphorylation of RUNX1 is thought to disrupt the 
interaction between RUNX1 and the co-repressor of transcription, Sin3A, activating 
the transactivation ability of RUNX1. Phosphorylation is also important for the 
turnover of the protein as the interaction with Sin3A protects RUNX1 from 
degradation. Phosphorylation of RUNX1 also plays a role in the subnuclear 
localisation of the protein to the nuclear matrix (Imai et al., 2004). In addition, a 
recent report from our group shows that HIPK2 phosphorylates heterodimerised-
RUNX1, on two Serine residues (249 and 273) and one Threonine residue (276) (Wee 
et al., 2008). This in turn induces the phosphorylation of p300 (Wee et al., 2008). 
Conversely, p300 has been shown to acetylate two Lysine residues (24 and 43), 
present N-terminal to the Runt domain, which leads to increased DNA binding 
affinity of RUNX1. Acetylation of these two residues also increases the 
transactivation activity of RUNX1, but does not affect heterodimerization with 
CBFβ/PEBP2β (Yamaguchi et al., 2004). 
Finally, a negative regulatory region that regulates DNA-binding activity and 
also dimerization with CBFβ/PEBP2β is found in the long RUNX1 isoforms. The 
conformation of these regions can change by interaction with other TF, thus allowing 
interactions with DNA. For example, the interaction between ETS-1 and RUNX1 
leads to reciprocal stimulation of their DNA affinity and activation of their 
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transactivation function by changing their 3D structure, leaving the DNA-binding 
domain unprotected and free for binding (Kim et al., 1999). 
 
1.2.4 Runx1 in hematopoiesis 
The TF Runx1, previously also known as PEBP2aB, AML-1, or CBFa2, is 
essential for definitive hematopoiesis (Speck et al., 1999).  Runx1 is a TF required for 
HSC formation, and is also an early marker for sites of hematopoietic cell emergence 
in the embryo (Cai et al., 2000; Ciau-Uitz et al., 2000; Kalev-Zylinska et al., 2002; 
Lacaud et al., 2002; North et al., 1999; North et al., 2002; Okuda et al., 1996; Rhodes 
et al., 2008; Wang et al., 1996; Zeigler et al., 2006).  The hematopoietic potential of 
Runx1 is closely related to its transcriptional activity (Goyama et al., 2004). Although 
the role of Runx1 in primitive hematopoiesis is less known than its role in definitive 
hematopoiesis, Runx1 has been implicated in primitive hematopoiesis in zebrafish 
and xenopus embryos (Kalev-Zylinska et al., 2002; Tracey et al., 1998), and more 
recently in mouse (Yokomizo et al., 2008) (Table 1.1). 
Runx1 knockout mice have largely illustrated the role of Runx1 in 
hematopoiesis. In WT mice, Runx1 expression is seen as early as E6.5 and is seen 
from about E8-E8.5 at all sites from which definitive hematopoietic cells emerge later, 
such as the YS, the VU and the AGM region (North et al., 1999; Goyama et al., 2004; 
Samokhvalov et al., 2007) (Figure 1.1). A Runx1 null mutation results in embryonic 
lethality, associated with a complete absence of definitive FL hematopoiesis and 
central nervous system (CNS) hemorrhage, at day 12.5 in mouse (Okuda et al., 1996; 
Wang et al., 1996). (Figure 1.14). Runx1 likely acts upstream of c-myb and PU.1, 
since Runx1-/- YS, AGM, or FL lacks c-myb or PU.1 expression, whereas the same 
tissues in c-myb-/- embryos do express Runx1 (Okada et al., 1998). More precise 
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Figure 1.14: Runx1 knockout embryos lack definitive hematopoiesis. Runx1 
knockout mice die at E12.5 due to absence of fetal liver hematopoiesis. Arrowhead 
shows areas of hemorrhaging.  Blue arrow points to the fetal liver of Runx1+/+ embryo 
which has a reddish hue indicative of definitive hematopietic cells in the liver. This 
reddish hue is clearly absent in Runx1-/- embryo. 
 
 
Runx1 plays an important role in the production of definitive hematopoietic 
cells from the hemogenic endothelium, visualised as intra-aortic cell clusters (Hirai et 
al., 2005; Speck et al., 1999). Runx1 is preferentially expressed in hemogenic EC and 
Runx1 serves to repress Flk-1 during the development of hemogenic EC into 
hematopoietic cells (Hirai et al., 2003; Hirai et al., 2005). Consequently, Runx1 
knockout embryos are unable to generate clusters of definitive hematopoietic cells in 
the AGM region (Figure 1.15) (Yokomizo et al., 2001) and they die at E12.5 (Okuda 
et al., 1996; Wang et al., 1996). Recent report confirms that Runx1 function is 
essential in EC for the formation of HSC/progenitor cells from the vasculature but not 
thereafter (Chen et al., 2009). Hemorrhaging is also seen in the Runx1 knockout 
embryos. The areas where hemorrhages occur are very specific and correspond to 
areas of high expression of Runx1. Cellular necrosis precedes hemorrhaging, 
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suggesting a developmental defect in the EC of the central nervous system capillaries 
(Wang et al., 1996). However, another mechanism was proposed for the 
















Figure 1.15: Absence of hematopoietic cell clusters in the DA, vitelline artery, 
and umbilical artery of a Runx1-/- embryo (E10.5). Wholemount immunostaining with 
anti-c-Kit antibody and subsequent transfer into BABB (benzyl alcohol and benzyl benzoate) 
solution revealed the hematopoietic cell clusters present within the DA, vitelline artery and 
umbilical artery. (A-D) The side view of the embryo proper. Arrowheads indicate the ventral wall 
of the DA. In a Runx1+/+ embryo, many c-Kit+ cells are attached to the ventral wall of the DA (A), 
whereas no c-Kit+ cells are present in the corresponding region of the Runx1-/- embryo (B). (C, D) 
Higher magnifications of (A, B), respectively. Note that the budding-like, c-Kit1 hematopoietic 
cell clusters seen in the Runx1+/+ embryo (C) are absent in the Runx1-/- embryo (D). Similar 
results were obtained in the vitelline (E, F) and umbilical (G, H) arteries. The size of 
hematopoietic cell clusters in the vitelline and umbilical arteries are larger than those seen in the 
DA. Scale bars: A, B . 40 mm; C, D . 10 mm; E, F . 20 mm; G, H . 15 mm. DA, dorsal aorta; NT, 
neural tube.  (modified from Yokomizo et al., 2001) 
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 Conditional Runx1 knockout mice demonstrated the role of Runx1 in adult 
mouse hematopoiesis (Growney et al., 2005; Ichikawa et al., 2004b; Motoda et al., 
2007; Putz et al., 2006; Taniuchi et al., 2002). Runx1-excised adult mice have an 
expanded, immunophenotypically defined HSC compartment. These mice survive for 
more than a year, indicating that there is LT-HSC activity in these animals. This 
finding is surprising in light of the hematopoietic defect observed in conditional 
Runx1 knockout embryos, which led to the conclusion that Runx1 may be dispensable 
for maintenance of HSC in adult hematopoiesis. On the other hand, Runx1 is required 
for efficient lymphoid maturation at multiple stages of differentiation. There is a 
significant reduction in the number of mature peripheral blood (PB) B-cells and BM 
derived B-cell precursors in primary Runx1-excised mice which suggests a significant 
block in B-cell maturation. In the T-cell lineage, there is a specific block in T-cell 
maturation during the transition from the double negative (DN)2 (CD44+CD25+) to 
the DN3 (CD44-CD25+) stage.  In contrast to the pronounced inhibition of the 
lymphoid lineage, excision of Runx1 does not inhibit maturation of the myeloid 
lineage.  Runx1-excised mice demonstrate expansion of the myeloid lineage by 
several phenotypic and functional criteria, with no evidence of a block in myeloid 
development. Runx1 loss has no apparent effect on the erythroid lineage, but it does 
have a significant effect on megakaryocytic maturation. Runx1 is required for normal 
maturation of the megakaryocyte lineage but not for the establishment of this lineage, 
leading to an accumulation of megakaryoblasts in Runx1-excised mice. Thus, Runx1 
deficient mice have a higher number of HSC/progenitor cell fractions, show abnormal 
differentiation of megakaryocytes leading to accumulation of megakaryoblasts and 
thrombocytopenia, and accumulation of immature lymphocytes cells due to defective 
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T- and B-cell development (Figure 1.16). However, the lack of Runx1 in adult mice 




Figure 1.16: Adult hematopoiesis and affected lineages due to Runx1 deficiency. 




Ichikawa et al. did not report the development of leukemia or other disease 
phenotypes in their conditional Runx1 knockout model. Another Runx1 conditional 
knockout mouse model developed by Taniuchi et al. which was also investigated by 
our group (Motoda et al., 2007) did not show any spontaneous leukemia phenotypes. 
Growney et al. showed a mild myeloproliferative phenotype in Runx1 excised mice, 
with mild expansion of myeloid cells in the BM and spleen. Nevertheless, there was 
no spontaneous leukemia development in these mice. Putz et al. also showed the 
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moderate myeloproliferation with splenomegaly in their Runx1 conditional knockout 
model and some of the mice progressed to develop lymphoma at late stages of 
adulthood.  
  
1.2.5 Runx1 and leukemia 
The role of Runx1 in hematopoiesis is further highlighted by its role in human 
diseases, particularly leukemia. The RUNX1 gene is one of the most frequently 
mutated genes in human leukemias and genetic alterations of this gene are found in 
approximately 30% of all human acute leukemia. Both chromosomal translocation 
mutants of RUNX1 and its partner PEBP2β, and point mutants of RUNX1 have been 
implicated in human diseases (Table 1.9). For example, one of the most frequent 
translocations of the RUNX1 gene is the t(8;21) that fuses RUNX1 to the Eight twenty-
one (ETO) gene (Licht, 2001). This translocation is found in 40% of patients with the 
AML M2 leukemia subtype. In addition, somatic point mutations in the RUNX1 gene 
have been identified in various sporadic myeloid malignancies including various 
AML subtypes, atypical chronic myeloid leukemia (CML) and myelodysplastic 
syndrome (MDS) (Osato, 2004; Osato et al., 1999; Osato et al., 2001). While 
monoallelic mutations in RUNX1 may predispose myeloid hematopoietic 
stem/progenitor cells to the development of a hematological malignancy, biallelic 
RUNX1 point mutations have been observed and are tightly associated with the AML 
M0 subtype (Table 1.9), characterized by minimal differentiation and accumulation 
of immature myeloid cells or blasts (Osato et al., 1999; Preudhomme et al., 2000). 
Furthermore, germ-line monoallelic RUNX1 mutations have been identified in 
pedigrees with an autosomal dominant familial platelet disorder (FPD/AML; 
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(Michaud et al., 2002; Song et al., 1999) wherein affected individuals develop 
thrombocytopenia and show a propensity to develop AML. 
 
Table 1.9: Description of selected leukemia subtypes and associated genetic 
defect. 
Type FAB Subtype Phenotype Associated genetic defects 
AML M0 Undifferentiated Biallelic RUNX1 mutations 
 M1 Myeloblastic with maturation  
 M2 Myeloblastic with maturation t(8;21) RUNX1-ETO 
 M3 Promyelocytic t(15;17) PML-RARα 
 M4 Myelomonocytic  
 M4Eo Myelomonocytic with BM eosinophilia inv(16) CBFβ-MYH11 
 M5 Monocytic  
 M6 Erythroleukemia  
 M7 Megakaryoblastic GATA1 mutation in DS patients, Overdosage of Runx1? 
ALL B Lymphocytic B-cell leukemia t(21;12) TEL-RUNX1 
 T Lymphocytic T-cell leukemia  
CML  Myelocytic t(9;22) BCR-ABL 
CLL  Lymphocytic  
MDS    
 
 
Increased RUNX1 gene dosage may be responsible for the leukemia 
predisposition observed in Down syndrome (DS) patients with a constitutional 
trisomy 21. The most frequent AML subtype observed in these children is the AML 
M7 subtype acute megakaryocytic leukemia. The etiological role of trisomy 21 in 
leukemogenesis is proposed to stem from increased proliferation of leukemic 
progenitor cells due to overexpression of a tumorigenic protein coded on the human 
chromosome 21 gene, such as RUNX1 (Osato and Ito, 2005). Interestingly, trisomy 21 
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is also among the most commonly observed acquired chromosomal abnormalities in 
leukemic BM, particularly in acute lymphoblastic leukemia (ALL) (Berger, 1997). 
Extra copies of RUNX1 (2-8 copies) due to tandem repetition of chromosome 21 or 
the presence of a non-constitutional chromosome 21 were also observed in several 
patients with ALL (Ferro et al., 2004; Mikhail et al., 2004). Together, an increase of 
RUNX1 dosage may also contribute to leukemogenesis. 
 
1.2.6 Regulation of Runx1 expression 
In contrast to the vast knowledge available on how Runx1 regulates the expression of 
downstream target genes, there is limited information on how Runx1 itself is 
transcriptionally regulated. Undoubtedly, Runx1 expression is strictly regulated in 
vivo, in different cell types and in response to physiological stimuli, at both the 
transcriptional and posttranscriptional levels (Pozner et al., 2000). In vertebrates, 
transcription of Runx1 is initiated at two promoter regions, the distal (P1) promoter 
and the proximal (P2) promoter (Ghozi et al., 1996; Miyoshi et al., 1995). Functional 
analyses using cell-based in vitro transfection assays have demonstrated that the P1 
and P2 regions of the Runx1 possess promoter activity (Ghozi et al., 1996). 
Interestingly, the RUNX1 P1 isoform is negatively regulated at the transcriptional 
level through the binding of the P2 isoform of RUNX3 to RUNX sites present in the 
RUNX1 P1 promoter in human B cells (Spender et al., 2005). Furthermore, the 
activity of the Runx1 P1 promoter is positively regulated by cotransfected Runx1 
(Pimanda et al., 2007a), consistent with a predicted autoregulatory loop (Levanon and 
Groner, 2004). In addition, Smad1, a positive mediator of Bmp4 signaling, binds to 
the Runx1 promoter resulting in transactivation of the promoter (Pimanda et al., 
2007a). Taken together, these data suggest that the regulation of Runx1 P1 isoform 
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expression has the potential to be heavily dependent on regulation at the 
transcriptional level. The expression of the Runx1 P2 isoform, on the other hand, has 
been shown to involve translation control via an IRES mechanism associated with the 
5’ untranslated region (UTR) unique to the P2 isoform which supports tightly 
regulated translation (Pozner et al., 2000). Furthermore, microRNA (miRNA) binding 
sites present on Runx1 3′UTR allows for the binding of miRNAs which post-
transcriptionally attenuate the expression of Runx1 and suppresses Runx1 protein 
expression (Ben-Ami et al., 2009; Fontana et al., 2007). 
In mouse embryos, Runx1 is expressed in a number of tissues at different time 
points during development (Figure 1.1, Table 4.2) (North et al., 1999; Nottingham et 
al., 2007; Samokhvalov et al., 2007; Simeone et al., 1995). Irregular and low-level 
Runx1 expression is seen as early as E6.5, mostly in the ectoplacental cone and extra-
embryonic visceral endoderm (Samokhvalov et al., 2007). At slightly later stages, 
Runx1 expression is seen at all sites from which definitive hematopoietic cells emerge 
later, such as the extra-embryonic YS (Lacaud et al., 2002; North et al., 1999), the P-
Sp (Nottingham et al., 2007), allantois and the chorion (Lacaud et al., 2002; Zeigler et 
al., 2006), the VU (North et al., 1999), the AGM region (North et al., 1999) and the 
placenta (Rhodes et al., 2008). Furthermore, the precise regulation of Runx1 
expression is exemplified by Runx1 expression within a transient population of EC 
populating the floor of the DA in the AGM region, as well as EC in the VU, where 
definitive hematopoietic cells are thought to emerge (North et al., 1999) from E10.5 
to E11.5 and Runx1 expression in these cells is rapidly down-regulated after E12 
(Pimanda et al., 2007a). Of note, Runx1 expression is also detected in some non-
hematopoietic tissues, such as the olfactory epithelium, spinal ganglia and maxillary 
processes at about E9.25-E10 (North et al., 1999; Samokhvalov et al., 2007). In adults, 
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Runx1 is expressed mainly in the hemapoietic system and reproductive tissues 
(Figure 2.4) (Miyoshi et al., 1995; Satake et al., 1995).   
In early zebrafish embryogenesis, runx1 is expressed in two discrete 
hematopoietic regions; the anterior lateral-plate mesoderm (ALM), which generates 
primitive myeloid cells, and the posterior lateral-plate mesoderm (PLM) from which 
primitive erythroid cells develop (Hsia and Zon, 2005). By around 18 hpf, cells in the 
PLM have migrated medially to form a central rod of hematopoietic precursors: the 
ICM. Hematopoietic expression of runx1 is downregulated in all but the most 
posterior cells of the ICM at 21 hpf, and subsequently reappears in definitive 
hematopoietic precursors in the ventral wall of the DA by 24 h.p.f. (Kalev-Zylinska et 
al., 2002). runx1 is also expressed in Rohon-Beard (RB) mechanosensory neurons and 
in specific neuronal cells (Kalev-Zylinska et al., 2002).  
Evidently, the expression of Runx1 is strictly regulated, spatially and 
temporally. Furthermore, the level of Runx1 expression is important and is likely to be 
regulated; germ-line deletion of both Runx1 alleles results in the absence of HSC 
(Nakagawa et al., 2006; North et al., 1999; Yokomizo et al., 2001), whereas 
haploinsufficiency results in early emergence of HSC in the AGM (Cai et al., 2000).  
However, detailed information about the positive and negative elements that regulate 
the spatially and temporally correct expression of Runx1 in the appropriate amounts, 
in vivo, remains largely unknown. Owing to the very large Runx1 gene locus (which 
spans approximately 1-Mb from neighbouring gene to neighbouring gene; 
furthermore, the distance between the P1 and P2 promoters alone span approximately 
120-kb) and the complex Runx1 gene structure, the search for regulatory regions 
outside of the immediate promoters proved to be a very daunting task. 
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Nevertheless, studies have been undertaken to elucidate the mechanisms by 
which the expression of Runx1 is regulated. Studies in zebrafish (Burns et al., 2005; 
Gering and Patient, 2005) and mice (Nakagawa et al., 2006) have shown that Runx1 is 
a transcriptional target of Notch signaling during definitive hematopoiesis. In 
zebrafish, Hedgehog signaling is required for the migration of hematopoietic 
progenitors to the midline, and for the subsequent formation of runx1+ definitive 
precursors (Gering and Patient, 2005). Early PLM runx1 expression appears to be 
downstream of a Hox pathway regulated by caudal-related homeobox genes cdx1a 
and cdx4 (Davidson et al., 2003; Davidson and Zon, 2006). Recent findings show that 
cohesin, a protein complex composed of four major subunits: SMC1, SMC3, RAD21 
and SA1, has a novel role in the specific regulation of early hematopoietic runx1 
expression in zebrafish, independent of both the Notch and Hox pathways (Horsfield 
et al., 2007). Notably, later initiation of neuronal runx1 expression is not cohesin-
dependent (Horsfield et al., 2007). Despite the reporting of several signaling pathways 
and TF which act upstream of Runx1 in these studies, no cis-regulatory elements were 
identified. 
 Recently, advances in ChIP technology paved the way for the identification of 
a conserved intronic enhancer element. This element was found to be regulated via the 
binding of a particular form of p63, ΔNp63, in mouse keratinocytes (Ortt et al., 2008). 
Since only the Runx1 P2 isoform is expressed in the skin, it remains to be determined 
whether this element regulates the expression of the Runx1 P1 isoform in other cell-




1.3 Aims of the project 
The general aim of this PhD project is to elucidate the transcriptional mechanisms 
regulating the spatially and temporally correct expression of Runx1. More specifically, 
given the important role of Runx1 in hematopoiesis, emphasis was placed on the 
identification of cis-regulatory elements which specifies hematopoietic-Runx1 
expression. The ultimate goal is to identify regulatory elements which are mutated or 
contain SNPs that are associated with human diseases such as leukemia.  
The search for a cis-regulatory element using an initial combinatorial in silico 
approach followed by in vivo verification of regulatory function in zebrafish, finally 
led to the identification of a conserved intronic Runx1 enhancer element which targets 
sites of hematopoiesis where Runx1 is expressed. Consistent with initial findings, this 
enhancer appeared to specifically mark clusters of HSC/progenitor cells in sites of de 
novo hematopoiesis in the early Tg mouse embryo. This discovery by means of 
simple microscope imaging of Tg mouse embryos prompted a series of experiments 
aimed at determining whether this Runx1 enhancer specifically marks HSC. 
Ultimately, the aim is to firmly establish this Runx1 enhancer as a useful molecular 
handle for the visualization and manipulation of HSC activity, in both in vitro and in 
vivo experimental settings. 
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Chapter 2 – cDNA cloning of Runx family genes from the pufferfish 
(Fugu rubripes) 
 
To improve our understanding of the functions of Runx genes, a comparative 
genomics approach was adopted. Comparative genomics is a powerful tool for 
identifying evolutionarily conserved protein domains that are likely to be important in 
the activity of the protein in question. It also facilitates the identification of conserved 
CNE in the promoter, intronic and intergenic regions that are likely to be involved in 
the regulation of gene expression. The pufferfish (Takifugu rubripes) is among the 
evolutionarily most distant (450 million years) of bony vertebrates from mammals. 
Furthermore, it has the smallest vertebrate genome, which has been fully sequenced 
(Aparicio et al., 2002). Hence, the fugu genome is an attractive reference in 
comparative genomics approaches that seek to identify evolutionarily conserved 
domains and CNE (Venkatesh and Yap, 2005). 
Computational predictions of Runx family genes in the fugu genome assembly 
identified four members, namely frRunx1, frRunx2, frRunx3 and frRunt (Eggers et al., 
2002; Glusman et al., 2004; Rennert et al., 2003). In this study, we verified these 
predictions by reverse transcription-PCR (RT-PCR) and rapid amplification of cDNA 
ends (RACE) analyses. The transcription start sites (TSS) and the exon–intron 
boundaries of the frRunx genes were thus defined, and different splice isoforms of 
these frRunx genes were cloned. Cloning of frRunt revealed a transcript that encodes 
an amino acid sequence that differs from computational predictions (Glusman et al., 
2004). In addition, we identified the equivalent of mammalian CBFB in fugu for the 
first time and have named it frCbfb. 
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2.1 Cloning and characterization of fugu α-subunit Runx family members 
The structural features of the fugu Runx genes were derived by mapping the frRunx 
cDNA sequences cloned in this study to the genomic sequence and are depicted in 
Figure 2.1. Like their mammalian counterparts, all frRunx genes have two alternative 
promoters denoted as P1 and P2 that are separated by a characteristically large intron. 
Most of the frRunx introns conform to the GT/AG rule and the exon–intron 
boundaries are largely conserved. However, the structure of the frRunx1 gene does 
differ from its mammalian homologue: while mammalian Runx1 has a single exon 2, 
in fugu this exon is split by additional introns (asterisks in Figure 2.1) into the three 
exons 2, 2.1 and 2.2. In addition, while mammalian Runx3 has seven exons, frRunx3 
has eight exons (like frRunx1 and frRunx2). Regarding the extra exon (exon 5.1) in 
frRunx3 (arrowhead in Figure 2.1), it is not clear whether it is due to a split from 
exon 5 or exon 6 since the amino acid residues encoded by exon 5.1 showed no clear 
homology to those of the neighboring exons of the mammalian Runx3 genes.  
Mammals express many different Runx isoforms arising from the use of 
alternative promoters and termination sites along with extensive alternative splicing 
(Bae et al., 1994; Bangsow et al., 2001; Levanon et al., 1996; Levanon et al., 2001; 
Miyoshi et al., 1995; Stewart et al., 1997; van Wijnen et al., 2004; Zhang et al., 
1997b). Of the isoforms generated by Runx1/AML1, three occur in particular 
abundance, namely AML1a (Runx1/p27), AML1b (Runx1/p49), and AML1c 
(Runx1/p52). AML1a and AML1b are P2-promoter-driven isoforms while AML1c is 
a P1-promoter-driven isoform. From fugu mRNA, we cloned frRunx1 isoforms that 
are equivalent to AML1a, AML1b and AML1c: these are referred to as frRunx1/p29, 
frRunx1/p53 and frRunx1/p54, respectively (Figure 2.1A). frRunx1/p29 mRNA 
encodes a 29 kDa protein with a C-terminal truncation due to alternative splicing in 
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exon 5 (Figure 2.1A). The full-length P1 and P2 isoforms, frRunx1/p54 and 
frRunx1/p53, are characterized by the C-terminal VWRPY sequence and are 
generated by an alternative splicing donor site present in exon 5 that is located 20 
nucleotides before the termination codon for the truncated frRunx1/p29 form. Two 
other P1 isoforms, frRunx1/p50 and frRunx1/p21 have been identified (Figure 2.1A). 
Isoforms similar to frRunx1/p29, frRunx1/p53 and frRunx1/p54 were cloned 
for frRunx2 and frRunx3 (Figure 2.1B and C). Two stop codons after the runt domain 
were identified in frRunx2 and frRunx3, one in exon 5 and the other in exon 6; the 
former results in the truncated product and the latter in the full length form of the 
frRunx protein. In addition, a P2 isoform frRunx2/p43 and a P1 isoform frRunx3/p41 





































Figure 2.1: Cloning of fugu α-subunit Runx genes. Schematic representation of the 
genomic structures and transcript isoforms of (A) frRunx1, (B) frRunx2, (C) frRunx3 
and (D) frRunt. The boxes indicate exons while the solid horizontal lines indicate 
introns. The vertical dashed lines indicate the internal splice sites located within an 
exon. The vertical solid lines indicate the polyA tail sites within exons. The Runt 
domains are indicated in grey. The two promoters are denoted as P1 and P2. The 
partially shaded boxes indicate 5′- and 3′-UTRs obtained from RACE results which 
have not been confirmed to be associated with the individual isoforms cloned. The 
asterisk (*) indicates additional introns present in the frRunx1 gene that are absent in 
the human RUNX genes. The sharp (#) highlights a P1 isoform of frRunx1 whose 
ATG start site has not been confirmed; the 50 kDa protein predicted is based on the 
first ATG identified from the cloned sequence. The arrowhead (▼) indicates an exon 
in frRunx3 that is absent in mammalian Runx3. 
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2.2 Comparison of frRunx α-subunit protein sequences with human Runx α-
subunit protein sequences 
Alignment of the P1 and P2 full-length isoforms of the frRunx proteins with human 
RUNX sequences revealed several highly conserved protein domains (Figure 1.11). 
As expected, the 128 amino acid Runt domain that is critical for DNA-binding and 
heterodimerisation with the β subunit is highly conserved throughout all α-subunit 
Runx proteins, regardless of whether they are from fugu or human. The NLS is also 
highly conserved. However, regions outside the Runt domain are less conserved apart 
from the VWRPY, PY motif and phosphorylation sites of Erk/cdc2. With regard to 
these sequences, the PY and VWRPY motifs are known to modulate the 
transcriptional activities of the Runx proteins by recruiting different interacting 
proteins. In human RUNX1/p49, serine/threonine residues 249 and 266 followed by 
proline residue are phosphorylation sites for Erk (Tanaka et al., 1996; Zhang et al., 
2004). In addition, in human RUNX2, the consensus phosphorylation site for cdc2, 
(S/T)PX(R/K), which starts at amino acid residue 451, is reported to be 
phosphorylated (Qiao et al., 2006). All three phosphorylation sequences are 
remarkably conserved amongst all α-subunit Runx proteins (Figure 1.11B). 
The N-termini of the P1 isoforms beginning with MAS(D/N)S are highly 
conserved whereas those of P2 isoforms vary among the frRunx proteins. 
Consequently, the N-termini for the frRunx1, frRunx2 and frRunx3 P2 isoforms are 
MVFLWDAKY, MRPIV, and MHIPV, respectively. The N-terminus of the frRunx1 
P2 isoform appears to be a teleost-specific feature since this sequence, which differs 
markedly from its mammalian counterparts, is identical to that of zebrafish (Kataoka 
et al., 2000). 
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A stretch of eight histidine residues located shortly after the Runt domain was 
found in fugu Runx1 but not in its human counterpart. Conversely, the stretch of 23 
glutamine residues followed by 17 alanine residues found in human RUNX2 is not 
present in frRunx2. There is one glutamine residue close to a stretch of four alanine 
residues in frRunx2 that may have expanded during evolution to form the Q/A stretch 
that is unique to the mammalian Runx2 genes (29Q/18A in the mouse and 31Q/17A 
in the rat) (Eggers et al., 2002; Fondon and Garner, 2004). It has been proposed that 
the Q/A stretch inhibits the heterodimerisation of Runx2 and PEBP2β 
(Thirunavukkarasu et al., 1998). Moreover, it has been found that when the number of 
alanines in the Q/A stretch increases to 27 residues, RUNX2 malfunctions which 
generates a CCD phenotype (Mundlos et al., 1997). 
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2.3 Cloning and characterization of frRunt 
frRunt spans a mere 3-kb and thus is much smaller than the other frRunx genes 
(Figure 2.1D). Its mRNA codes for a 33 kDa protein. Consistent with its small size, 
the frRunt protein shares little similarity to other canonical Runx proteins apart from 
the Runt domain and the C-terminal VWRPY sequence (Figure 1.11). Part of the 
amino acid sequence at the C-terminal moiety of frRunt, which was cloned from fugu 
gill mRNA, differs from that previously predicted in silico by Glusman et al. Exon 1 
to exon 4 of frRunt cloned is completely the same as what was previously predicted. 
However, the start and end of exon 5 is located five nucleotides before and 16 
nucleotides after that predicted respectively. In addition, exon 6 of cloned frRunt 
starts 38 nucleotides earlier than predicted. It thus appears that the difference between 
the predicted and the cloned sequences of frRunt is likely to have arisen from 
misprediction of splice sites in exons 5 and 6. 
 Although the function of the frRunt gene remains unknown, its origin is 
extensively discussed in the paper published by Glusman et al., and can be 
summarised as follows. Based on phylogenetic analysis, frRunt appears to represent 
an ancestral form of the Runx family in vertebrates, subsequently lost in the tetrapod 
lineage.  Additionally, gene structure analysis shows interlocking of the frRunt with 
frSupt3h, reminiscent of the synteny observed in the human RUNX2 gene (Figure 
2.2). Furthermore, the nucleotide similarity of first exon of frRunt to the first exon of 
Runx2 suggests that frRunt is a derivative of frRunx2. However, the amino acid 
sequence of frRunt appears to be of equidistant from all three frRunx genes. The 
conundrum as to whether frRunt is an ancestral form or is derived from Runx2 is well 
discussed through the various hypothesis put forth by the authors (Glusman et al., 
2004). 
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 Figure 2.2: Comparative genomic organization. The genomic neighborhoods of the 
human and fugu Runx genes are compared and contrasted, highlighting synteny 
conservation (same color between the two species) and gene loss (green features). 
Feature widths represent rough gene size but are not exactly proportional to gene 
lengths; likewise intergenic distances are not meant to be precise. Arcs indicate larger 
genomic distances with one or more intervening genes (not displayed). The numbers 
associated with the arcs represent the distance in Mb. Boxes in green represent 
regions absent in human. (Glusman et al., 2004) 
 
 
Cloning and characterization of frCbfb 
Screening for the β subunit-encoding gene in the fugu genome identified two 
scaffolds, namely, #3714 and #2060 (Figure 2.3A). Sequencing of RACE and RT-
PCR products revealed that frCbfb spans approximately 13-kb, which is 5.5 times 
smaller than its 72-kb human orthologue. All the frCbfb introns conform to the 
GT/AG rule and conservation of the genomic structure between human CBFB and 
frCbfb genes was very high (Figure 2.3A). Two isoforms of frCbfb that are 
homologous to hsCBFB types 1 and 2 were isolated. The type 1 and type 2 frCbfb 
encode proteins of 175 and 189 amino acids, respectively. The two isoforms are 
largely similar except for the C-terminal end, which results from differential 
termination exon usage (Figure 2.3B). An isoform that corresponds to hsPEBP2β 
type 3 was not identified in fugu in our current work. At the protein level, frPebp2β 
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shows high conservation of amino acid residues 1 to 165 (before the vertical dashed 
line in Figure 2.3B), which is required for heterodimerisation with α subunits and 




Figure 2.3: Pebp2β subunit proteins from fugu and human. (A) Cloning of 
frCbfb. Schematic representation of the genomic structure of frCbfb and the two 
transcripts cloned (frCbfb types 1 and 2). The boxes indicate exons and the solid 
black horizontal lines indicate introns. The vertical dashed lines indicate an internal 
splice site located within an exon. The 5′ and 3′ UTRs are represented as partially 
shaded boxes. (B) Sequence alignment of fugu and human Pebp2β amino acid 
sequences by using ClustalV. fr, Fugu rubripes; hs, Homo sapiens. The regions 
(amino acids 1–165) before the vertical dashed line are highly conserved and are 
known to be important for heterodimerisation with α-subunit proteins. 
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2.5 Expression of frRunx family genes 
mRNA expression of the frRunx family genes was investigated in a variety of fugu 
tissues by RT-PCR (Figure 2.4). Hematopoietic tissues in fugu, namely the blood, 
kidney and spleen express all three forms of frRunx mRNAs (Figure 2.4A), mirroring 
the expression of Runx genes in mouse hematopoietic organs comprising blood, BM, 
spleen and thymus (Figure 2.4B). In fugu, the kidney serves as a source for blood 
cells throughout life like BM in mammals. The low expression of frRunx1 in blood is 
likely due to poor quality of the RNA obtained from fugu blood, since the level of β-
Actin amplified is significantly lower than the other tissues. Additionally, all three 
frRunx mRNAs are expressed in fugu gills, heart, intestine and stomach, while frRunt 
is only expressed in the gills and testis. Surprisingly, the fugu heart expressed all three 
frRunx mRNAs while the mouse heart did not show expression of all three Runx 
genes. The fugu brain predominantly expressed frRunx2, corresponding to results 
obtained from mouse brain albeit low levels of mmRunx2 was detected. Expression of 
Runx genes in the fugu gonads (ovary and testis) differs from that in mouse. Mouse 
gonads expressed all three Runx mRNAs (Figure 2.4B) while fugu ovary and testis 
lack the expression of frRunx2 and frRunx3 respectively (Figure 2.4A). Interestingly, 
the expression of Runx1 and Runx2 was not detected in both the fugu and mouse 
livers which expressed only extremely low levels of Runx3. As expected, frCbfb was 
ubiquitously expressed, although there was a difference between type 1 and 2 
expressions: while type 2 was expressed at high levels in all tissues examined, type 1 
was expressed weakly in several tissues (Figure 2.4A). Differential expression of the 
P1 and P2 isoforms of frRunx1 was also observed (Figure 2.4C). In particular, the P2 
isoform was generally expressed at much higher levels than the P1 isoform.  
Interestingly, the P1 promoter-driven frRunx1 isoform was expressed in greater 
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abundance in fugu kidney and thymus compared with other tissues, which is 
consistent with the high expression of the P1 isoform in mouse hematopoietic stem 





Figure 2.4: Expression patterns of fugu Runx family genes. (A) The frRunx and 
frCbfb cDNAwere amplified by using primers complementary to the respective genes. 
frβ-Actin-1 was amplified as a control. (B) The mouse Runx and Cbfb cDNA were 
amplified by using primers complementary to the respective genes. Mouse Gapdh was 
amplified as a control. (C) The P1 and P2 isoforms of frRunx1 were amplified by 
semi-nested multiplex PCR that employed 2 rounds of PCR. frβ-Actin-2 serves as a 
control. 
 74
2.6 Promoter analysis 
2.6.1 frRunx1 promoter region 
The TSS of the frRunx1 P1 and P2 promoters were mapped by 5′-RACE to positions 
1659-bp and 397-bp upstream of the P1 and P2 start codons, respectively. Analysis of 
the frRunx1 P1 and P2 regions revealed significantly different repertoires of 
transcription factor binding sites (TFBS) (Figure 2.5A). Similar to those of human 
Runx1 promoters, three Runx-binding sites at positions -211, -174 and -139 were 
found in the P1 promoter while none were detected in the P2 promoter region. Many 
of the TFBS in the frRunx1 P2 promoter regions were conserved relative to the 
human sequence. However, putative c-Myb and GATA-binding sites were present 
only in fugu. 
 
2.6.2 frRunx2 promoter region 
The TSS of the P2 promoter of frRunx2 was determined by 5′-RACE. Significantly, 
the P2 promoter region used for analysis comprises a region that was previously 
predicted to be a conserved P2 promoter (Eggers et al., 2002). The TSS of the 
frRunx2 P1 promoter was determined by primer walking. The dotted horizontal line 
in Figure 2.5B highlights the sequence of the primer used to obtain the specific PCR 
product that maps to this region. An upstream primer with two bases that overlapped 
the underlined primer sequence failed to amplify significant product levels. Hence, it 
can be deduced that a TSS is probably located within a few bases of the position we 
have tentatively assigned as +1. Two Runx-binding sites were found in the 5′ UTR 
near the P1 promoter and one at position -357 in the P2 promoter. Auto-regulation of 
mammalian Runx2 transcriptional expression has been proposed (Drissi et al., 2000; 
Ducy et al., 1999), although its functional significance remains to be determined. 
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2.6.3 frRunx3 promoter region 
The TSS of frRunx3 P1 and P2 promoters were mapped by 5′-RACE to positions 638-
bp and 525-bp upstream of the P1 and P2 start codons, respectively (Figure 2.5C). 
Analysis of the promoter region reveals conserved CCAAT box and Sp1-binding sites 
that are reported to play a role in the basal activity of the human Runx3 P2 promoter 
(Bangsow et al., 2001). One Runx-binding site was identified in the P1 promoter 
region at position -171. 
 
2.6.4 Features seen in all fugu α-subunit Runx gene promoters 
Analysis of the TFBS in the P1 and P2 promoter regions of all the α-subunit frRunx 
genes reveals that CpG dinucleotides are significantly more abundant in the P2 
promoter regions (Figure 2.5). These CpG dinucleotides in fugu might have given 
rise to the CpG islands that characterise the P2 promoters in mammalian Runx genes. 
The presence of CpG islands in mammalian Runx genes suggests possible regulation 
by methylation. Consistent with this hypothesis, aberrant methylation of the Runx3 
promoter has been associated with human cancers (Lau et al., 2006; Li et al., 2002; 
Oshimo et al., 2004; Subramaniam et al., 2009; Tan et al., 2006; Tan et al., 2007). 
c-Myb and PU.1-binding sites were also found in all promoters analysed. 
Furthermore, Runx-binding sites were found in the P1 promoters of all α-subunit 
frRunx genes, which suggests either transcriptional auto-regulation or cross-
regulation among the Runx family genes. Interestingly, negative transcriptional cross-
regulation of the RUNX1 P1 isoform by RUNX3 in human B cells has been reported 


















































Figure 2.5: Fugu Runx family gene promoter regions. The sequences of the P1 and 
P2 promoter regions for frRunx1 (A), frRunx2 (B) and frRunx3 (C) are shown. The numbers 
indicate the positions relative to the TSS, which is indicated by a bent arrow. Putative TFBS 
identified by TESS are underlined and their names written above. TFBS present in human 
RUNX promoter regions as well are boxed. CpG dinucleotides are highlighted in grey. 
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2.6.5 frCbfb promoter region 
The TSS of frCbfb was mapped by 5′-RACE to a position 412-bp upstream of the 
start codon. TESS identified a number of putative binding sites that are conserved 
between the fugu frCbfb and human CBFB promoters (Figure 2.6). In addition, an 
abundance of putative c-Myb sites was also identified. The significance of these 
binding sites remains to be determined since the transcriptional regulation of CBFB 
remains largely unknown. 
 
Figure 2.6: frCbfb promoter analysis. The numbers indicate the positions relative to 
the TSS, which is indicated by a bent arrow. Putative TFBS identified by TESS are 
underlined and their names written above. TFBS also present in human CBFB are 





2.7 Comparative genomics using fugu Runx genes as a reference may help 
identify CNE 
A series of in vitro functional analyses using the DNA fragments arbitrarily cloned 
from the promoter regions of three mammalian α-subunit Runx genes has suggested 
possible cell type-specific promoter activity (Bangsow et al., 2001; Drissi et al., 2000; 
Fujiwara et al., 1999; Ghozi et al., 1996; Rini and Calabi, 2001; Xiao et al., 2001; 
Zambotti et al., 2002). However, the promoter regions are insufficient for driving the 
specific spatial and temporal expression of Runx genes, which has also been observed 
with regard to the transcriptional regulation of many other mammalian genes. Hence, 
it is likely that cis regulatory element(s) or enhancer/silencer(s) that govern the 
specific in vivo expression of Runx genes exist. The identification of the putative cis-
regulatory regions by conventional methods such as the DNase I hypersensitivity 
assay has been difficult due to the extremely large size of the mammalian Runx gene 
loci, which span over 200-kb. Instead, a better approach may be a comparative 
genomic study. Such a study is facilitated by our annotation of the frRunx family 
genes. The suitability of this approach is further suggested by the fact that the TFBS 
in frRunx promoters are highly conserved compared to human RUNX genes. These 
similarities suggest that the mechanisms that regulate the expression of the Runx 
genes of the two species, including the CNE-mediated enhancer/silencer effects, may 
have been maintained during evolution. A comparative genomic study using the 
frRunx family genes we have annotated may thus help identify the CNE that are 





2.8 First attempts at the identification of a Runx1 regulatory element 
Using information obtained from the cloning of fugu Runx genes, a comparative 
genomics approach was first taken to align the Runx1 gene locus using genomic 
sequences from human, mouse, rat, chicken and fugu (Figure 2.7). The fugu Runx1 
gene was used as the reference sequence. Two elements were identified (boxed out in 
red in Figure 2.7), one more evolutionarily conserved than the other. Interestingly, an 







Figure 2.7: Identification of highly conserved elements, termed PRE. VISTA plot 
obtained from global alignment of the, human, mouse, chicken and fugu Runx1 locus, 
using mLAGAN. Predicted regions of significant identity are shown as peaks. 
Conserved non-coding elements are shaded in pink; conserved exons are shaded in 
blue. The two elements identified are boxed out in red. The identical stretch of 
sequences found in both elements is boxed out in pink. A stretch of 28-bp which are 
100% conserved throughout all the organisms compared is underlined in red. 
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 Based solely on evolutionary conservation as a selection criterion, the 
regulatory function of a 1.5-kb fragment from fugu, named putative regulatory 
elements (PRE) comprising both of these conserved elements was assessed using an 
expression construct containing either the fugu distal (either 2-kb or 5-kb) or proximal 

















Figure 2.8: PRE drives EGFP expression but fails to target regions of 
endogenous Runx1 expression. Relative positions of the promoter and PRE used for 
construction of this expression construct is illustrated at the top. E1 and E2 denote 
distal-specific exons while E3 denotes the proximal-specific exon.  
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On its own, the 1.5-kb fugu PRE was able to drive low expression of EGFP 
(Figure 2.8B). The 779-bp fugu proximal promoter alone was able to drive 
constitutively strong expression of reporter gene in the zebrafish embryo whereas the 
distal promoter on its own failed to drive EGFP expression (Figure 2.8B). When the 
PRE was fused to the proximal promoter, strong EGFP expression was again 
observed (Figure 2.8B). However, like the proximal promoter, the PRE failed to 
target EGFP expression to sites of endogenous Runx1 expression in the zebrafish 
embryo (Figure 2.8B). Conversely, PRE appeared to cooperate with the distal 
promoter to drive EGFP expression in only very few cells in the RBI of the zebrafish 
embryo (Figure 2.8B). Taken together, these results suggest that although the fugu 
PRE has enhancer function it was insufficient to dictate the specific spatial-temporal 
expression of the reporter gene to regions/cells known to express endogenous Runx1. 
These preliminary results were not encouraging since I was trying to identify 
Runx1 regulatory elements which target regions of endogenous Runx1 expression in 
zebrafish. Hence, this work involving fugu promoters and fugu PRE was terminated. I 
continued to search for highly evolutionarily conserved elements by means of 
comparative genomics incorporating genome sequences from more organisms.  As 
expected, this new alignment confirms that this fugu PRE (highlighted in yellow) is 
highly conserved from fugu to human, across all organisms used for the comparison 
(Figure 4.1C). Instead of focusing on fugu-human conserved elements, I paid more 
attention to frog-human and chicken-human conserved elements which eventually led 
to the identification of an intronic Runx1 enhancer that is specific to sites of 
hematopoiesis and endogenous Runx1 expression. The successful identification of this 
Runx1 regulatory element is detailed in Chapter 4 of this thesis.  
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Chapter 3 – Retroviral Integration Sites (RIS)                                
mark cis-regulatory elements 
Transcription is a highly complex process in multicellular eukaryotic organisms, 
involving an elaborate orchestration of the core promoter and cis-regulatory elements 
which include enhancers, matrix attachment regions (MARs), locus control regions 
(LCRs), insulators and silencers (Pennacchio and Rubin, 2001), to drive 
spatiotemporally and quantitatively correct gene expression. Such cis-regulatory 
elements may reside in introns or within several kb up- and downstream of the 
transcription unit; in some extreme cases, they may even reside within neighbouring 
gene(s) one to several Mb away from the locus that they regulate. In addition to these 
intrachromosomal interactions, interchromosomal interactions between promoter and 
regulatory regions have also been implicated in coordinating gene expression 
(Spilianakis et al., 2005). Evidently, the scattered location of critical regulatory 
elements makes it difficult to define the appropriate region in which to perform a 
search for novel regulatory elements. 
The identification of cis-regulatory elements is central to the understanding of 
gene transcription and might explain mechanisms of human diseases. Defects in long-
range regulatory elements have recently emerged as previously underestimated factors 
in the genesis of human congenital disorders (Kleinjan and van Heyningen, 2005; 
Sabherwal et al., 2007). The deletion of a 39.5-kb LCR-containing region upstream of 
the β-globin gene is shown to cause Hispanic-type thalassemia, while common types 
of β-thalassemia are caused by mutations in the coding region (Schubeler et al., 
2000). Besides such obvious chromosomal changes, we are now aware of mere point 
mutations in non-coding regulatory regions being implicated, as exemplified by the 
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case of human preaxial polydactyly (PPD) where dysregulation of sonic hedgehog 
(shh) resulting from a single point mutation within an enhancer located 1Mb away 
produces a severe genetic defect (Gurnett et al., 2007; Lettice et al., 2003). 
Furthermore, in the case of cancer, somatic mutations accumulating in the 5’ non-
coding regulatory region of BCL-6 proto-oncogene are reported to be associated with 
lymphoma progression, namely the transformation of follicular lymphomas to more 
aggressive large cell lymphomas (Lossos and Levy, 2000a; Lossos and Levy, 2000b). 
It is foreseeable that the rapid identification of growing numbers of functional 
regulatory elements will pave the way for screening of these distally located elements 
for disease-associated mutations. 
3.1 Identification of cis-regulatory elements 
Several experimental approaches are currently available to identify distally located 
cis-regulatory elements. Of these, Tg approaches in animals is widely believed to be 
the best method. Large genomic constructs such as yeast artificial chromosome 
(YAC), bacterial artificial chromosome (BAC), or P1-based artificial chromosome 
(PAC) clones, which hold the promise of containing most, if not all, of the regulatory 
elements required for the complex orchestration of gene expression, have been 
successfully used for reproducing accurate expression of mammalian genes as well as 
delineating critical distal elements for gene regulation in Tg mouse models. 
Subsequent identification and characterization of critical elements within these large 
constructs frequently involves the use of deletion and site directed mutant constructs. 
To ascertain the physiological function of cis-regulatory elements, further analyses by 
knocking out the element of interest would also be helpful. Besides mouse, the current 
line-up of model animals includes chick, zebrafish, medaka and xenopus, which could 
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be cheaper alternatives for in vivo models. Nevertheless, Tg animal experiments are 
still laborious and time-consuming. 
A comparative genomics approach, which relies on evolutionary conservation 
as a criterion for determining potentially functional elements, can also be taken as an 
initial strategy for the identification of distal regulatory elements. This approach has 
become increasingly popular owing to the electronic availability of genomic sequence 
from numerous vertebrates as well as the concurrent development of genomic 
alignment, visualization, and analytical bioinformatics tools. Such an in silico 
approach exponentially increases our ability to generate biological hypotheses which 
aid in the prioritization of putative functional sequences for subsequent experimental 
testing involving in vivo Tg animal study and in vitro experiments: luciferase reporter 
assays of transfected cells, DNase I hypersensitivity assays and electrophoretic 
mobility shift assays (EMSA). Additionally, chromatin immunoprecipitation (ChIP) 
assays also can be employed to confirm the in vivo association of proteins with 
promoters and other regulatory regions. Recent advances in ChIP technologies, such 
as the ChIP-on-chip, ChIP-PET (paired-end-ditags) and ChIPSolexa 1G sequencing 
technology, contribute to the study of mammalian transcriptional regulation by 
serving as powerful tools in genome-wide location analyses of TFBS (Barski et al., 
2007; Euskirchen et al., 2007; Hudson and Snyder, 2006; Ji et al., 2006). 
Mapping of DNase I hypersensitive (HS) sites has traditionally been 
recognised as an inceptive experiment for the identification of regulatory elements. 
The presence of a HS site is thought to indicate an open chromatin state and to 
suggest the binding of a transcription regulatory complex. Genome-wide mapping of 
HS sites revealed that they are enriched near promoters at the 5’ end of genes, TFBS, 
CpG islands, and active genes, reinforcing the idea that they are markers for 
 87
regulatory regions (Crawford et al., 2004; Crawford et al., 2006b). Traditional 
methods involving southern blotting techniques to identify HS sites are labour-
intensive and thus their applications are limited to small-scale studies covering at 
most several hundred kbs. In contrast, several protocols have been developed in recent 
years aimed at large-scale mapping of HS sites for regions of Mb order (Crawford et 
al., 2006a; Crawford et al., 2004; Crawford et al., 2006b; Dorschner et al., 2004; 
Sabo et al., 2004; Sabo et al., 2006) using high-throughput approaches which require 
either cloning and sequencing (Crawford et al., 2004; Sabo et al., 2004), real-time 
PCR (Follows et al., 2007) or microarray (Follows et al., 2006) analyses. However, 
these techniques may not be attainable in many laboratories. Interestingly, retroviral 
integration sites (RIS), in particular that of the gammaretrovirus, murine leukemia 
virus (MuLV), map within 500–1000-bp of HS sites (Berry et al., 2006; Lewinski et 
al., 2006; Rohdewohld et al., 1987; Vijaya et al., 1986). The preference of MuLV 
integration near HS sites has been long hypothesized (Rohdewohld et al., 1987; 
Vijaya et al., 1986), and it is with the recent high-throughput and large-scale studies 
that conclusive evidence is provided for such an integration preference (Berry et al., 
2006; Lewinski et al., 2006; Wu et al., 2003). 
3.2 Retroviral integration sites selection 
All retroviruses contain three genes, gag (structural), pol (reverse transcriptase and 
integrase) and env (envelope glycoprotein). One of the key characteristics of 
retroviruses is their ability to integrate a copy of the DNA reverse transcribed from 
their viral RNA genome into host cell DNA. This integration is mediated by a 
preinitiation complex (PIC) comprising viral DNA (provirus), reverse transcriptase, 
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and integrase, as well as host proteins such as cellular TF or chromatin-associated 
factors (Coffin et al., 1997). 
Interest in the integration site selection of retroviruses is longstanding. This 
interest stems mainly from the need to understand the molecular mechanisms that 
dictate integration-site selection which is important in basic retrovirology and to the 
clinical applications of retroviral-derived vectors as delivery vehicles in human gene 
therapy research.  Retroviral vectors, mostly MuLV-derived retroviral vectors, have 
been used extensively to deliver therapeutic genes in clinical applications of human 
gene therapy because they stably integrate into the genome and therefore provide an 
opportunity for sustained clinical effects. In more than 175 clinical trials, over 1600 
patients have received retroviral vectors (Schagen et al., 2000). However, with the 
successes in retrovirus-based human gene therapy came the first major setback when 
three patients undergoing gene therapy for X-linked severe combined 
immunodeficiency (SCID-X1) developed monoclonal acute lymphoblastic leukemia-
like lymphoproliferation associated with transcriptional activation of LMO2, resulting 
from integration of a therapeutic MuLV vector near this protooncogene (Hacein-Bey-
Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b). These serious adverse events 
have spurred on the need to better understand the retroviral integration process to 
allow further assessment of the potential risks associated with gene therapy protocols 
utilizing retroviral vectors. 
 
3.2.1 Retroviruses integrate near DNase I hypersensitive sites 
Several large-scale studies using in vitro cell culture systems investigated the 
integration site preference of different retroviruses into the human genome. These 
studies have confirmed unanimously that the process of retroviral integration is a non-
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random process and different retroviruses, for example gammaretroviruses versus 
lentiviruses, exemplified by MuLV and human immuodeficiency virus (HIV), 
respectively, have differential preferences in retroviral site targeting (Berry et al., 
2006; Lewinski et al., 2006; Mitchell et al., 2004; Wu et al., 2003). MuLV integration 
sites in particular are enriched near TSS and CpG islands (Berry et al., 2006; 
Lewinski et al., 2006; Mitchell et al., 2004; Wu et al., 2003). Of striking significance, 
genomewide analyses of RIS from human cells (Lewinski et al., 2006; Wu et al., 
2003) revealed that approximately 11% of MuLV integration sites are flanked by two 
HS sites independent of proximity to promoters (Lewinski et al., 2006), reiterating the 
fact that MuLV in particular has an obvious propensity for targeting near sites which 
regulate gene expression. 
 
3.2.2 Retroviruses integrate near matrix attachment regions 
Furthermore, integrations near cis-regulatory MARs have been shown to be a 
common mechanism of RIS selection in both tumor-derived cells from mice and in 
vitro cell culture systems (Johnson and Levy, 2005). MARs are DNA sequences 
located at the bases of DNA loops that attach to the nuclear matrix, and are thus 
positioned near the machinery for DNA replication, transcription, RNA processing 
and transport (Holth et al., 1998). Retroviral integrations near MARs are consistent 
with the previous identification of preferred integration sites that contained sequence 
motifs such as HS sites (Berry et al., 2006; Lewinski et al., 2006; Rohdewohld et al., 
1987; Vijaya et al., 1986; Wu et al., 2003), AT-rich regions (Leclercq et al., 2000), 
transcriptionally active regions (Mooslehner et al., 1990; Narezkina et al., 2004; 
Ozawa et al., 2004; Scherdin et al., 1990; Weidhaas et al., 2000), and regions of DNA 
bending, specifically regions with the most DNA distortion (Muller et al., 1994; Pruss 
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et al., 1994a; Pruss et al., 1994b; Pryciak and Varmus, 1992), all of which are motifs 
shared by MARs. Parallel to these findings, the majority of MuLV integrations were 
found to occur 1- to 2-kb from a predicted MAR using a publicly available MARs 
prediction program termed MARFinder (http://futuresoft.org) (Johnson and Levy, 
2005). The parameters and limitations of MAR prediction by computational means 
are well discussed in a study reporting the comparative study of MAR prediction tools 
(Evans et al., 2007). 
 
3.2.3 Retrovirus insertional mutagenesis and retroviral tagged cancer gene 
database (RTCGD) 
Replication-competent retroviruses are used in animal models mostly for insertional 
mutagenesis purposes. Retroviral insertional mutagenesis (RIM) is a powerful tool to 
identify genes involved in leukemogenesis. In mice which are inoculated with 
ecotropic retrovirus, the retrovirus integrates into the host genome resulting in the 
activation of oncogenes or the disruption of tumor suppressor genes (Jonkers and 
Berns, 1996). Consequently, mice infected by retroviruses develop leukemia within a 
relatively short period. The integrated proviral DNA in turn can be used as a tag to 
identify proximal or distantly located oncogenes and less frequently tumor suppressor 
genes (Sauvageau et al., 2008). Many oncogenes identified in these screenings have 
been shown to be associated with the development of human cancers. The availability 
of the mouse genome sequence (Waterston et al., 2002) coupled with recent advances 
in high-throughput PCR-based methods for cloning and an everdecreasing cost of 
sequencing has dramatically increased our ability to identify cancer genes via RIM.  
The retroviral tagged cancer gene database (http://rtcgd.ncifcrf.gov) was 
launched in 2004 (Akagi et al., 2004) to catalogue the large numbers of potential 
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cancer-related genes generated from individual analyses of retrovirus-induced tumors 
in mice. It is currently home to a wealthy resource of almost 7000 RIS near more than 
3000 genes, comprising a large number of RIS which have been deposited for 
MuLVs, such as moloney murine leukemia virus (MoMuLV), BXH2 and AKV, in 
hematopoietic disease organs, and for the mouse mammary tumor virus (MMTV) in 
mammary carcinomas. Many of these data sets have been annotated onto the mouse 
genome browsers at UCSC (http://genome.ucsc.edu/ also linked from RTCGD) and 
also the Ensembl genome browser (http://www.ensembl.org/Mus musculus/) of the 
European Bioinformatics Institute and Wellcome Trust Sanger Institute. This publicly 
available database is fast growing and is constantly updated to incorporate RIS 
information from more recent publications. The use of the abundant RIS information 
from RTCGD to map HS and MARs has an unrealized potential to aid in the 
discovery of a plethora of novel cis-regulatory elements. 
The preference of RIS for HS and MARs described earlier are based on the 
results from in vitro cell culture systems immediately after retroviral transduction 
which avoids any bias by selection effects during long periods of time in culture, 
suggesting that retroviruses per se have an inherent preference to integrate near these 
sites. On the other hand, it should be noted that RIS in the RTCGD represent 
integrations which have undergone further selection by in vivo pressure.A clone 
carrying a particular integration may have a growth advantage, thereby overriding 
other coexisting clones with integrations that do not confer selective growth 
advantage. Such selection is also seen in the patients under human gene therapy (Aiuti 
et al., 2007; Deichmann et al., 2007; Schwarzwaelder et al., 2007). As a result, there 
is a bias for some specific genes to be selectively targeted by retroviral integration 
under different in vivo conditions. Hence, the list of RIS from RTCGD is not 
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exhaustive and may not represent all genes present in the genome. Nevertheless, the 
list is highly likely to be enriched for the genes which play critical roles in biological 
phenomenon. Indeed, TF constitute the largest class of retroviral targets in RIM 
(Suzuki et al., 2002).  
3.3 A combinatorial in silico approach: case studies 
Accumulating evidence shows that retroviruses have an apparent preference for 
integration near HS and predicted MARs, both of which are indicative of regulatory 
regions. Herein, by extending our knowledge of retroviral integration preferences to 
the study of gene expression regulation, we propose the use of RIS mapping as an 
efficient way to enhance the accuracy of the prediction process for putative cis-
regulatory elements. In support of this hypothesis, murine retroviral vectors carrying 
the GATA2 promoter have been used successfully in a MuLV-derived enhancer 
trapping (ET) approach in zebrafish (Ellingsen et al., 2005). ET constructs like the 
one used in this study typically contain a reporter gene that encodes a fluorescent 
protein under the control of an attenuated promoter. When such a construct is inserted 
into the genome, the promoter senses the tissue-specific enhancers nearby and drives 
expression of the reporter gene with a particular expression pattern which is easily 
visualized. 
Taking this one step further, we propose the use of a combinatorial in silico 
approach involving an already well established comparative genomics approach, 
coupled with RIS mapping and predicted MARs mapping to enhance the efficiency of 
functional regulatory element prediction. To establish a proof of principle, we took a 
combinatorial retrospective analyses approach for a few selected genes using VISTA 
output obtained from global alignments using LAGAN 
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(http://lagan.stanford.edu/lagan web/index.shtml), RIS (from RTCGD) mapping and 
predicted MARs (using MARFinder). Three genes, namely Pu.1, Runx1, Hoxa7 and 
Wnt1 were selected based on two criteria, (1) the availability of previously reported 
and well-characterized cis-regulatory regions and (2) the availability of RIS in the loci 
of these genes from RTCGD. It should be emphasized that most of the RIS 
information used for mapping of Pu.1 and Hoxa7 were data derived from MuLV 
mutagens, hence it follows that these RIS could be indicative of HS sites. Although 
RIS used for mapping of Wnt1 locus is derived from MMTV whose integration 
preference is not as well studied, we hypothesize that since the MMTV–long terminal 
repeat (LTR) contains a MAR which binds a well-characterized MAR-binding 
protein, SATB1 (Liu et al., 1997), this may allow MMTV to preferentially integrate 
near MARs in the host genome. Since MARs contain HS (Berry et al., 2006; 
Lewinski et al., 2006; Rohdewohld et al., 1987; Vijaya et al., 1986; Wu et al., 2003), 
it is assumed, in this study, that MMTV integrate near HS sites.  
 
3.3.1 PU.1: RIS map within a distally located 5’ cis-regulatory region initially 
identified by DNase I hypersensitive site mapping 
PU.1, encoded by the Sfpi1 gene (named after SFFV proviral integration 1), is an ets-
family TF (also known as Spi-1). It plays a critical role in the development of myeloid 
lineages in hematopoiesis. The complete regulatory region of the PU.1 locus as 
defined by correct expression in Tg mice is located on a 91-kb fragment of genomic 
DNA (Li et al., 2001). By using HS site mapping, several regulatory regions were 
identified. Two elements have been extensively characterized, the Pu.1 promoter and 
a 3.5-kb fragment located 14-kb upstream of the transcription start site, termed the 
URE (upstream regulatory element; highlighted in green in Figure 3.1) (Li et al., 
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2001). Coincidentally, the URE falls in the same region where SFFV integrations 
were found to cluster which initially led to the discovery of PU.1 as a Sfpi1-encoded 
gene product (Paul et al., 1991). 
Subsequent targeted deletion of the URE in mouse models revealed that this 
region was critical for regulating the precise level of Pu.1 transcript. Interestingly, this 
deletion resulted in an 80% loss of Pu.1 expression which induced a precancerous 
state leading to AML with frequent cytogenetic aberrations in mice (Rosenbauer et 
al., 2004). This result came largely as a surprise since neither a 50% nor a 100% loss 
of Pu.1 expression was ever found to be associated with such precancerous state. The 
URE was later found to be a Pu.1 enhancer in B cells but a repressor in T cell 
precursors (Rosenbauer et al., 2006). This 3.5-kb region contains two highly 
conserved 300-bp homology regions (HS1 and 2) critical for URE activity 
(highlighted in yellow in Figure 3.1) and appears to confer the ability for 
autoregulation by Pu.1 (Okuno et al., 2005). Yet another significant discovery of this 
URE was made when a single nucleotide polymorphism (SNP) was found within the 
first homology region in the URE in humans which results in decreased enhancer 
activity. This in turn leads to a decrease in Pu.1 expression in myeloid progenitors in 
a development-dependent manner (Steidl et al., 2007). This SNP was found to be 
more frequent in AML with a complex karyotype, suggesting that this SNP may play 
a role in the disease progression of AML. 
When the seven RIS from RTCGD (Slape et al., 2007; Suzuki et al., 2006; 
Suzuki et al., 2002; Yanagida et al., 2005) that mapped to the Sfpi1 locus were 
analysed, three RIS (Suzuki et al., 2006; Suzuki et al., 2002) mapped within the URE 
of which one mapped between the two highly conserved 300-bp regions. 
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 Figure 3.1: RIS-mapped VISTA plot of Pu.1. VISTA plot obtained from global 
alignment of the mouse, human, rat, dog, horse, opossum, chicken and lizard Pu.1 
locus, using mLAGAN (Min Y= 50, Min ID = 70, Min length = 100). Predicted 
regions of significant identity are shown as peaks. Conserved non-coding elements are 
shaded in pink; conserved exons are shaded in blue. RIS mapped to the vista plot are 
shown as arrows; red and green arrows indicate retroviral insertions in the reverse and 
same transcriptional orientations, respectively. Pu.1 URE of 3.5-kb is highlighted in 
green. The two highly conserved 300-bp homology regions (HS1 and 2) critical for 
URE activity are highlighted in yellow. Plot of MAR potential sites are shown at the 
bottom of the figure. 
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3.3.2 Hoxa7: many RIS map within a 5’ cis-regulatory region 
Hoxa7 is an important developmental gene involved in the control of region-specific 
differentiation during embryogenesis. A highly conserved cis-regulatory region 
(highlighted in green in Figure 3.2) which is responsive to retinoic acid signals 
(highlighted in yellow in Figure 3.2) and Cdx gradient (highlighted in orange in 
Figure 3.2) was identified about 1.6-kb upstream from the TSS and was found to 
specify the anterior boundary of Hoxa7 expression in mice (Gaunt et al., 2004; Kim et 
al., 2002; Knittel et al., 1995; Min et al., 1998). A total of 25 RIS are deposited in 
RTCGD for Hoxa7|Hoxa9 loci and 16 of these have been used for RIS mapping 
analysis (Bijl et al., 2005; Suzuki et al., 2002; Yamashita et al., 2005; Yanagida et al., 
2005). The regulatory region is not only well-flanked by RIS but also maps within 2-
kb of a predicted MAR. 
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Figure 3.2: RIS-mapped VISTA plot of Hoxa7. VISTA plot obtained from global 
alignment of the mouse, human, rat, dog, horse, opossum, platypus, chicken, lizard 
and frog Hoxa7 locus, using mLAGAN (Min Y= 50, Min ID = 70, Min length = 100). 
Predicted regions of significant identity are shown as peaks. Conserved non-coding 
elements are shaded in pink; conserved exons are shaded in blue. RIS mapped to the 
vista plot are shown as arrows; red and green arrows indicate retroviral insertions in 
the reverse and same transcriptional orientations, respectively. The conserved 
enhancer reported in Ref.(Knittel et al., 1995), is highlighted in green; the retinoic 
acid response element in Hoxa7 regulatory region reported in Refs. (Kim et al., 2002; 
Min et al., 1998) is highlighted in yellow; additional enhancer copies with Cdx 
binding sites reported in Ref. (Gaunt et al., 2004) is highlighted in orange. Plot of 
MAR potential sites are shown at the bottom of the figure. 
 
 98
3.3.3 Wnt-1: many RIS map within a 3’ cis-regulatory region 
The Wnt-1 protooncogene which encodes a secreted glycoprotein, Wnt-1, was initially 
identified as an ectopically expressed gene by MMTV integration into int-1 locus in 
mammary tumors. Wnt-1 is expressed during development only in the CNS wherein 
its expression is initiated early in a region predicted to give rise to the midbrain. A 
5.5-kb cis-acting 3’-enhancer element (highlighted in green in Figure 3.3) was found 
to drive lacZ expression which recapitulates the correct temporal and spatial 
expression of Wnt-1 (Echelard et al., 1994). Further deletion of this 5.5-kb region 
from mouse proved that this enhancer is both necessary and sufficient for Wnt-1 
expression in vivo (Danielian et al., 1997). Subsequently, a highly conserved 110-bp 
element (highlighted in yellow in Figure 3.3) within this 5.5-kb region was reported 
to be sufficient for driving the temporally-restricted but spatially correct expression of 
Wnt-1 only during early embryogenesis, at the neural plate stages (Rowitch et al., 
1998). A total of 28 RIS (Theodorou et al., 2007) are deposited in RTCGD for this 
locus, of which 12 RIS have been found within this 5.5-kb enhancer region, 2 of 
which map close to the 110-bp element. Interestingly, many of the mapped RIS are 




 Figure 3.3: RIS-mapped VISTA plot of Wnt-1: VISTA plot obtained from global 
alignment of the mouse, human, rat, dog, horse, lizard, frog, zebrafish and fugu Wnt1 
locus, using mLAGAN (Min Y= 50, Min ID = 70, Min length = 100). Predicted 
regions of significant identity are shown as peaks. Conserved non-coding sequences 
are shaded in pink; conserved exons are shaded in blue. RIS mapped to the vista plot 
are shown as arrows; red and green arrows indicate retroviral insertions in the reverse 
and same transcriptional orientations, respectively. Red asterisk indicates “hotspot” 
where five RIS are clustered. The 5.5-kb cis-acting 3’-enhancer element reported in 
Refs. (Danielian et al., 1997; Echelard et al., 1994) and highly conserved 110-bp 
element reported in Ref. (Rowitch et al., 1998) is highlighted in green and yellow, 
respectively. Plot of MAR potential sites are shown at the bottom of the figure. 
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3.4. Discussion: orientation of retroviral integrations 
Transcriptional enhancement is probably the most frequent mechanism of gene 
activation by retroviral insertional mutagenesis (Jonkers and Berns, 1996). Such 
transcriptional activation is dependent on the integration site and the transcriptional 
orientation of the provirus with respect to the affected cellular gene. It is widely 
accepted that transcriptional enhancement is caused by the integration of a provirus 
either at the 5’ end of a gene in the reverse transcriptional orientation, or at the 3’ end 
in the same transcriptional orientation (Jonkers and Berns, 1996). Consistent with this 
notion, majority of the RIS mapped in the four case studies discussed above abide by 
such rules. In contrast, some proviral orientations near or within known cis-regulatory 
elements do not appear to adhere strictly to such rules, as shown in the cases of Pu.1 
and Hoxa7 whereby integrations in both orientations are found near or within the 
functionally characterized cis-regulatory elements. This suggests that retroviral 
integrations which occur within open regions of chromatin in the vicinity of cis-
regulatory elements, irrespective of the orientation, may inadvertently affect the 
transcriptional regulation of the cellular gene. However, this phenomenon requires 
further investigation. 
3.5. Conclusion 
The three case studies discussed illustrate RIS mapping in close vicinity to known 
regulatory elements/regions. Furthermore, a combinatorial in silico approach 
enhances the ability to predict functional cis-regulatory elements. All the 
bioinformatics tools and databases used in our analyses are freely accessible to the 
public. Therefore, our proposed approach carries enormous potential. 
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A schematic illustration of how elements can be scored for potential 
regulatory function is provided in Table 3.1. By assigning scores to different 
parameters, one can prioritize elements for further verification of function by 
experimental means. Essentially, the higher the score is, the higher the chance to 
identify a functional cis-regulatory element. In particular, our proposed scheme may 
be especially powerful in prioritizing CNE identified from the alignment of genomic 
sequences from closely related organisms, which often yields a great abundance of 
CNE, most of which are not conserved in distantly related species. Furthermore, 
application of this scheme by specifically aligning genomic sequences from mammals 
could potentially lead to the discovery of novel mammalian-specific regulatory 
elements. 
 

























a See text, Section 3.4 
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The only limitation for researchers keen on using RIS mapping as a way for 
identification of potential regulatory elements lies in the availability of RIS 
information for one’s gene of interest. Currently, only the RIS information from 
mouse, but not from human, is readily available in the form of a comprehensive 
database, the RTCGD. However, there is a lack of such a database for human RIS 
despite the many large scale studies carried out in recent years which generated large 
amounts of RIS information found in the human genome (Aiuti et al., 2007; Berry et 
al., 2006; Deichmann et al., 2007; Lewinski et al., 2006; Schwarzwaelder et al., 2007; 
Wu et al., 2003).We look forward to the setting up of an electronically available 
public database for RIS found in human. The easy electronic-access to these large 
catalogues of RIS information will definitely be beneficial to our search for cis-














Chapter 4 - An intronic Runx1 enhancer                                        
marks hematopoietic stem cells 
4.1 Identification of regulatory elements through a combinatorial in silico 
approach 
The important role of comparative genomics as an initial tool for the identification of 
transcriptional regulatory elements, in the genome of vertebrates, is now firmly 
established. Extensive use of this method reveals that there is insufficient evolutionary 
divergence between human and rodents to facilitate resolution of conserved, 
functionally significant DNA from similar, yet irrelevant sequences; comparing the 
human genome to that of more distant species such as birds, amphibians and fish 
effectively increases the specificity of conserved regulatory sequences identification. 
Generally, the phylogenetic distance between the compared species is proportional to 
the degree of conservation of regulatory elements, as is the case for coding sequences.  
A comparative genomics approach was first taken to compare the genomic 
sequence from the Runx1 locus of 11 different vertebrate species, including seven 
mammals (human, Homo sapiens; mouse, Mus musculus; rat, Rattus norvigecus; dog, 
Canis familiaris; horse, Equus caballus; opossum, Monodelphis domestica; platypus, 
Ornithorhynchus anatinus), one avian (chicken, Gallus gallus), one reptile (lizard, 
Anolis carolinensis), one amphibian (frog, Xenopus tropicalis) and one teleost fish 
(pufferfish, Takifugu rubripes). Genomic sequences spanning the entire Runx1 gene 
locus, from neighbouring gene to neighbouring gene, were downloaded from the 
UCSC genome browser and aligned using the multi-LAGAN (MLAGAN) multiple 
global alignment tool (http://lagan.stanford.edu) (Brudno et al., 2003). The mouse 
sequence (corresponding to mouse Chromosome 16: 92541486-93583706 from the 
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July 2007 mouse (Mus musculus) genome data obtained from the Build 37 assembly) 
is used as a reference for analysis.  VISTA plots show evolutionary conservation of 
the Runx1 gene locus (Figure 4.1 and 4.2) (Frazer et al., 2004). The threshold of 70% 
sequence identity over 30-bp provides specificity to detect relatively small, highly 
conserved sequences while excluding the majority of background signal (Kaelin et al., 
2007). As such, we defined a search for short, nearly identical sequences by using this 
defined threshold. Despite the considerable evolutionary distance of 310 million years 
between birds and mammals (Hughes et al., 2005), our search yielded 192 CNE (126 
located in intergenic region, 5’ of the transcription unit of Runx1; 29 in intron 1; 26 in 
introns other than intron 1; 11 located in intergenic region, 3’ of the transcription unit 
of Runx1) conserved between chicken and mouse Runx1 locus. Comparison between 
frog and mouse identified 81 CNE, 5 of which are not conserved with chicken. 
However, only 2 CNE, as discussed in Section 2.8, were found in the fugu-mouse 


















Table 4.1: RIS within the Runx1 gene locus, obtained from RTCGD and UCSC. 
No. (#) Clone name Direction Relative to Runx1 Chr16 Within 2-kb of CNE (nm-m) 
1 S113_3_1_14 Same intergenic, 5’ 93424265 fr (1,769) Y fr (602) 
2 PDGFB.H4101 Same intergenic, 5’ 93389062  Y l (887) 
3 VST27222U3 Same intergenic, 5’ 93271618 fr (1,095) Y  
4 230.dKON040.06 Same intergenic, 5’ 93172446  N  
5 Lnz16-4 inverse intergenic, 5’ 93139853 l (862) Y  
6 Dkm119.36 Same intergenic, 5’ 93139138 l (1,936) Y l (1,285) 
7 X3_7070C inverse intergenic, 5’ 93106558  N  
8 229.dKON006.01 Same intergenic, 5’ 93050103  N  
9 Dkm37.61 Same intergenic, 5’ 92928043  N  
10 Dkm240.9 inverse P1 promoter 92827259  Y fr (791) 
11 Dkm191.11 inverse P1 promoter 92826610  Y fr (142) 
12 B5_7389B2 Same Intron 1 92819316  N  
13 Dkm110.6 inverse Intron 1 92800825 fr (1,181) Y  
14 Dkm85.5 inverse Intron 1 92793607 fr (1,089) Y fr (1,437) 
15 275.dKON090.05 inverse Intron 1 92757357  N  
16 ME89-5B8ii inverse Intron 1 92744270  N  
17 Dkm4.21 inverse Intron 1 92725390  Y c (333) 
18 513_5_5kb4 inverse Intron 1 92720576  Y f (1,429) 
C, chicken; f, fugu; fr, frog; l, lizard; m, mammal; nm, non-mammal; N, no; Y, yes; 
numbering under column labeled Chr16 indicates position of RIS on mouse 
chromosome 16 as per the Mouse July 2007 (mm9) assembly. RIS present within 2-
kb of highly conserved elements (i.e. conserved from non-mammals to mouse/human) 
are indicated with “Y” and position of RIS relative to CNE is indicated (i.e. left 
versus right); Organism from which the evolutionary conservation starts are labeled c, 
f, fr or l. Distance (bp) of RIS from CNE is given in brackets. RIS which led to the 
identification of the Runx1 +24.1 mCNE as an enhancer is highlighted in yellow. RIS 
#1-8 are not assigned as RIS within Runx1 gene locus in RTCGD; RIS #9-18 are 
assigned to Runx1 in RTCGD.  
 
 
Building upon this already well-established comparative genomics prediction 
method, RIS mapping, utilizing RIS information from the publicly available database, 
RTCGD, was carried out to indicate potential DNase I hypersensitive sites which 
have been shown to coincide with regulatory regions (Ng et al., 2008). Ten RIS 
(Figure 4.1B) assigned to the Runx1 mouse locus are available in the RTCGD (Table 
4.1). Of these, seven RIS map within intron 1, while two map within the distal P1 
promoter of the Runx1 gene (Figure 4.3). The remaining RIS (RIS #9), together with 
an additional eight RIS not assigned to Runx1 in the RTCGD (RIS #1-8) (Table 4.1; 
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Figure 4.1), map within the intergenic region 5’ to the transcriptional unit of Runx1. 
Excluding the two RIS (RIS #10 & RIS #11) which map within the Runx1 P1 
promoter, nine of these eighteen RIS mapped within 2-kb of twelve CNE conserved 
from non-mammalian sequences to mouse (Table 4.1, Figure 4.1). By defining RIS 
mapping within 2-kb of CNE to indicate the presence of elements which are more 
likely to have a functional regulatory role, the number of elements was dramatically 
reduced from more than one hundred to a mere twelve which have not been assigned 
regulatory function. These twelve RIS-flanked CNE will henceforth be referred to as 
RIS-CNE. Notably, RIS #18 is located near one of the two elements previously 
identified in the 1.5-kb fugu PRE fragment (Table 4.1; Figure 2.6). Using this 
innovative and simple in silico approach, CNE more likely to possess regulatory 
function were assigned high priority for further validation of their function by 
experimental means. Within this group of RIS-CNE, CNE were further scored based 
on the scheme devised as discussed in Section 3.5 and illustrated in Table 3.1. High-
scoring CNE were then given higher priority and first subjected to subsequent 
experimental validation.  
While this work was in progress, another database, the mutapedia 
(http://mutapedia.nki.nl/), containing a plethora of RIS data was launched. More than 
one hundred RIS in our defined Runx1 gene locus were extracted from this database 
and used for RIS mapping. This new mapping validated previously identified RIS-
CNE and also revealed several ‘hotspots’, regions within which clusters of multiple 








































Figure 4.1: RIS mapped onto VISTA plots reveal potentially functional 
regulatory elements. VISTA plot obtained from global alignment of the mouse, human, 
rat, dog, horse, opossum, platypus, chicken, lizard, frog and fugu Runx1 locus, with the 
mouse sequence as reference, using mLAGAN (Min Y= 50, Min ID = 70, Min length = 30). 
(B) Gene (intron-exon) structure for mouse Runx1 is illustrated at the top. (A-C) Predicted 
regions of significant identity are shown as peaks. CNE are shaded in pink; conserved UTRs 
are shaded in cyan; conserved exons are shaded in blue. (A-B) RIS from RTCGD mapped to 
the vista plot are shown as red arrows; red dotted vertical lines extend from the indicated RIS 
to aid in visualisation of nearby CNE if there are any (C) RIS from RTCGD and mutapedia 
mapped to the vista plot are shown as red arrows; counterparts of fugu PRE fragment are 















Figure 4.2: RIS-mapped VISTA plot, Runx1 (partial). VISTA plot obtained from 
global alignment of the mouse, human, rat, dog, horse, opossum, platypus, chicken, 
lizard and frog Runx1 intronic region (between the distal P1 and proximal P2 Runx1 
promoters) including the flanking exons,  using LAGAN(Min Y= 50, Min ID = 70, 
Min length = 100). Predicted regions of significant identity are shown as peaks. 
Conserved non-coding sequences are shaded in pink; conserved exons are shaded in 
blue. RIS mapped to the vista plot are shown as arrows; red and green arrows indicate 
retroviral insertions in the reverse and same transcriptional orientations, respectively. 
The highly conserved non-coding intronic Runx1 +24.1 enhancer is highlighted in 









4.2 Validation of RIS-mapped-CNE for regulatory function in a zebrafish in vivo 
system 
Our initial enhancer screening strategy in zebrafish embryos involves the injection of 
EGFP-expression constructs containing mouse RIS-CNE, followed by analysis of the 
spatial-temporal expression of EGFP in live zebrafish embryos during early 
development. Since the expression of Runx1 is regulated by two functionally distinct 
promoters, designated distal P1 and proximal P2, we decided to simplify the screen 
for enhancer function using a single heterologous promoter which has previously been 
shown to be effective in screens for enhancers, in our expression construct. We used a 
638-bp 3’-fragment of the promoter of the zebrafish heat shock protein 70 (zhsp70) 
gene. This fragment, which contains the TATAAA, CCAAT, GC and heat-shock 
elements, functions as a basal promoter which shows little or no activity at normal 
temperature (28.5°C), but is robustly induced at 37°C ambient temperatures (Halloran 
et al., 2000; Lele et al., 1997; Shoji and Sato-Maeda, 2008). Coincidentally, the 
normal progression of zebrafish embryo development proceeds regularly only 
between 23°C and 34°C, while embryos incubated at temperatures above or below 
these limits did not complete embryogenesis (Schirone and Gross, 1968). Hence, we 
expected the transcription from the hsp70 promoter to be activated in zebrafish 
embryos incubated at 28°C only when it was influenced by putative enhancers cloned 
upstream in the expression construct. 
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4.2.1 Initial validation for regulatory function of selected RIS-CNE using a 
transient zhsp70p:EGFP expression assay in zebrafish embryos 
Primers were designed from repeat-masked genomic sequence to flank selected RIS-
CNE by 100-200-bp on either side. These elements were then amplified  from mouse 
tail genomic DNA (amplicons are generally of about 500bp) and cloned individually 
into an expression construct containing the zebrafish heatshock protein 70 basal 
promoter (zhsp70p) driving the expression of the reporter gene EGFP. The biological 
potential of sequences identified through this combinatorial in silico strategy were 
assayed using a transient expression system in developing zebrafish embryos to detect 
in-cis modulation of tissue-specific transcription by RIS-CNE. All the RIS-CNE 
tested had the ability to drive the expression of EGFP (data not shown).  However, 
only one of these CNE which is located near a predicted MAR within the intron 1 
(highlighted in green in Figure 4.2) of the Runx1 gene and is found within a RIS 
‘hotspot’ (highlighted in green in Figure 4.1C), was able to drive the spatial- and 
temporal-specific expression of EGFP in the hematopoietic sites: ICM and the RBI at 
about 19-20 hpf, which are known sites of endogenous runx1 expression in the early 
zebrafish embryo (Figure 4.3). Notably, there are more EGFP+ cells in the ICM than 
in the RBI. Interestingly, no GFP was observed in neuronal cells which have been 
reported to express runx1 in the zebrafish embryo (Figure 4.3) (Kalev-Zylinska et al., 
2002). This CNE, which is located approximately 24.1-kb downstream from the TSS 
of the distal P1 isoform (highlighted in green in Figure 4.2), does not fully 
recapitulate endogenous runx1 expression but instead serves as a hematopoietic-

















Figure 4.3: Runx1 +24.1 enhancer drives specific expression of EGFP in the ICM. 
EGFP positive cells are in green. The ICM is the region just above the yolk extension.  
 
 
By definition, an enhancer should be able to function independent of distance, 
orientation and promoter (Allende et al., 2006; Blackwood and Kadonaga, 1998; 
Dillon and Sabbattini, 2000; Ptashne, 1986; Serfling et al., 1985). Indeed, we 
identified a 561-bp fragment containing the +24.1 mCNE which co-operates with the 
heterologous zhsp70 minimal promoter to drive the precise expression of EGFP at 
sites of hematopoiesis and where runx1 is known to be expressed in the early 
zebrafish embryo. Nonetheless, the strategy employed precludes the identification of 
regulatory elements that are strictly dependent on their structural organization, with 
respect to the basal promoter, and that show promoter specificity or have repressor 
function. In extreme cases, the regulatory element may be incompatible with the 
chosen heterologous promoter. For example, enhancers were found to show different 
regulatory activity with TATA-less and downstream core promoter element (DPE)-
containing promoters than with TATA-containing promoters (Butler and Kadonaga, 
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2001; Ohtsuki et al., 1998). This observation may be explained by the differential 
ability of enhancer-binding proteins to interact with alternative protein complexes 
forming on the core promoter (Muller and Tora, 2004). 
 
4.2.2 Runx1 +24.1 enhancer is only active in immature precursor cells in the ICM 
In the ICM, runx1 localizes in early scl+ precursor cells which, at this stage, 
represent hemangioblasts or independently-derived populations of HSC and vascular 
precursors (angioblasts) that simultaneously develop adjacent to each other. Most of 
these scl+ precursor cells are fated to develop into EryP and EC (Burns et al., 2002; 
Hsia and Zon, 2005). Immunohistochemical analysis using antibodies against scl, beta 
e1 globin (βe1; a gene found in mature erythrocytes) and EGFP reveals that EGFP 
expression is strictly restricted to immature scl+βe1- precursor cells (Figure 4.4). Our 
initial analysis revealed that the Runx1 +24.1 enhancer drives the precise spatial-
temporal expression of EGFP in the ICM and also in the RBI at 19-20 hpf. However, 
the number of EGFP+ cells varied in different embryos, likely reflecting the mosaic 
distribution of injected DNA together with delayed integration during the early rounds 
of cell division. Moreover, attempts to decrease the effects of mosaicism using either 
the Tol2-transposon system or co-injection with the I-SceI meganuclease enzyme 
resulted in a greater number of EGFP-expressing cells in the same spatial-temporal 
manner (data not shown). Interestingly, these EGFP+ precursor cells at 24 hpf are no 
longer present in the AGM region (a derivative of the ICM) and are instead visualised 















Figure 4.4: Runx1 +24.1 enhancer activity marks immature precursor cells in the 
ICM.  EGFP+, scl+ and βE1+ cells are shown in green, red and purple respectively. 
DAPI staining of DNA in the nucleus of all cells is shown in blue. 
 
The restriction of EGFP expression driven by the Runx1 +24.1 enhancer to 
scl+βe1- non-erythroid precursor cells in the ICM at 19-20 hpf presents an interesting 
possibility that our enhancer marks early precursors involved in definitive 
hematopoiesis, and maybe even hemangioblasts from which these precursors may 
have arisen. Visualisation of EGFP+ circulating blood cells at 24 hpf led to the 
postulation that these rare, circulating cells might have first emerged from the 
EGFP+scl+βe1- precursor cells, perhaps through an as yet identified mechanism that 
may be analogous to that of HSC budding from hemogenic endothelium in mice.  
 The runx1 P1 and P2 promoter zebrafish Tg lines, where EGFP was used as a 
reporter gene, were recently reported (Lam et al., 2008). The segregated and 
successive emergence of definitive blood progenitors was shown to be regulated, in 
part, by the alternative use of runx1 promoters. Interestingly, the P1 promoter was 
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found to be active in the PLM, as early as 16 hpf via the detection of EGFP 
transcripts. Notably, EGFP fluorescence signals were only visualised transiently from 
18 hpf in the ICM (derivative of the PLM); and by 24 hpf, only weak expression 
remained. In contrast, hematopoietic EGFP expression was first observed in the 
ventral wall of the DA in the AGM at 22 hpf in P2 promoter Tg zebrafish. 
Interestingly, the EGFP expression driven by the Runx1 +24.1 enhancer appears to 
tightly correlate with that of the zebrafish P1 promoter and conversely, is completely 
not reflective of the P2 promoter activity. This strongly suggests that the Runx1 +24.1 
mCNE co-operates with the Runx1 P1 promoter in the regulation of P1 isoform 
expression. Notably, HSC predominantly express the P1 isoform of Runx1 (Telfer and 
Rothenberg, 2001). Morpholino knock-down of the Runx1 P1 isoform in zebrafish led 
to findings which suggested that the Runx1 P1 isoform is neither involved in 
primitive hematopoiesis nor initiation of definitive hematopoiesis in the AGM. 
Instead, the authors suggested that the ontogeny of the EGFP+ cells in the P1 
promoter Tg zebrafish resembles that of the definitive EMP where the the Runx1 P1 
isoform plays a yet defined role preceding the emergence of EMP but is not involved 
in the specification and maintenance of EMP. It will be meaningful to determine 
whether the Runx1 +24.1 enhancer activity-marked cells in the ICM are EMP as 
postulated by Lam et al., or if they represent a subset of cells within this presumed 
EMP population that are capable of multilineage reconstitution in the zebrafish. 
The establishment of a stable Tg line using our enhancer construct holds great 
promise for better understanding of the sequence of events that occurs during 
definitive hematopoiesis in zebrafish. Unfortunately, despite great efforts to establish 
such a stable Tg line in our laboratory, I failed to visualise EGFP expression in F1 
embryos, even though germline transmission was detected by PCR using primers to 
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amplify the EGFP gene (data not shown). One possible explanation for this 
observation, which remains to be proven, is that our +24.1 mouse enhancer element, 
not conserved on the sequence level in zebrafish, is selectively silenced in the 
zebrafish system. The successful establishment of a stable Tg zebrafish line that fully 
recapitulates the reporter gene expression driven by +24.1 enhancer, may involve the 
search for a zebrafish element which contains a cluster of TFBS corresponding to 











4.3 TFBS predictions within the conserved intronic enhancer element 
To begin to ascertain the basis of transcriptional regulation by this enhancer, we 
identified putative TFBS by sequence comparison. We focused on the relevant 
sequences obtained from all the various species in which this enhancer is conserved. 
These regions identified by VISTA were extracted and aligned using CLUSTALW. 
We analyzed this enhancer element using both the TRANSFAC and JASPAR 
databases, looking for proteins that might bind this conserved element. Many of the 
phylogenetically-conserved motifs corresponded to known sites of functional 
importance that have been previously shown to bind TF in vitro and in vivo. Upon 
closer examination of this element, we found an unusual clustering of binding sites for 
factors associated with hematopoiesis within a central core region of approximately 
245-bp. 
Within this element, individual TFBS have been completely conserved across 
all species, as is the case for ets3,6,7,9, ets/Gata2, Myb, Runx, Gata and Cebpα, while 
some like those of Tcf and E2F are conserved only in mammals (Figure 4.5). Other 
sequences are almost fully conserved but have one or more critical residues that 
would alter binding in different species, as exemplified in Tcf3/E2F2 (Figure 4.5). 
Generally, despite lower conservation at the sequence level between frog and mouse, 
the TFBS are largely conserved. Interestingly, this enhancer appears to remain 
functionally-conserved in the zebrafish i.e. produce highly similar expression, over 
large evolutionary distances, even in the apparent absence of sequence conservation 
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Figure 4.5: TFBS associated with hematopoiesis are clustered within the 
conserved +24.1 mCNE. DNA sequences were aligned using ClusalW; sequences 
which match the consensus are highlighted in grey. Consensus binding sites of 
various factors have been boxed out in different colors matching the color of the 
labeling used for the different factors. Binding sites for the various factors are also 
highlighted with corresponding colors to show the conservation of TFBS which are 








4.4 Chromatin structure at Runx1 +24.1 mCNE locus tightly correlates with the 
expression of Runx1 
Selected mouse cell lines were first screened by quantitative real-time PCR (qRT-
PCR) for Runx1 expression. Runx1 expression was detected in two hematopoietic cell 
lines, A20 and Factor-dependent cell Paterson mixed potential (FDCPmix) cells. A20, 
a mouse B lymphoma cell line, expresses almost exclusively the distal P1 isoform of 
Runx1 while FDCPmix cells express the proximal P2 isoform in much greater 
abundance than the distal P1 isoform (Figure 4.7). Conversely, two non-












Figure 4.6: Location of primers used for qChIP analysis. A) 14 sets of primers 
were designed as shown to amplify regions across the +24.1 mCNE locus. The red 
region represents the conserved +24.1 mCNE. Light grey regions represent repeats 
which have been masked. B) 14 sets of primers were designed as shown to amplify 
regions across the Runx1 distal P1 promoter locus. The red vertical line indicates the 
+1 site (TSS). White, light grey and dark grey regions represent masked repeat, exons 




To probe for selective accessibility of the Runx1 +24.1 mCNE, we examined 
histone 3 lysine 4 (H3K4) trimethylation and histone 3 lysine 9 (H3K9) trimethylation 
at this region in the abovementioned cell lines. H3K4 methylation correlates with 
‘open’ chromatin or active gene loci while H3K9 trimethylation correlates with 
‘close’ chromatin or inactive gene loci (Barski et al., 2007; Bernstein et al., 2005; 
Fuks, 2005; Robertson et al., 2008; Wang et al., 2008). Quantitative chromatin 
immunoprecipitation (qChIP) was carried out wherein a locus of about 3.6-kb, 
encompassing the Runx1 +24.1 mCNE of the immunoprecipitated DNA, is probed by 
14 primer pairs designed to amplify different regions across the defined locus using 
real-time quantitative PCR (Figure 4.6A). Primer sets were similarly designed to 
probe the Runx1 P1 promoter region (Figure 4.6B). 
 
Figure 4.7: Runx1 +24.1 mCNE and P1 promoter are accessible only in mouse 
cell lines which express Runx1. Peaks indicate association of the antibody used for 
ChIP enriching for particular regions in the locus. Flat-lines indicate no particular 
enrichment across the locus analysed by antibody used for ChIP. 
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The results conclusively show that the Runx1 +24.1 mCNE is ‘open’ 
(visualised as peaks in the case of H3K4me3 ChIP) only in cells which express 
Runx1, regardless of whether the P1 or P2 isoform is expressed (Figure 4.7). In 
contrast, this region is not accessible in cells which do not express Runx1 and, in the 
case of Neuro2a, is actively ‘closed’ (visualised as a peak in the case of H3K9me3 
ChIP in Figure 4.7). However, subtle differences in “chromatin signature” exist at 
each of these sites in the different cell lines tested, likely reflecting the cell-dependent 
modulation of these sites by chromatin remodeling factors. For example, the loci of 
the P1 promoter in the P1 isoform-expressing A20 cell shows two peaks of 
enrichment whereas the loci of the P1 promoter in the FDCPmix cells, which express 
predominantly the P2 isoform, shows only a single peak of enrichment by H3K4me3 
ChIP (Figure 4.7). Furthermore, the Runx1 +24.1 mCNE locus is “open” along a 
larger distance across the stipulated 3-kb locus in FDCPmix cells than in A20 cells 
(Figure 4.7). Interestingly, another enhancer element was found at the +24.9 region, 
which is located within the locus probed with ChIP. This +24.9 mCNE (highlighted in 
blue in Figure 4.8) is in fact located closer to RIS #13 than the +24.1 mCNE 
(highlighted in yellow in Figure 4.8). However, this +24.9 mCNE is only conserved 
amongst mammals and was hence missed during our initial search for highly 
evolutionarily conserved (i.e. from frog-to-human or chicken-to-human) elements. 
Intriguingly, the region encompassing the +24.9 mCNE is only accessible in 













Figure 4.8: MAR prediction plot of the locus encompassing +24.1 mCNE and 
+24.9 mCNE. +24.1 mCNE is highlighted in yellow while +24.9 mCNE is 
highlighted in blue. RIS #13 maps within predicted MAR, closer to +24.9 mCNE than 
to +24.1 mCNE. 
 
Corroborating results from zebrafish, the chromatin state of the Runx1 +24.1 
mCNE locus tightly correlates with that at the P1 distal promoter region, strongly 
suggesting that they may co-operate in regulating the expression of Runx1. qChIP 
analysis was not carried out for the P2 proximal promoter in these cells lines largely 
because of the GC-rich nature of this region which poses difficulty in designing 
primer sets across this entire locus and in PCR amplification. Although qChIP 
analysis was not carried out for the P2 promoter, it is postulated that this +24.1 mCNE 
may also co-operate with the P2 proximal promoter since it is also found within 
‘open’ chromatin structure in cells which dominantly express the P2 proximal isoform 
of Runx1. However, chromosome conformation capture (3C) technique remains to be 





4.5 Generation and analyses of Runx1 +24.1 enhancer transgenic mice 
To assay the regulatory potential of this element in a more relevant in vivo model,  
+24.1 mCNE-EGFP transgenic (Tg) mouse lines were generated, wherein EGFP is a 
reporter gene that is driven by a minimal mouse hsp68 promoter (mhsp68p). Notably, 
the mhsp68 promoter is a well established heterologous minimal promoter used for 
the analysis of putative regulatory elements in a reporter construct. We established 
three distinct Tg mouse lines, numbered #523, #540 and #542 (Figure 4.9). To 
determine the mouse line to use for further analyses, EGFP expression was first 
compared to the previously described Runx1 gene expression pattern in mouse 
embryo (North et al., 1999; Zeigler et al., 2006; Samokhvalov et al., 2007; 
Nottingham et al., 2007) (Table 4.2). In addition, EGFP expression within the 
hematopoietic compartments of adult Tg mice, were also compared amongst the three 
Tg mouse lines (Table 4.3). In all three mouse lines, majority of immature 
HSC/progenitor cells but only low percentage of lineage-positive, differentiated cells 
exhibited GFP expression. Notably, only HSC/progenitor cells but not differentiated 
hematopoietic cells exhibited strong EGFP expression. Consistent with previous 
reports of Runx1 expression (Table 4.2; North et al., 2004), the +24.1 enhancer 
activity targets HSC/progenitor cells but not erythroid cells. However, myeloid and 
lymphoid cells which express Runx1 were not marked by the +24.1 enhancer. Taken 
together, the Runx1 +24.1 enhancer appears to preferentially target immature 
HSC/progenitor cells and does not recapitulate the wider expression of endogenous 




Figure 4.9: EGFP expression in E10.5 embryos from three distinct transgenic 
mouse lines, #523, #540 and #542. AGM, aorta-gonad-mesonephros; H, heart; VU, 
Vitelline & umbilical arteries; S, somites; YS, yolk sac. 
 
 
All further analyses were carried out with the Tg mouse line #523 which 
shows: (1) strong and precise expression of EGFP in hematopoietic sites where the de 
novo generation of HSC first occur in the mouse embryo, namely, the YS, the VU and 
the DA within the AGM region; and (2) a greater specificity in the marking of 
immature lineage-negative cells in the adult BM.  
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Table 4.2: Sites of endogenous Runx1 expression and Runx1 intronic enhancer 
activity 
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Table 4.3: Summary of FACS analysis of adult hematopoietic cells in the three 































*Percentages of EGFP+ cells in indicated lineage/fraction are shown. 
**Lineage markers comprising cocktail of antibodies against CD3, CD4, CD8, 
B220, Ter119, Gr-1, Mac-1 and IL-7 receptor. 
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4.5.1 Runx1 +24.1 mCNE has hematopoietic Runx1-specific enhancer activity in 
the mouse embryo 
 
4.5.1.1 Runx1 +24.1 mCNE drives EGFP expression in E8.5 Tg embryos 
Taking the lead from the findings in zebrafish embryo, I started by examining Tg 
mouse embryos at E8.5 and E10.5 for expression in hematopoietic sites. At these time 
points, the +24.1 mCNE consistently showed enhancer activity at hematopoietic sites. 
In E8.5 embryos, the +24.1 mCNE targeted expression to EC and hematopoietic cell 
clusters which appeared closely associated with the endothelium in the YS blood 
islands, and to the paired DA in the P-Sp (Figure 4.10), consistent with previous 
reports of endogenous Runx1 expression pattern (North et al., 1999; Nottingham et al., 
2007; Samokhvalov et al., 2007). Furthermore, there was a lack of +24.1 enhancer 
activity in EryP in the mouse YS (Figure 4.10), recapitulating the lack of enhancer 
activity in EryP in the the ICM of zebrafish embryos (Figure 4.4). Unexpectedly, 
reporter gene expression was observed in the primitive heart of the E8.5 mouse 
embryo (Figure 4.10) since the primitive heart is neither a known site of 
hematopoiesis nor of endogenous Runx1 expression.  
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 Figure 4.10: Runx1 +24.1 enhancer is active in hematopoietic sites in E8.5 mouse 
embryo. In the first row, EGFP expression is observed in the YS. Figures in the third 
row are magnified from the regions boxed out in the middle row, showing the 
expression of EGFP in the paired DA of the P-Sp. bi, YS blood island; DA, dorsal 







4.5.1.2 Runx1 +24.1 mCNE drives EGFP expression in E10.5 Tg embryos 
In the E10.5 Tg embryo, the Runx1 +24.1 enhancer was active in the YS, the 
VU and the DA of the AGM (P-Sp derivative) (Figure 4.11 A-H). Enhancer activity 
appeared to particularly target hematopoietic cells attached to the walls of these 
arteries (Figure 4.11D, F, and H) - sites where the first definitive HSC of the embryo 
are found. On inspection of histological images obtained from transverse sections of 
E10.5 embryos, EGFP expressing cells ‘budding’ from the wall of the DA and a small 
subset of EGFP+ EC were observed (Figure 4.12). This pattern of activity though 
consistent with endogenous Runx1 expression in these arteries did not recapitulate the 
wider endothelial and mesenchymal expression of Runx1 as previously reported 
(North et al., 1999; Nottingham et al., 2007). In particular, the Runx1 +24.1 mCNE 
targeted EGFP expression to a few cells of the endothelium of the E10.5 DA, but did 
not recapitulate the wider endothelial endogenous Runx1 expression (Figure 4.12).  
In line with this, the Runx1 +24.1 mCNE particularly targeted reporter gene 
expression to the clusters of hematopoietic cells “budding” from the walls of the aorta 
and VU where HSC were previously found (Figure 4.11). Interestingly, reporter 
gene-marked clusters mostly obvious at the ventral wall of the DA (where 
hematopoietic clusters were historically described), were also present along the dorsal 
wall of the DA, albeit weaker EGFP intensity (Figure 4.11H). Recently, Taoudi et al. 
reported on the presence of clusters at the dorsal wall of the aorta, and showed that 
this side of the vessel contains clonogenic hematopoietic progenitor cells, whilst the 




Consistent with the observation in E8.5 Tg mouse embryos, reporter gene 
expression was also observed in the heart of the E10.5 mouse embryo. Interestingly, 
the purported Scl +18/+19, FLI1 +12 and Gata2-3 HSC enhancers, have previously 
been shown to target expression to the heart of similarly staged mouse embryos 
(Donaldson et al., 2005; Pimanda et al., 2007b). This expression though not relevant 
to endogenous Runx1 expression pattern, may likely reflect the similarities in the 
TFBS, especially the Ets, Gata, and E-Box motifs, within these purported HSC 
enhancers and the Runx1 +24.1 mCNE. 
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 Figure 4.11: Runx1 +24.1 enhancer is active in hematopoietic sites in E10.5 
mouse embryo. (A-B) Runx1 +24.1 enhancer activity targets EC in the YS. (C, E, G) 
Bright-field images of the umbilical cord, vitelline artery and DA respectively. (D, F, 
H) Fluorescence images of the umbilical cord, vitelline artery and DA respectively 
shows that Runx1 +24.1 enhancer activity targets all these hemogenic sites. In (H), 
clusters of EGFP+ cells are observed in the ventral wall of the DA. D, dorsal wall of 













Figure 4.12: Runx1 +24.1 enhancer activity targets HSC/progenitor cells  
budding from the wall of the DA in the AGM region. Figure on the right is 
magnified from the region boxed out with dash-lines on the left. Notably only few EC in 
the wall of the DA are EGFP+. These EGFP+ EC are later shown to be hemogenic EC. 




Taken together, the results obtained from our Tg embryos show that the 561-
bp Runx1 +24.1 Runx1 enhancer targets reporter gene expression to all known 
hematopoietic tissues of the mouse embryo in a spatio-temporal pattern that is specific 
and consistent with the hematopoietic expression of the endogenous Runx1 gene 
(North et al., 1999; North et al., 2002; Nottingham et al., 2007; Samokhvalov et al., 
2007).  
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4.5.1.3 Runx1 +24.1 enhancer drives EGFP expression specifically in hemogenic EC 
Further analysis of the Runx1 +24.1 mCNE enhancer activity involved cells 
harvested from the caudal part of E10.5 EGFP-expressing mouse embryos by FACS 
analysis using antibodies against platelet/endothelial cell adhesion molecule 
(PECAM)-1 (an EC marker), CD45 (a pan-leukocyte marker) and Ter119 (an 
erythrocyte marker). Almost all CD45+ HSC/progenitor cells were EGFP+ while 
almost all Ter119+ primitive erythroid cells were EGFP- (Figure 4.13B), consistent 
with previously reported Runx1 expression (North et al., 2002). On the other hand, 
only about one third of all ECs were EGFP+ (Figure 4.13B). 
It was previously shown that EC from WT mice but not from Runx1-/- mouse 
embryos, gave rise to hematopoietic cells when cultured on an OP9 stromal layer in 
the presence of cytokines (Yokomizo et al., 2001). Using this in vitro system for 
studying the hemogenic activity of EC, we investigated the hemogenic capability of 
EGFP- and EGFP+ EC. PECAM+CD45-Ter119- EC were sorted by FACS into EGFP- 
and EGFP+ fractions and cultured on OP9 stromal cells (Figure 4.13A and B). 
Amazingly, consistent results obtained from all three mouse lines show that only the 
EGFP+ but not EGFP- EC from E10.5 mouse embryos gave rise to hematopoietic cells, 
visualised as bright round cells (Figure 4.13D). It is hence apparent that the Runx1 
+24.1 enhancer activity marks specifically hemogenic EC from which HSC ‘bud’.  
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 Figure 4.13: Only the EGFP+ EC gives rise to hematopoietic cells when cultured 
in vitro on OP9 feeder cells. There is a complete lack of generation of hematopoietic 
cells from EGFP- EC (C). Hematopoietic cells are visualized as bright, round cells in 
(D). 
 
The establishment of the Runx1 +24.1 enhancer activity as a positive marker 
for hemogenic EC draws strength from previous reports that EC from WT mice, but 
not from Runx1-/- mouse embryos, gave rise to hematopoietic cells when cultured on 
an OP9 stromal layer (Yokomizo et al., 2001), and that Runx1 is preferentially 
expressed in hemogenic EC (Hirai et al., 2003) where Runx1 is reported to be 
involved in the transition of EC to hematopoietic cells during the development of 
hemogenic EC into hematopoietic cells (Hirai et al., 2005). Significantly, this is the 
first report of a positive marker for hemogenic EC. Previous attempts to isolate this 
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population of cells involved using the Flk-1 promoter/enhancer driving EGFP 
expression where EGFP- EC were determined to have hemogenic potential (Hirai et 
al., 2003). Finally, the Runx1 +24.1 enhancer now provides us the molecular handle to 
manipulate hemogenic EC, from which more knowledge will be gained about the 
emergence of HSC. 
Collectively, results obtained from analyses of Tg embryos indicate that the 
+24.1 Runx1 enhancer faithfully targets hemogenic endothelium as well as emerging 






4.5.2 Runx1 +24.1 enhancer activity marks HSC in the adult mouse BM – 
immunophenotypically and functionally 
  
4.5.2.1 Runx1 +24.1 enhancer activity marks immunophenotypically defined HSC 
To characterize the function of Runx1 +24.1 mCNE in the adult hematopoietic tissues, 
cells from the adult Tg mouse BM, spleen and thymus, were analyzed by FACS for 
EGFP expression (Table 4.3). In our selected mouse line, Line #523, 
immnuophenotypic analysis shows that Runx1 +24.1 enhancer activity marks the 
majority of BM c-kit+Sca-1+Lin- (KSL) cells (Figure 4.14B; Table 4.3), and only a 
very low percentage (<5%) of lineage-positive differentiated blood cells (boxed out in 
blue in Figure 4.14). Notably, the EGFP intensity of lineage-positive cells is 
significantly lower than that observed in HSC/progenitor cells. Furthermore, less than 
8% of the c-kit+Sca-1-Lin- fraction of immature progenitor hematopoietic cells, which 
are less immature than HSC/progenitor cells within the KSL fraction, exhibit 
significantly reduced GFP intensity (Figure 4.14A). Taken together, these results 
suggest that the Runx1 +24.1 enhancer is preferentially active within HSC/progenitor 
cells in the KSL compartment and that the enhancer activity is likely to be rapidly 















































Figure 4.14: Runx1 +24.1 enhancer activity marks majority of KSL 
HSC/progenitor cells and only few lineage-positive BM cells. Immature, Lin- cells 
are boxed out in red and gated based on c-kit and Sca-1 expression. A) c-kit+Sca-1-
Lin- cells; B) c-kit+Sca-1+Lin- cells; C) c-kit-Sca-1-Lin- cells and D) c-kit-Sca-1+Lin- 
cells. Lin+ cells are boxed out in blue. 
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The low levels of EGFP intensity in small percentages of BM cells outside the 
KSL compartment can be explained by either (i) low activity of the +24.1 enhancer in 
a small subset of these cells or (ii) EGFP protein, which exhibits a 26 hr half-life 
(Ward and Stern, 2002), is passed on during cell division, from more immature 
HSC/progenitor cells to daughter cells which are starting to differentiate. Unlike the 
original EGFP protein which is extremely stable, d2EGFP, a destabilized variant of 
EGFP, has a half-life of approximately 2 hours in vivo (Eggermont and Proudfoot, 
1993). This issue can be resolved by the use of d2EGFP as a reporter gene in place of 
EGFP may help to eliminate the “carry-over” effect from mother to daughter cells 
during cell division and hence enable a more precise delineation of the population of 
cells in which the Runx1 +24.1 enhancer functions.  
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4.5.2.2 In vitro analysis of HSC function 
To assess the stem cell function of the two different sub-populations of KSL cells, we 
first compared the colony-forming ability of KSL-EGFP- and KSL-EGFPhi cells when 
cultured in vitro in methylcellulose. 
 
 
Figure 4.15: Runx1 +24.1 enhancer activity enriches for multipotential 
HSC/progenitor cells. A) results from primary culture using intially sorted cells, 
after 10 days in culture. B) results from secondary culture 10 days after replating. 
CFU-, Colony forming unit; GEMM, granulocyte, erythrocyte, macrophage, 
megakaryocyte; GM, granulocyte, macrophage; M, macrophage; G, granolulocyte. 
 
 
Table 4.4: Comparison of the colony-forming ability of GFP- and GFP+ KSL 
cells 
 
Difference in number of colonies formed by GFP- and GFP+ cells with P-values of 
significance (P <0.05) are bolded and italicised. 
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The generation of single-lineage colonies [i.e. granulocytes (G), macrophages 
(M)] is indicative of restriction of parent cells to one lineage; in contrast, the presence 
of multilineage colonies (GM, GEMM/mixed) is indicative of more immature parent 
cells with the capacity to differentiate into multiple lineages. Interestingly, the 
population derived from KSL-EGFP+ cells gave rise to a greater frequency of 
multilineage colonies, particularly CFU-GEMM, both during the intial plating as well 
as the subsequent replating (Figure 4.15; Table 4.4). Although the KSL-EGFP- 
fraction contains immature cells which gave rise to comparable numbers of CFU-GM 
colonies as compared to the KSL-EGFP+ cells, these GFP- cells were less successful 
in forming multilineage colonies when replated (Figure 4.15; Table 4.4). Together, 
these data suggest that a higher fraction of multipotential cells reside in the KSL 
fraction marked by Runx1 +24.1 enhancer activity. While informative about the 




4.5.2.3 In vivo analysis of HSC function 
The most rigorous way to functionally identify and/or define HSC is to perform 
transplantation assays that allow for the assessment of long-term (LT) multilineage 
engraftment. Long term reconstitution experiments were performed, using the 
congenic Ly5.1/Ly5.2 system, where irradiated adult mice were used as recipients. 
BM cell suspensions were obtained from individual adult 
+24.1mCNE/mhsp68P/EGFP Tg mice. Three different sets of transplantation 
experiments were carried out, using either ungated, c-kit+Lin- (KL)-gated or c-
kit+Sca-1+Lin- (KSL)-gated BM cells. In each case, two sorting regions were set 
according to the relative levels of EGFP expression. Equal numbers of either sorted 
EGFPneg and EGFPhigh cells were transferred into irradiated recipient mice with 2x105 
non-Tg female BM cells to provide short-term radioprotection. Donor cell 




 Figure 4.16: Runx1 +24.1 enhancer activity enriches for HSC. Results obtained 
from (Top) WBM, (middle) KL, and (bottom) KSL transplantation experiments. Left 
panel: green and black lines represent results obtained from transplantation using 
EGFP+ cells and EGFP- cells, respectively. Right panel shows chimerism for specific 
cell lineages checked to determine multilineage reconstitution; determined at Week 28 
for WBM and KL transplanted & Week 24 for KSL transplanted. 
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Consistent with the immunophenotype of the EGFP+ cells in the WBM, these 
donor cells exhibited higher chimerism at all time points analysed compared to their 
EGFP- counterparts (Figure 4.16). The difference in percentage chimerism decreases 
with increased stringency in gating for immature stem/progenitor hematopoietic cells. 
Nevertheless, these data suggest that the vast majority of HSC were in the EGFP+ 
fraction. Furthermore, Runx1 +24.1 enhancer activity appears to enrich for LT-HSC 
within the KSL compartment.  
True multipotent LT-HSC should have the ability to (1) engraft, (2) effectively 
regulate its ability to self-renew, and (3) to differentiate into cells of myeloid, B- and 
T-lineages without biase for any particular lineage. Hence, the read out for such 
“true” LT-HSC should include high levels of chimerism (defined as >50% percentage 
chimerism) and also the presence of a relatively equal distribution of myeloid, B- and 
T-cells in the reconstituted system. Based on this definition, none of the EGFP- WBM 
or KL-gated cells used for transplantation appeared to possess such stem cell qualities. 
Only 1 out of 6 EGFP- KSL-gated cases exhibited LT-HSC abilities. Conversely, 
EGFP+ WBM and KL-gated populations of cells used for transplantation showed high 
levels of engraftment, with relatively even multilineage reconstitution. Six out of 7 
EGFP+ KSL-gated cases showed similar successful reconstitution, reiterating the fact 
that the Runx1 +24.1 enhancer activity enriches for HSC, even within the KSL 
compartment. Interestingly, a very small number of the cells in the PB of EGFP+ 
cells-transplanted recipients were weakly EGFP positive. These weakly positive 
EGFP cells in KSL-transplant cases were determined to be mostly myeloid and T 
cells. B cells in the PB, however, were never EGFP positive. 
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4.5.3 Runx1 +24.1 mCNE, a HSC enhancer? 
There has been considerable interest in identifying a regulatory element that targets 
expression to HSC. Characterisation of such an enhancer, termed HSC enhancer, 
holds the promise of generating important insights into the transcriptional 
programmes responsible for hematopoiesis, and will also provide a powerful tool for 
experimental manipulation of HSC. HSC enhancers, in combination with reporters 
such as EGFP or LacZ, can be used for the isolation of HSC. Furthermore, the use of 
fluorescence reporters, like EGFP, enables the live imaging of HSC either in vitro or 
in vivo. Alternatively, HSC enhancers when used to drive the expression of the Cre 
recombinase gene can be used to knockout genes of interest specifically in HSC, 
thereby allowing for the manipulation of HSC behavior in vivo. However, very few 
candidate HSC enhancers have been identified. These proposed candidates include 
regulatory elements from Sca-1, Bmi-1, Notch1, Scl, Fli-1 and Gata-2 genes. 
The mouse hematopoietic marker Sca-1 is encoded by the Ly-6E.1 and Ly-
6A.2 genes. Given the instrumental role of Sca-1 in the enrichment and 
characterization of adult HSC, genomic fragments within a 14-kb genomic casette 
from the Ly-6E.1 gene were used to target the lacZ reporter gene to adult HSC in vivo 
(Miles et al., 1997). However, the use of this expression construct to target HSC had 
its limitations since the expression of Sca-1 in HSC is mouse strain dependent (Codias 
et al., 1989; Spangrude et al., 1988). Moreover, the Ly-6E.1 expression casette is not 
expressed in the FL or YS progenitors and no individual enhancer has been shown to 
be sufficient to target HSC. 
More recently, the Bmi-1GFP/+ reporter mouse using GFP as a surrogate marker 
demonstrated in adult mice that Bmi-1 expression levels were highest in the most 
immature LT-HSC, within the KSL compartment, and down-regulated along with 
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differentiation, while terminally differentiated cells expressed low levels of Bmi-1 
(Hosen et al., 2007).  However, there is currently a lack of information on the activity 
of this reporter during embryonic development. Besides, Bmi-1 targeted GFP 
expression is exhibited in several non-hematopoietic tissues. Clearly, this reporter 
mouse allows for the isolation of HSC within the hematopoietic compartment. 
Conversely, if precise regulation in HSC (excluding non-hematopoietic tissues) is 
required, for example, to knockout a gene specifically in HSC to study their behavior 
in vivo, this reporter is not suitable. 
The transgenic Notch reporter (TNR) mouse, in which EGFP fluorescence 
indicates the status of Notch signalling, has a transgene composed of a CBF-1 
response element with four CBF-1-binding sites and a minimal SV40 promoter 
followed by EGFP (Duncan et al., 2005). Like in Bmi-1GFP/+ reporter mice, EGFP in 
these mice is highly expressed in populations enriched for HSC and downregulated as 
these cells differentiate (Duncan et al., 2005), allowing GFP to serve as both a 
surrogate marker for HSC and a sensor of the undifferentiated state. Interestingly, 
cells from the TNR mice were used for live cell imaging to track hematopoietic 
precursor division (Wu et al., 2007). However, Notch signalling regulates stem cells 
in many different settings, including the nervous system, hematopoietic system, skin 
and gut (Chiba, 2006). This reporter is hence expected to be unable to specifically 
mark HSC and should target stem cells from non-hematopoietic tissues as well. 
Indeed, the TNR mice have also been used to distinguish neural stem cells from 
intermediate progenitors (Mizutani et al., 2007). 
 Regulatory elements from the Fli1, Gata2 and Scl genes have also been shown 
to target HSC, sharing the commonality of the reliance on a combination of Ets, Gata, 
and E-Box motifs for their regulatory functions (Pimanda et al., 2007b). They are the 
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500-bp human FLI1 +12 enhancer, the 496-bp Gata2-3 enhancer fragment and the 
5.5-kb scl 3’ (+18/+19) enhancer which contains a 644-bp core +19 enhancer 
(Pimanda et al., 2007b). Consistent with their essential roles in hematopoiesis, Scl, 
Gata2, and Fli transcripts are all present in hematopoietic intra-aortic clusters located 
within the floor of the DA, in the aortic endothelium, and in FL cells in E11.5 mouse 
embryo. Enhancers identified from these genes have comparable ability to target 
reporter gene expression to the DA endothelium, blood vessels and intra-aortic cell 
clusters during embryonic development (Donaldson et al., 2005; Pimanda et al., 
2007b). In addition, the Scl and Fli1 enhancers have been verified by in vivo 
transplantation assays to have the ability to target FL LT-HSC.  
The 496-bp Gata2-3 enhancer element was identified as a potential HSC 
enhancer through genome-wide computational screens using the number of conserved 
Ets, Gata, and E-box motifs within the in vivo validated Fli1+12 hematopoietic 
enhancer for comparison (Pimanda et al., 2007b). The Gata2-3 enhancer is actually 
comprised within the 3.1-kb Gata2-EHRD promoter fragment previously shown to be 
sufficient and necessary for Gata2 expression in the hemogenic DA (Kobayashi-Osaki 
et al., 2005). Notably, the Gata2-3 enhancer directs very strong reporter gene 
expression to neural tissues (Pimanda et al., 2007b). This calls into question the 
validity of the Gata2-3 enhancer as a good HSC enhancer, especially if one would like 
to use this enhancer as a molecular tool to target very specifically HSC. 
 The Scl 3’ enhancer is by far the best characterized element amongst these 
purported HSC enhancers. The activity of the Scl 3’ enhancer has been characterised 
in both embryos as well as adults. In addition to FL LT-HSC, the Scl +18/19 enhancer 
targets adult BM LT-HSC but beyond that this enhancer also maintains significant 
reporter gene expression in differentiated mast cells and megakaryocytes. This 5.5-kb 
 147
fragment has also been shown in certain cases to target reporter gene expression to 
erythrocytes, ranging from a small percentage up to 49% of Ter119+ erythroid cells 
(Sanchez et al., 1999; Silberstein et al., 2005). The Scl +18/+19 enhancer has been 
used in a Cre-containing expression construct for in vivo fate-tracing studies to show 
that embryonic HSC significantly contribute to adult hematopoiesis (Gothert et al., 
2005). Even though the SCL +18/19 stem cell enhancer has been shown to mark 
lineage-positive hematopoietic cells other than LT-HSC, this enhancer is currently 
one of the most popular tools to engineer transgene expression in HSC in vivo (Chen 
et al., 2002; Eguchi et al., 2005; Gothert et al., 2005; Koschmieder et al., 2005; 
Murphy et al., 2003; Sanchez et al., 2001). 
In contrast, the Runx1 +24.1 enhancer, has a more restricted activity in the DA 
than the previously identified Gata2, Fli-1 or SCL stem cell enhancers, in that it 
targets specifically hemogenic EC and emerging hematopoietic clusters but not the 
general endothelium. According to the hemogenic endothelium theory, a special 
subset of EC, the hemogenic EC are the source of the first definitive HSC/progenitor 
cells during embryonic development; these HSC/progenitor cells in turn contribute to 
continued hematopoiesis throughout the life span of an organism. Significantly, while 
Runx1 was found to be preferentially expressed in hemogenic EC, Scl and Gata2 were 
found to be expressed at equal levels in both hemogenic and non-hemogenic EC 
populations (Hirai et al., 2003). Hence the discovery of a Runx1 enhancer which 
targets specifically hemogenic EC does not come as a surprise. Despite common Gata, 
Ets and E-box motifs present in all these enhancers, suggesting a common mode of 
regulation by the binding of a Gata2, Fli-1 and SCL containing protein complex, the 
deep conservation of other binding motifs (absent in the purported HSC enhancers) 
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and their precise spacing with respect to the Gata, Ets and E-box motifs present in the 
Runx1 +24.1 mCNE may account for the enhanced specificity of the Runx1 enhancer. 
Collectively, the results generated from my work, show unambiguously that 
the Runx1 +24.1 enhancer activity targets specifically hemogenic EC as well as adult 
BM LT-HSC. It is hence apparent that the 561-bp Runx1 +24.1 enhancer is an 
extremely ideal HSC enhancer candidate. Significantly, the Runx1 +24.1 enhancer 
activity appears to mark very specifically HSC and does not direct reporter gene 
expression to lineage-positive hematopoietic cells. Therefore, the Runx1 +24.1 stem 
cell enhancer may prove to be a better regulatory element for the experimental 
manipulation of HSC. In conclusion, the Runx1 +24.1 enhancer is anticipated to serve 
as a molecular handle for tracing and/or manipulating hemogenic EC / HSC behavior 
in vivo and consequently become an invaluable tool for research on stem cell and 
cancer biology. 
 
4.5.4 Note in proof 
While this work was in progress, Nottingham et al., published their findings of an 
intronic Runx1 enhancer that, coincidentally, is the same enhancer we identified 
independently. A highly conserved 531-bp intronic Runx1 enhancer located between 
the distal (P1) and proximal (P2) Runx1 promoters (+23 CNE) was reported where a 
combinatorial approach of applying comparative genomics together with traditional 
DNase I hypersensitivity was used in the initial identification of this element that 
targets reporter gene expression to all known hematopoietic tissues of the E8.0 and 
E10.0 mouse embryos in a spatio-temporal pattern that is specific and consistent with 
the hematopoietic expression of the endogenous Runx1 gene (Nottingham et al., 
2007). Like the Runx1 +24.1 mCNE, the +23 CNE activity did not recapitulate the 
 149
wider endothelial and mesenchymal expression of Runx1 as previously reported (North et 
al., 1999; Nottingham et al., 2007). The notion that Nottingham et al., had that this 
enhancer may only target aortic endothelial/mesenchymal Runx1-expressing cells that are 
the precursors of the HSC and clonogenic progenitors (i.e. the proposed hemogenic 
endothelium/hemangioblasts) has been confirmed by the results obtained as shown in 
Figure 4.13. Moreover, ChIP experiments showed that Gata2, the Ets factors Fli-1, 
Elf-1, Pu.1, and the SCL/Lmo2/Ldb1 complex are bound to the enhancer in vivo.  
(Landry et al., 2008; Nottingham et al., 2007). Significantly, transplantation assays 
confirmed that the +23 CNE targets LT-HSC in the FL and AVU of E11 Tg mouse 
embryos. Notably, there are two key differences between their construct and ours for 
establishing Tg mice: (i) LacZ is used as a reporter gene instead of EGFP and (ii) the 
intronic enhancer element is cloned downstream of both the mshp68 promoter and the 
reporter gene instead of upstream.  
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Chapter 5 – Future Directions 
The work presented in this thesis has shown unambiguously that the Runx1 +24.1 
enhancer activity targets specifically hemogenic EC and adult BM LT-HSC. 
Collectively, the Runx1 +24.1 enhancer activity appears to target LT-HSC in early 
mouse embryos and in adults. The identification of this enhancer as a HSC enhancer 
creates new opportunities for future research.  
 Beyond the characterization of the Runx1 +24.1 mCNE, I have moved on to 
using this Tg mouse model for the visualization of the emergence of HSC/progenitor 
cells from hemogenic EC. There is considerable interest in the field to visualize HSC 
activity, especially in vivo, to further our understanding of HSC behavior. However, 
there are very few published work showing HSC activities captured in videos / 
movies in vivo. I have attempted to visualize the emergence of HSC/progenitor cells 
from hemogenic EC using DA explants and confocal microscopy. Results obtained 
thus far are still preliminary and more troubleshooting is required to obtain the best 
images possible. In addition to imaging of explants from Tg mouse embryos, the 
activity of hemogenic EC and HSC will also be imaged in vitro using cells sorted by 
FACS and grown in co-culture on OP9 stromal cells. 
As an extension of the work presented in this thesis, Tg mice with Cre 
recombinase as a reporter gene in place of EGFP have been generated. One of the first 
goals with these new Tg mice will be to confirm that the Runx1 +24.1 mCNE drives 
the expression of Cre to the same hematopoietic / hemogenic sites as reported in this 
thesis. Subsequently, I plan to cross the Cre Tg mice to Runx1 flox/flox mice to 
determine whether knocking out Runx1 specifically in hemogenic EC is sufficient to 
obtain an embryonic lethal phenotype like that observed in conventional Runx1 
knockout mice. Such a Cre Tg mouse will also create collaborative opportunities for 
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other researchers to knockout their gene of interest specifically in hemogenic EC and 
HSC. Ultimately, inducible-Cre Tg mice will be generated to enable the study of HSC 
at different stages during ontogeny.  
 Beyond studies involving the Runx1 +24.1 mCNE, I would also like to be 
involved in the identification of other regulatory elements which will help to elucidate 
the entire machinery for the regulation of Runx1 expression. The ultimate goal will be 
to identify elements which are mutated or contain SNPs that has predisposition for 
human diseases, such as leukemia. Although I have screened genomic DNA samples 
from leukemia patients, neither mutations nor SNPs have been identified in the human 
equivalent of the Runx1 +24.1 mCNE enhancer. Hence, it is likely that there are other 
regulatory elements waiting to be discovered which may further elucidate the 
involvement of Runx1 in dieases such as leukemia. One quick way of identifying 
additional regulatory elements will be to carry out ChIP-on-chip experiments which 
allows for the entire Runx1 gene locus to be probed using antibodies against specific 
histone modifications indicating ‘open’ or ‘close’ regions. The chromatin state of 




Chapter 6 - Materials and Methods 
Identification of the fugu Runx family genes from the fugu genome database 
The fugu genome database at http://www.fugu-sg.org (fourth assembly) was BLAST-
searched with human RUNX1, RUNX2 and RUNX3 protein sequences by using the 
‘TBLASTN’ algorithm. Scaffolds #36, #16, #464/#23 containing putative exons 
homologous to human RUNX1, RUNX2 and RUNX3 exons, respectively, were thus 
identified. The additional scaffold #39 that was identified through this search was 
found to contain the frRunt gene. A similar BLAST search using the human PEBP2β 
protein sequence identified fragments of a fugu homologue on two different scaffolds, 
#2060 and #3714. 
mRNA expression of fugu and mouse Runx family genes 
Total RNA was extracted from various tissues of adult fugu (Takifugu rubripes) and 
mouse (Mus musclus) by using Trizol reagent (Gibco BRL, Grand Island, NY) 
according to the manufacturer's protocol. The purified total fugu RNA was reverse 
transcribed into cDNA by using the AMV reverse-transcriptase first-strand cDNA 
synthesis kit (Gibco BRL) whereas total mouse RNA was reverse-transcribed into 
cDNA by using the Expand Long reverse-transcriptase (Roche). The cDNA was used 
as a template in PCR reactions with AmpliTaq DNA Polymerase (Roche) for fugu 
and Flexi GoTaq DNA polymerase (Promega) for mouse. The gene-specific primers 
complementary to fugu and mouse Runx1, Runx2, Runx3, Cbfb and frRunt genes used 
are available in Table 7.1. A fragment of frβ-Actin was amplified as an internal 
control. All primer pairs span at least one intron which helps to distinguish cDNA 
from genomic DNA products. 
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 Table 7.1: Primers for RT-PCR 
Gene Primer Name Primer Sequence (5'→ 3') 
frRunx1 fRUNX1(RT-PCR) FW ACGGCCGCCATCAAGAACCAG fRUNX1 (RT-PCR) RV CCTCTCAGAGAAGGCCAGAGC 
frRunx2 fRUNX2 (RT-PCR) FW GGTGCAACAAGACGCTACCTGTC fRUNX2 (RT-PCR) RV CTCGTGGTCCATCGACGGTAAC 
frRunx3 fRUNX3 (RT-PCR) FW TCGTGGCTCTTGGGGATGTGC fRUNX3 (RT-PCR) RV GGTCCATCCACGGTGACTTTG 
frRunt 
frRUNT RT-PCR FW AGACAGACAGCCCAAACTTCC 
frRUNT RT-PCR RV-R1 TGTCCATCCACGGTCACCTTG 
frRUNT RT-PCR RV-R2 GTAAAGTGGCGATCTGAGGTG 
frRunxb *frCbfb 3' RACE FW1 CTGGATGGGATGGGATACCTC frCbfb cloning RV-R1a TCAGCACATCTTTTGTCCTGCATC 
frβ-Actin-1 frB-actin-1-FW ACAGACCTCATGAAGATCCT frB-actin-1-RV GAGGCCAGGATGGAGCCTCC 




frRUNX1 Distal-FW CTGTGTTGTCCTGCCACTCAGC 
frRUNX1 Proximal-FW CGCAGTGACTCTGAAATTGGAACG 
fRUNX1 (5' RACE R2) CTTCACCAGCTCACCTGGATGATC 
mmRunx1 mmRunx1-RT-PCR-FW2b TGGCCAGCAAGCTGAGGAG mmRunx1-RT-PCR-RV2b TTCTGCCGAGTAGTTTTCATCG 
mmRunx2 mmRunx2-RT-PCR-FW1 TCCGAAATGCCTCCGCTGTTATG mmRunx2-RT-PCR-RV1 TCTTGGTTCCCGGGGACCG 
mmRunx3 mmRunx3-RT-PCR-FW2b TCGATGGTGGACGTGCTG mmRunx3-RT-PCR-RV2bi GCTGGGTGTGCTTGGTGTTA 
mmCbfb mCBFB-RT-FW1 AACAGCGACAAACACCTAGC mCBFB-RT-RV1 CGCCACCTAAGTTAGAACCA 
mGAPDH GAPDH-S ACCACAGTCCATGCCATCAC GAPDH-AS TCCACCACCCTGTTGCTGTA 
 
fugu cDNA cloning using RT-PCR and 5′- and 3′-RACE 
The genomic structures of the Runx family members, including the exon–intron 
structures and TSS, were deciphered by mapping the cloned cDNA obtained from 
RT-PCR and 5′-and 3′-RACE to the genomic sequence. 5′-and 3′-RACE were 
performed on RNA from the fugu gill, kidney and spleen by using the SMART RACE 
cDNA Amplification kit (Clontech, Palo Alto, CA) in a nested PCR. The RACE 
products were cloned into the TA-cloning vector pDrive (Qiagen), and sequenced by 
using an Applied Biosytems 377 automated DNA sequencer. Primer walking by using 
multiple primers for PCR was employed to identify the TSS for the frRunx2 P1 
promoter driven transcript only, since 5′-RACE failed to amplify the cDNA, probably 
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due to a low abundance of these transcripts. Various isoforms of frRunx transcripts 
were cloned from the fugu gill and kidney by semi nested PCR and a total of sixteen 
frRunx gene sequences have been deposited to the DDBJ database (Accession 
numbers AB280002–AB280014, AB304811–AB304813). The gene-specific primers 
used are available in Table 7.2. 
Table 7.2: Primers for RACE & RT-PCR 
Gene Primer Name Primer Sequence (5'→ 3') 
frRunx1 
fRUNX1 (5' RACE R1) GTGTGTGGGCAGCACAGAGCAGAG 
fRUNX1 (5' RACE R2) CTTCACCAGCTCACCTGGATGATC 
fRUNX1 (5' RACE R1a) AGCCGAGCGTGGTGGAGGGTG 
fRUNX1 (5' RACE R2a) GTGTAACGCCGGCCAGGCGCT 
fRUNX1 (5' RACE R3a1) GCTGAGTGGCAGGACAACACAG 
fRUNX1 (5' RACE R3a2) TCCCAGAGAAACACCATTGGTGC 
fRUNX1 (3' RACE FW1) GTCATCGTCAGAAGATGGACGAGG 
fRUNX1 (3' RACE FW2) GCTCTGGCCTTCTCTGAGAGG 
fRUNX1 (3' RACE FW1a) TGGCAACGACGCCAACAGGAAGG 
fRUNX1 (3' RACE FW2a) TGCCTCCTCCGTACCCAGCAAAC 
fRUNX1 (3' RACE FW1b) GATCCTGCCACCGTGCACCAAC 
fRUNX1 (3' RACE FW2b) CTGCACCCATCTTTGCCGAATC 
frRUNX1 internal-FW2 GTGATTTCGGATCATCCAGGTGAG 
frRUNX1 internal-RV2 GAAACGCAGGTCGTTGAATCTGG 
frRunx2 
frRUNX2 5' RACE RV1 TTCGTGGGGACGCAGCCTGGGTAC 
frRUNX2 5' RACE RV2 TCCCTGGGACCGGCTGGAGGCTAC 
frRUNX2 3' RACE FW1 AGCGCCCACTACCACACATAC 
frRUNX2 3' RACE FW2 AGCACGCCATATCTCTACTACGG 
frRUNX2 3' RACE FW1a GTAGCCTCCAGCCGGTCCCAGGGA 
frRUNX2 3' RACE FW2a GTACCCAGGCTGCGTCCCCACGAA 
frRUNX2 internal FW1 AGGGGAGGCCCGGGAACTGAC 
frRUNX2 internal RV1 TCACCAACCCGCCACAAGTGGC 
frRunx3 
frRUNX3 5' RACE RV1 TCCTGCCCACGAAGCGCAGGTCG 
frRUNX3 5' RACE RV2 TCGTCGTTTCCGGCCATCACCGTG 
frRUNX3 5' RACE RV1a AGGAAGTTTGGGCTGTCTGTCC 
frRUNX3 5' RACE RV2a CGGTCTTGACCTTAAGGGACC 
frRUNX3 3' RACE FW1 ACCAGTTCTCCATGGTGGCCC 
frRUNX3 3' RACE FW2 ACCGGAGGAGCAAACAGCTTGATG 
frRUNX3 internal FW1 TCGCCACCTACCACCGCGCCATC 







*frCbfb 3' RACE FW1 CTGGATGGGATGGGATACCTC 
frCbfb 3' RACE FW2 CGAATATGATGAGGAGAGGGCAC 
frCbfb 5' RACE RV1 GTGCCCTCTCCTCATCATATTCG 
frCbfb 5' RACE RV2 GAGGTATCCCATCCCATCCAG 
frCbfb 3' RACE FW1a GCAAACTGAGCCGAGAATGTG 
frCbfb 3' RACE FW2a GCTCGTTTCCAGAATGCTTGC 
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Amino acid alignments 
The protein sequences for human RUNX genes were retrieved from the National 
Center for Biotechnology Information (NCBI) database. Multiple sequence 
alignments of proteins were performed by using ClustalW for α-subunit Runx proteins 
and ClustalV for Pebp2β. 
Prediction of transcription factor-binding sites (TFBS) in the promoter regions 
Analyses of TFBS were carried out by using TESS (http://www.cbil.upenn.edu/tess/) 
(for the −500 to +140 promoter regions of all fugu and human Runx genes. Only the 
TFBS that met the criteria of La≥12, La=2, Lq=1 and Ld=0 were identified as 
putative TFBS. In addition to TESS, analyses of TFBS carried out in Chapter 4 also 
involved the JASPAR_CORE database (http://jaspar.genereg.net/cgi-
bin/jaspar_db.pl). 
Comparative genomics 
Masked genomic sequences surrounding the Runx1 locus for human (Homo sapiens), 
mouse (Mus musculus), and rat (Rattus norvegicus), dog (Canis familiaris), horse 
(Equus caballus), opossum (Monodelphis domestica), platypus (Ornithorhynchus 
anatinus), lizard (Anolis carolinensis), chicken (Gallus gallus), frog (Xenopus 
tropicalis), fugu (Takifugu rubripes)   was obtained from publicly available genome 
assemblies (human Mar. 2006 (hg18) assembly, mouse July 2007 (mm9) assembly, 
rat Nov. 2004 (rn4) assembly, dog May 2005 (canFam2) assembly, horse Jan. 2007 
(equCab1) assembly, opossum Jan. 2006 (monDom4) assembly, platypus Mar. 2007 
(ornAna1) assembly, lizard Feb. 2007 (anoCar1) assembly, chicken May 2006 
(galGal3) assembly, X. tropicalis Aug. 2005 (xenTro2) assembly, respectively) on the 
UCSC genome browser (http:// genome.ucsc.edu). These genome sequences were 
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subject to multiple alignments generated by using MLAGAN 
(http://lagan.stanford.edu/lagan_web/index.shtml) and visualized using VISTA. CNE 
were identified by using a criterion of 70% identity across 30-bp or 100-bp windows. 
Genomic sequence from fugu was obtained from the fugu genome database at 
http://www.fugu-sg.org (fourth assembly). 
Plasmid construction 
A pBSK-based vector containing I-Sce recognition sites flanking the multiple cloning 
sites (MCS) was used for cloning the expression vector used in both zebrafish and in 
mouse studies. This vector will henceforth be referred to as the target vector. Several 
steps of sequential cloning were carried out to obtain the final expression constructs. 
First, EGFP was amplified from the pEGFP-1 vector using specific primers, with 
EcoR I recognition sequence attached to the forward primer and Sal I recognition 
sequence attached to the reverse primer. The EGFP PCR product was purified by 
Qiagen gel extraction kit (QIAGEN, Germany), digested with EcoR I and Sal I and 
cloned into similarly digested target vector using standard protocol. Next, the 
zebrafish heatshock protein 70 promoter (zhsp70p) was amplified from the pHspIG 
heat-shock vector using specific primers with EcoR I recognition sequence attached to 
both the forward and reverse primers. The zhsp70p PCR product was purified by 
Qiagen gel extraction kit (QIAGEN, Germany), digested with and cloned into 
similarly digested EGFP-containing target vector using standard protocol. The mouse 
heat shock protein 68 promoter was amplified from hsp68-lacZ vector using specific 
primers followed by subcloning of PCR product into the pDrive vector; The mhsp68 
promoter was then excised from the TA vector using EcoR I restriction enzymes, 
purified by Qiagen gel extraction kit (QIAGEN, Germany), and cloned into the target 
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vector already containing EGFP. RIS-CNE fragments were amplified from mouse tail 
genomic DNA using specific primers with BamH I recognition sequence attached to 
both the forward and reverse primers. The PCR products were purified by Qiagen gel 
extraction kit (QIAGEN, Germany), digested with BamH I and cloned into similarly 
digested target vector containing EGFP with either the zebrafish or mouse heat shock 
promoter fused upstream, using standard protocol. All fragments were amplified by 
PCR method using Accuprime Taq (Invitrogen, USA). PCR cycling conditions 
included preheating step at 95°C for 5 min followed by 35 cycles of 95°C for 30 sec, 
58°C for 40 sec and 68°C for 3 min, and a final extension step at 68°C for 10 min. 
The sequence of each clone was verified by cycle sequencing (Applied Biosystems).  
Maintenance of zebrafish 
The WT zebrafish (Danio rerio) AB line was maintained at 28.5°C under a light and 
dark cycle of 14:10 hr, respectively; according to established protocols (Westerfield, 
1993) and in agreement with the IACUC regulations and rules of the IMCB zebrafish 
facility. Embryos were produced using natural matings and staged according to hours 
postfertilization (hpf) or days  post fertilization (dpf). 
Microinjection and microscopic observation 
For DNA microinjection, plasmid DNA was dissolved in distilled H2O to a final 
concentration of 50-100 ng/ul. Just a little (approximately 1ul or less) of phenol red 
was added to the DNA solution to facilitate visualization during microinjection. 
Approximately 1-2 nl of DNA solution was microinjected into one-cell stage 
zebrafish embryo. Green fluorescence was visualised under a Leica DMIRE2 
fluorescence microscope. 
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Imaging to determine enhancer activity in zebrafish 
EGFP was visualized under an Olympus BX51 microscope and images were captured 
with an Olympus DP70 camera. For imaging of live Tg embryos, embryos were first 
anethesized with 0.02% Tricaine, mounted in 0.5% low melting agarose and imaged 
under an Olympus BX51 microscope with an Olympus DP70 camera. Photo recording 
was carried out using the timelapse function provided in DP70capture software. 
Immunohistochemistry staining 
Zebrafish embryos were washed with PBST [(0.1% Tween 20 in phosphate buffered 
saline (PBS)), subsequently treated with pronase to remove the chorion, and then 
washed with PBST again before fixing the embryos in 4% paraformaldehyde (PFA) at 
room temperature for 2 hr. Fixed embryos were washed in PBST (2 x 5 min), rinsed 
in 50% methanol and soaked in 100% methanol at -20°C overnight. Embryos were 
rehydrated sequentially with 75% methanol (1 x 5 min), 50% methanol (1 x 5 min), 
25% methanol (1 x 5 min) followed by PBST (2 x 5 min) and incubated with cold 
acetone (stored at -20˚C) for 5-10 min. Embryos were washed immediately with 
PBST (5 x 3 min). Following that, embryos were blocked in PBDT (PBS, 1%BSA, 
1% DMSO, 0.5% Triton-X) containing 2% lamb serum, at room temperature for 1 hr 
with shaking. Towards the end of this incubation period, fresh PBDT with 2% lamb 
serum was prepared to which primary antibodies used for staining were added. 
Embryos were incubated with the primary antibodies at 4˚C overnight. Embryos were 
washed with PBDT (3 x 10 min) and then stained with secondary antibodies for 1-2hr 
at room temperature washed with PBDT (3 x 15 min) and mounted using Vectashield 
containing DAPI (Vector Laboratories). Primary antibodies used are as follows: goat-
anti-EGFP (biotin) (abcam; ab6658), guinea pig anti-Scl-C, rabbit anti-beta E1 globin 
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(BE1). The anti-scl and anti-beta E1 antibodies were made by Dr Wen Zilong’s 
laboratory (WZL lab). Secondary antibodies (from molecular probes) used are as 
follows: donkey streptavidin (SA) Alexa 488 (S-11223), goat-anti guinea pig Alexa 
555 (A-21435), donkey-anti goat Alexa 647 (A-21447). All antibodies were 
generously provided by the WZL laboratory. Imaging was carried out using 100X 
objective lens on an Olympus  fluoview confocal microscope. 
Cell Culture 
A20 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine 
serum (FBS), 0.05 mM 2-mercaptoethanol, 2 mM L-glutamine, and 
penicillin/streptomycin/ amphotericin (PSA). FDCPmix cells were grown in Iscove’s 
modified Dulbecco’s medium supplemented with 20% FBS, 10ng/ml IL-3, and PSA. 
Neuro-2a cells were grown in Dulbecco’s Modified Eagle’s Medium (high glucose; 
4500 mg/L glucose) supplemented with 10% FBS, 2mM L-glutamine, 0.1mM non-
essential amino acid, 1.0mM sodium pyruvate, and PSA. P19 cells were grown in 
αMEM medium supplemented with 10% FBS, and PSA. All cells were incubated in a 
37°C incubator in an atmosphere of 5% carbon dioxide (CO2) in air. 
Quantitative real-time PCR (qRT-PCR) 
Cell pellets were collected in TRIZOL LS Reagent (Invitrogen, USA). RNA 
extraction was performed following the manufacturers instruction. The RNA was 
further purified using the RNeasy kit (Qiagen) as per the manufacturer’s protocol. 
cDNA was synthesized by Expand Reverse Transcriptase (Roche Molecular 
Biochemicals) and subjected to qRT-PCR. The real-time PCR was performed using 
ABI prism 7500 Fast real-time PCR system (Applied Biosystems) with an initial step 
of 95°C for 10 min followed by 40 cycles of 94°C for 15 sec and 60°C for 1 min. 
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Primers specific for distal P1 isoform, proximal P2 isoform and regions common to 
both isoforms were designed and generated for use in a power SYBR green reaction 
mix (Applied Biosystems). All the reactions were performed in triplicate. Relative 
quantity of expression was calculated by SDS software ver.2.2.2 using hypoxanthine-
guanine phosphoribosyltransferase (HPRT) as an endogenous internal control. 
Quantitative Chromatin immunoprecipitation (qChIP) 
Adherent cells were washed twice with cold PBS and fixed with 1% formaldehyde in 
10 ml cold PBS for 10 min at room temperature with gentle shaking. 0.125 M glycine 
was added and further incubated for 10 min at room temp with gentle shaking. Liquid 
was poured off and cells were washed twice with cold PBS before the cells were 
scraped off and transferred to a falcon tube. Suspension cells were collected from 
media and centrifuged at 1,000 rpm to obtain the cell pellet. Cell pellet was dissolved 
in 10 ml cold PBS. Proteins were crosslinked with 1% formaldehyde for 10 min in 
cold PBS, at room temperature with gentle shaking. 0.125 M glycine was then added 
and incubated for 5 min at room temperature with gentle shaking, to quench the 
fixation. The suspension was then centrifuged at 1,000 rpm for 3 min and the cell 
pellet obtained was further washed with ice-col PBS twice before a final wash with 
ice-cold PBS containing protease inhibitor and PMSF in a 1.5 ml eppendorf tube. The 
cell pellet was then snap frozen in liquid nitrogen and stored at -80˚C until further 
manipulation. 
The cell pellets were resuspended in 10x the pellet volume of SDS lysis buffer 
(1% SDS, 10 mM EDTA, 50 mM Tris pH8.0) plus protease inhibitor and PMSF, 
incubated on ice for 10min and then sonicated to shear the DNA till majority of the 
fragments ranged in size from 300 to 500-bp. 10ug protein (determined by Bradford 
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assay) equivalent of sample was reverse cross-linked with the addition of 21 ul of 5 M 
NaCl in 300 ul of 0.1 M NaHCO3 containing 1% SDS and incubated at 65˚C for 4-5  
hr; the rest of the sample was stored at -80˚C till further use. 2 ul RNase A was added 
to the sample and incubated at 37˚C for 45 min. Following that, 12 ul of 0.5 M 
EDTA, 24 ul of 1M Tris (pH6.5), 2.4 ul 10 mg/ml proteinase K were added and 
incubated at 45˚C for 1 hr. DNA from the samples were then purified using the 
Qiagen gel extraction kit as per the manufacturer’s protocol and finally eluted in 50 ul 
deionised and distilled water (ddH2O; pre-warmed to >50˚C). 5 ul of the eluate was 
then checked for size on 1% agarose (ethidium bromide) gel. 
Each lysate was then diluted 10-fold in chromatin immunoprecipitation 
dilution buffer (0.01% SDS, 1.1% TX-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.02, 
167 mM NaCl) and precleared with protein A-agarose beads (1 hr at 4˚C). Precleared 
lysates were then incubated with ChIP-grade antibodies from Upstate, with inversion, 
at 4˚C overnight. Samples were then centrifuged at 2,000 rpm at 4˚C for 5 min. The 
supernatant was then transferred to Protein A agarose beads and incubated, with 
inversion, for 1 hr at 4˚C. Samples were then centrifuged again at 2,000 rpm at 4˚C 
for 5 min. This time, the supernatant is discarded and the beads are retained. Beads 
were washed sequentially with low salt buffer (0.1% SDS, 1% TX-100, 2 mM EDTA, 
20 mM Tris pH 8.02, 150 mM NaCl) (2 x 15 min at 4˚C), LiCl wash buffer (10 mM 
Tris pH 8.02, 10 mM EDTA, 0.25 M LiCl, 1% IGEPAL-CA630, 1% Deoxycholic 
acid) (1 x 15 min at 4˚C) and ice-cold TE (2 x 15 min at 4˚C). Samples were 
centrifuged after each wash. Finally the supernatant was aspirated, leaving behind the 
Protein A agarose beads. 150 ul of freshly made solution containing 0.1 M NaHCO3 
plus 1% SDS was added to the beads and incubated, with inversion, for 15 min at 
room temperature. After a quick spin-down, the supernatant was then collected into a 
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1.5 ml eppendorf tube.  This process was repeated and the supernatant obtained were 
pooled to obtain about 300 ul of sample. Reverse crosslinking and subsequent DNA 
purification was carried out as described above. 
 
























ChIP for histone specificity were performed using antibodies against sites of 
methylation on histone H3. The following antibodies from Upstate were used: anti-
trimethyl-Histone H3 (Lys4) monoclonal rabbit antibody, clone MC315 (Cat. No. 
#05-745), and anti-trimethyl-Histone H3 (Lys9) rabbit polyclonal IgG (Cat. No. #07-
442). The real-time PCR was performed using ABI prism 7900HT (Applied 
Biosystems) with an initial step of 95°C for 10 min followed by 40 cycles of 94°C for 
15 sec and 60°C for 1 min. Primers listed in Table 7.3  were used in a power SYBR 
green reaction mix (Applied Biosystems). All values obtained were first normalized to 








Generation and maintenance of Tg mice 
Briefly, the process leading up to microinjection is as follows. 3-week old FVB/N 
female mice are superovulated with 10 IU of pregnant mare’s serum (Sigma-Aldrich, 
USA) followed by 10 IU of human chorionic gonadotrophin (Sigma-Aldrich, USA) 
46 to 48 hours later. They are then mated with 3 to 6-month old FVB/N stud males 
and the following morning the mated females are checked for ‘ovulatory plugs’. The 
presence of the ovulatory plugs on the mice is taken to be a sign of successful mating. 
The plugged females are sacrificed using CO2 and the oocyte-cumulus complex 
(OOC) is then surgically retrieved from the ampulla of the oviduct in M2 medium 
(Sigma-Aldrich, USA). The oocytes are further released from the oocyte-cumulus 
complex using hyaluronidase (Sigma-Aldrich, USA). The oocytes are then cultured in 
M16 medium (Sigma-Aldrich, USA) and covered with mineral oil (Sigma-Aldrich, 
USA) in a 5% CO2 incubator at 37oC. During microinjection of DNA, DNA is 
introduced into one of the pronucleus of two-pronuclear embryos under 400x 
magnification using Leica micromanipulator with Nikon 2000 Eclipse microscope. 
Embryos that have survived DNA injection are transferred into the oviducts of 
CBAB6F1 pseudo pregnant female mice. F0 mice at about 2 months of age are then 
handed over to me for genotyping to identify Tg mice. For initial identification and 
subsequent maintenance of Tg mice, genotyping was carried out by PCR at the age of 
two months. Primers specific for EGFP were used to confirm EGFP Tg mice by using 
mouse tail genomic DNA extracted by Direct PCR Lysis Reagents (Viagen Biotech, 
USA) as template in a GoTaq DNA polymerase reaction mixture (Promega). Tg mice 
were out crossed to C57BL/6 (B6) mice and maintained as heterozygotes. All mice 
were maintained in Biological Resource Center (BRC), Biopolis, Singapore and all 
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animal experiments followed the strict guidelines set by National Advisory 
Committee for Laboratory Animal Research (NACLAR). 
Analysis of enhancer activity in transgenic mouse embryo 
Embryos from timed matings were dissected at either E8.5 or E10.5. The day of 
discovery of the vaginal plug was designated as E0.5. EGFP on the whole mount 
embryos was imaged by a fluorescence microscope, Model MZ16 FA (Leica), and 
photographed with a digital color camera, Model DFC300 FX (Leica). 
Preparation of tissue sections and immunohistochemistry 
Mouse embryos were fixed in 4% PFA overnight at 4˚C, washed with PBS (multi 
washes and finally overnight at 4˚C), soaked in 20% sucrose overnight and embedded 
in Optimal Cutting Temperature Compound (OCT). Frozen sections were cut by using 
a cryostat at a thickness of 5 μm. Sections obtained were first washed with PBS (1 x 
30 min) and then stained with biotinylated-goat-anti-GFP primary antibody from 
abcam (ab6658), in DakoCytomation Antibody Diluent with Background Reducing 
Components (Product # 53022, Carpinteria, CA), at 4˚C overnight. Sample was 
washed with PBS (3 x 10 min) and then stained with SA-Alexa 350 (molecular 
probes). Sample was washed with PBS, and imaged using an Olympus fluorescence 
microscope. 
E10.5 mouse embryo: cell preparation, sorting and culture on OP9  stromal cells 
Dissections were performed as follows: Only the EGFP-expressing embryos were 
bisected at a level near the heart. The part above the heart was discarded while the 
part below the heart was pooled with the YS for further manipulation. Media was 
added to the remaining embryo which is pooled with the YS, and was centrifuged at 
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1,500 rpm for 5min at 4˚C. Media was aspirated and 5ml of dispase (Gibco BRL, 
Grand Island, NY) was added and incubated at 37˚C for 20 min, with vigorous 
shaking by hand a few times during this incubation period to really break up the 
tissue. 10ml of washing buffer (Hanks buffered saline solution containing 20% FBS, 
5mM CaCl2 and 50ug/ml DNase) was added and the sample was centrifuged at 1,500 
rpm for 5min at 4˚C.  The supernatant was aspirated and the cell pellet was washed 
with PBS before the addition of 5ml Cell Dissociation Buffer (Gibco BRL) to the 
pellet followed by another 20 min incubation at 37˚C. Once again, the sample was 
shaken vigourously by hand a few times during this incubation period to separate the 
cells. At the end of this incubation period, the sample was centrifuged and the cells 
were collected. 
 Cells obtained were first blocked in mouse serum for 15 min prior to staining 
with antibodies purchased from BD. The following antibodies were used: biotin-
conjugated-anti-PECAM antibody followed by SA-APC Cy7, and PE-conjugated 
anti-CD45 and anti-Ter119 antibodies. Flow cytometric analysis and sorting was 
performed using FACS vantage instrument with the Cellquest program after addition 
of 2 mg/ml of propidium iodide to exclude dead cells. PECAM+CD45-Ter119- EC 
were sorted for collection and were subsequently cultured in vitro on OP9 stromal 
cells in αMEM media supplemented with 10% FBS,  10 ng/ml recombinant murine 
IL-3, 10 ng/ml SCF, 100 ng/ml G-CSF, 10 ng/ml EPO (all cytokines are from Pepro 
Tech EC Ltd, USA) and PSA.  
Flow cytometric analysis and sorting 
For flow cytometric analyses, BM cells directly collected from mice were first 
processed to lyse the RBC by incubation in lysis buffer (150 mM NH4Cl, 10 mM 
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KHCO3, 0.1 mM Na2EDTA) on ice for 5-10 min. Cells were then washed with ice-
cold PBS and centrifuged at 1,500 rpm for 5 min at 4˚C. BM cells were then 
preincubated with mouse serum for 15 min on ice before staining. The antibody 
reaction was carried out in the mouse serum for additional 20 min on ice. All the 
labeled monoclonal antibodies were purchased from BD PharMingen, USA.  
 The following single stains were carried out to analyze cells from the BM, 
spleen and thymus. BM: PE-conjugated antibodies against Gr1 (RB6-8C5), Mac-1 
(M1/70), c-kit (2B8), Fas, Ter119 (TER-119), B220 (RA3-6B2), CD19 (1D3) and 
CD61 (2C9.G2). Spleen: Ter119 (TER-119), B220 (RA3-6B2), CD19, CD3 (145-
2C11), Dx5 (DX5), CD4 (RM4-5) and CD8 (53-6.7). Thymus: PE-conjugated 
antibodies against CD4 (RM4-5) and CD8 (53-6.7). For the sorting of KL and KSL 
cells, PE-conjugated antibodies against Gr1 (RB6-8C5), Mac-1 (M1/70), Ter119 
(TER-119), CD4 (RM4-5), CD3 (145-2C11), CD8 (53-6.7), B220 (RA3-6B2) and  
IL7Rα (SB/199) were used to exclude lineage positive BM cells; APC-conjugated-
anti-c-kit antibody and biotin-conjugated-anti-Sca-1 (E13-161.7) followed by SA-
APC C7 was used for positive selection of immature cells. Flow cytometric analysis 
and sorting was performed using FACS vantage instrument with the Cellquest 
program after addition of 2 mg/ml of propidium iodide to exclude dead cells.  
Colony-forming unit-culture (CFU-C) assay 
Approximately 500 cells were cultured in 35-mm dishes in triplicate in 1 ml 
Methocult M3231 methylcellulose medium (StemCell Tec., Canada) containing 1% 
antibiotic-antimycotic supplemented with 10 ng/ml recombinant murine IL-3, 10 
ng/ml SCF, 100 ng/ml G-CSF and 10 ng/ml EPO. The dishes were cultured at 37°C. 
Colony formation (one colony consists of more than 30 cells) was scored on day 10. 
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For serial replating assays, colonies were harvested in cold PBS, centrifuged at 1,500  
rpm for 5 min to collect cells and colony assay was repeated using 5 x 104 cells for 
next round.  
Bone marrow transplantation (BMT) 
Three different transplantation experiments using differently sorted cells for 
transplantation were carried out. WBM cells, KL-gated or KSL-gated cells from Ly-
5.1/5.2 donor Tg mice were sorted into EGFP- and EGFP+ populations, and 
subsequently used for transplantation into sub-lethally 8.0-Gy irradiated Ly-5.1/5.1 or 
Ly-5.2/5.2 recipient C57BL/6 mice. WBM and KL sorted donor cells were 
transplanted into Ly-5.1/5.1 recipient mice while KSL sorted donor cells were 
transplanted into Ly-5.2/5.2 recipient mice. 
In all cases, BM cells were collected from all four limbs of donor Ly-5.1/5.2 
mice by flushing media (αMEM supplemented with either 10% or 20% FBS and 
PSA) through the marrow of the bone. Under sterile conditions, the RBC were first 
lysed by lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) on ice for 
5-10 min. Cells were then washed with ice-cold PBS and centrifuged at 1,500 rpm for 
5 min at 4˚C. Cells were then blocked with mouse serum prior to incubation with 
fluorochrome-labelled antibodies. BM cells were then sorted by FACS as discussed 
above. 
Recipient Ly-5.1/5.1 or Ly 5.2/5.2 mice were subjected to acid-water 
treatment for at least a week before being subjected to sub-lethal irradiation one day 
prior to BM transplantation. Sorted BM cells (2 x 105 for WBM cells, 1 x 104 for KL-
gated cells and 650 for KSL-gated cells) from donor mice were intravenously co-
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injected with 2 x 105 radioprotective support cells in 200ul serum-free media (αMEM 
plus PSA) in the retro-orbital plexus of each anaesthesized recipient mouse.  
Transplanted mice were first monitored 4 weeks post-BMT and at several time 
points thereafter. At each of these time points, blood was drawn from the retro-orbital 
plexus and subjected to flow cytometric analysis of Ly-5.1/5.2 cells to assess the 
reconstitution ability of donor cells using PE-conjugated-anti-CD45.1 (A20), APC-
conjugated-anti-CD45.2 (104) from BD. Multilineage chimerism was assessed at 
week 28 for WBM and KL transplanted recipients and at week 24 for KSL 
transplanted recipients, using biotinylated-antibodies against Gr1 (RB6-8C5), Mac-1 
(M1/70), CD3 (145-2C11) and B220 (RA3-6B2) followed by SA-APC Cy7. 
Statistical analysis 
Student’s two-tailed, unpaired t-test was used to determine statistical significance. P- 
values less than 0.05 were considered significant. The statistical tests were performed 










Abkowitz, J. L., Robinson, A. E., Kale, S., Long, M. W., and Chen, J. (2003). 
Mobilization of hematopoietic stem cells during homeostasis and after cytokine 
exposure. Blood 102, 1249-1253. 
Adolfsson, J., Borge, O. J., Bryder, D., Theilgaard-Monch, K., Astrand-Grundstrom, 
I., Sitnicka, E., Sasaki, Y., and Jacobsen, S. E. (2001). Upregulation of Flt3 
expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is 
accompanied by loss of self-renewal capacity. Immunity 15, 659-669. 
Aiuti, A., Cassani, B., Andolfi, G., Mirolo, M., Biasco, L., Recchia, A., Urbinati, F., 
Valacca, C., Scaramuzza, S., Aker, M., et al. (2007). Multilineage hematopoietic 
reconstitution without clonal selection in ADA-SCID patients treated with stem cell 
gene therapy. J Clin Invest 117, 2233-2240. 
Akagi, K., Suzuki, T., Stephens, R. M., Jenkins, N. A., and Copeland, N. G. (2004). 
RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 32, D523-527. 
Akashi, K., Traver, D., Miyamoto, T., and Weissman, I. L. (2000). A clonogenic 
common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193-
197. 
Al-Adhami, M., and Kunz, Y. (1977). Ontogenesis of hematopoietic sites in 
Brachydanio rerio (Hamilton-Buchanan) (Teleostei). Dev Growth Differ 19, 171-179. 
Allende, M. L., Manzanares, M., Tena, J. J., Feijoo, C. G., and Gomez-Skarmeta, J. L. 
(2006). Cracking the genome's second code: enhancer detection by combined 
phylogenetic footprinting and transgenic fish and frog embryos. Methods 39, 212-219. 
Anderson, K. L., Smith, K. A., Perkin, H., Hermanson, G., Anderson, C. G., Jolly, D. 
J., Maki, R. A., and Torbett, B. E. (1999). PU.1 and the granulocyte- and macrophage 
colony-stimulating factor receptors play distinct roles in late-stage myeloid cell 
differentiation. Blood 94, 2310-2318. 
Aparicio, S., Chapman, J., Stupka, E., Putnam, N., Chia, J. M., Dehal, P., Christoffels, 
A., Rash, S., Hoon, S., Smit, A., et al. (2002). Whole-genome shotgun assembly and 
analysis of the genome of Fugu rubripes. Science 297, 1301-1310. 
Arai, F., Hirao, A., Ohmura, M., Sato, H., Matsuoka, S., Takubo, K., Ito, K., Koh, G. 
Y., and Suda, T. (2004). Tie2/angiopoietin-1 signaling regulates hematopoietic stem 
cell quiescence in the bone marrow niche. Cell 118, 149-161. 
Avraham, K. B., Levanon, D., Negreanu, V., Bernstein, Y., Groner, Y., Copeland, N. 
G., and Jenkins, N. A. (1995). Mapping of the mouse homolog of the human runt 
domain gene, AML2, to the distal region of mouse chromosome 4. Genomics 25, 603-
605. 
Bae, S. C., and Lee, J. (2000). cDNA cloning of run, a Caenorhabditis elegans Runt 
domain encoding gene. Gene 241, 255-258. 
 171
Bae, S. C., Ogawa, E., Maruyama, M., Oka, H., Satake, M., Shigesada, K., Jenkins, N. 
A., Gilbert, D. J., Copeland, N. G., and Ito, Y. (1994). PEBP2 alpha B/mouse AML1 
consists of multiple isoforms that possess differential transactivation potentials. Mol 
Cell Biol 14, 3242-3252. 
Bae, S. C., Takahashi, E., Zhang, Y. W., Ogawa, E., Shigesada, K., Namba, Y., 
Satake, M., and Ito, Y. (1995). Cloning, mapping and expression of PEBP2 alpha C, a 
third gene encoding the mammalian Runt domain. Gene 159, 245-248. 
Balazs, A. B., Fabian, A. J., Esmon, C. T., and Mulligan, R. C. (2006). Endothelial 
protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine 
bone marrow. Blood 107, 2317-2321. 
Bangsow, C., Rubins, N., Glusman, G., Bernstein, Y., Negreanu, V., Goldenberg, D., 
Lotem, J., Ben-Asher, E., Lancet, D., Levanon, D., and Groner, Y. (2001). The 
RUNX3 gene--sequence, structure and regulated expression. Gene 279, 221-232. 
Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Schones, D. E., Wang, Z., Wei, G., 
Chepelev, I., and Zhao, K. (2007). High-resolution profiling of histone methylations 
in the human genome. Cell 129, 823-837. 
Ben-Ami, O., Pencovich, N., Lotem, J., Levanon, D., and Groner, Y. (2009). A 
regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proc Natl 
Acad Sci U S A 106, 238-243. 
Berger, R. (1997). Acute lymphoblastic leukemia and chromosome 21. Cancer Genet 
Cytogenet 94, 8-12. 
Bernstein, B. E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D. K., Huebert, 
D. J., McMahon, S., Karlsson, E. K., Kulbokas, E. J., 3rd, Gingeras, T. R., et al. 
(2005). Genomic maps and comparative analysis of histone modifications in human 
and mouse. Cell 120, 169-181. 
Berry, C., Hannenhalli, S., Leipzig, J., and Bushman, F. D. (2006). Selection of target 
sites for mobile DNA integration in the human genome. PLoS Comput Biol 2, e157. 
Bertrand, J. Y., Giroux, S., Cumano, A., and Godin, I. (2005a). Hematopoietic stem 
cell development during mouse embryogenesis. Methods Mol Med 105, 273-288. 
Bertrand, J. Y., Giroux, S., Golub, R., Klaine, M., Jalil, A., Boucontet, L., Godin, I., 
and Cumano, A. (2005b). Characterization of purified intraembryonic hematopoietic 
stem cells as a tool to define their site of origin. Proc Natl Acad Sci U S A 102, 134-
139. 
Bertrand, J. Y., Jalil, A., Klaine, M., Jung, S., Cumano, A., and Godin, I. (2005c). 
Three pathways to mature macrophages in the early mouse yolk sac. Blood 106, 
3004-3011. 
Bertrand, J. Y., Kim, A. D., Teng, S., and Traver, D. (2008). CD41+ cmyb+ 
precursors colonize the zebrafish pronephros by a novel migration route to initiate 
adult hematopoiesis. Development 135, 1853-1862. 
 172
Bertrand, J. Y., Kim, A. D., Violette, E. P., Stachura, D. L., Cisson, J. L., and Traver, 
D. (2007). Definitive hematopoiesis initiates through a committed erythromyeloid 
progenitor in the zebrafish embryo. Development 134, 4147-4156. 
Bijl, J., Sauvageau, M., Thompson, A., and Sauvageau, G. (2005). High incidence of 
proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell 
leukemia. Genes Dev 19, 224-233. 
Blackwood, E. M., and Kadonaga, J. T. (1998). Going the distance: a current view of 
enhancer action. Science 281, 60-63. 
Blyth, K., Cameron, E. R., and Neil, J. C. (2005). The RUNX genes: gain or loss of 
function in cancer. Nat Rev Cancer 5, 376-387. 
Bowie, M. B., McKnight, K. D., Kent, D. G., McCaffrey, L., Hoodless, P. A., and 
Eaves, C. J. (2006). Hematopoietic stem cells proliferate until after birth and show a 
reversible phase-specific engraftment defect. J Clin Invest 116, 2808-2816. 
Brudno, M., Do, C. B., Cooper, G. M., Kim, M. F., Davydov, E., Green, E. D., Sidow, 
A., and Batzoglou, S. (2003). LAGAN and Multi-LAGAN: efficient tools for large-
scale multiple alignment of genomic DNA. Genome Res 13, 721-731. 
Bruhn, L., Munnerlyn, A., and Grosschedl, R. (1997). ALY, a context-dependent 
coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. Genes 
Dev 11, 640-653. 
Burns, C. E., DeBlasio, T., Zhou, Y., Zhang, J., Zon, L., and Nimer, S. D. (2002). 
Isolation and characterization of runxa and runxb, zebrafish members of the runt 
family of transcriptional regulators. Exp Hematol 30, 1381-1389. 
Burns, C. E., Traver, D., Mayhall, E., Shepard, J. L., and Zon, L. I. (2005). 
Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev 
19, 2331-2342. 
Butler, J. E., and Kadonaga, J. T. (2001). Enhancer-promoter specificity mediated by 
DPE or TATA core promoter motifs. Genes Dev 15, 2515-2519. 
Cai, Z., de Bruijn, M., Ma, X., Dortland, B., Luteijn, T., Downing, R. J., and Dzierzak, 
E. (2000). Haploinsufficiency of AML1 affects the temporal and spatial generation of 
hematopoietic stem cells in the mouse embryo. Immunity 13, 423-431. 
Calabi, F., Rhodes, M., Williamson, P., and Boyd, Y. (1995). Identification and 
chromosomal mapping of a third mouse runt-like locus. Genomics 26, 607-610. 
Calvi, L. M., Adams, G. B., Weibrecht, K. W., Weber, J. M., Olson, D. P., Knight, M. 
C., Martin, R. P., Schipani, E., Divieti, P., Bringhurst, F. R., et al. (2003). 
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846. 
Camargo, F. D., Chambers, S. M., Drew, E., McNagny, K. M., and Goodell, M. A. 
(2006). Hematopoietic stem cells do not engraft with absolute efficiencies. Blood 107, 
501-507. 
 173
Caprioli, A., Jaffredo, T., Gautier, R., Dubourg, C., and Dieterlen-Lievre, F. (1998). 
Blood-borne seeding by hematopoietic and endothelial precursors from the allantois. 
Proc Natl Acad Sci U S A 95, 1641-1646. 
Challen, G. A., Boles, N., Lin, K. K., and Goodell, M. A. (2009). Mouse 
hematopoietic stem cell identification and analysis. Cytometry A 75, 14-24. 
Chen, C. Z., Li, M., de Graaf, D., Monti, S., Gottgens, B., Sanchez, M. J., Lander, E. 
S., Golub, T. R., Green, A. R., and Lodish, H. F. (2002). Identification of endoglin as 
a functional marker that defines long-term repopulating hematopoietic stem cells. 
Proc Natl Acad Sci U S A 99, 15468-15473. 
Chen, M. J., Yokomizo, T., Zeigler, B. M., Dzierzak, E., and Speck, N. A. (2009). 
Runx1 is required for the endothelial to haematopoietic cell transition but not 
thereafter. Nature. 
Chiba, S. (2006). Notch signaling in stem cell systems. Stem Cells 24, 2437-2447. 
Christensen, J. L., Wright, D. E., Wagers, A. J., and Weissman, I. L. (2004). 
Circulation and chemotaxis of fetal hematopoietic stem cells. PLoS Biol 2, E75. 
Ciau-Uitz, A., Walmsley, M., and Patient, R. (2000). Distinct origins of adult and 
embryonic blood in Xenopus. Cell 102, 787-796. 
Clark, S. C., and Kamen, R. (1987). The human hematopoietic colony-stimulating 
factors. Science 236, 1229-1237. 
Codias, E. K., Cray, C., Baler, R. D., Levy, R. B., and Malek, T. R. (1989). 
Expression of Ly-6A/E alloantigens in thymocyte and T-lymphocyte subsets: 
variability related to the Ly-6a and Ly-6b haplotypes. Immunogenetics 29, 98-107. 
Coffin, J. M., Hughes, S., and Varmus, H. (1997). Retroviruses. Cold Spring Harbor 
Laboratory Press, 475-585. 
Corbel, C., Salaun, J., Belo-Diabangouaya, P., and Dieterlen-Lievre, F. (2007). 
Hematopoietic potential of the pre-fusion allantois. Dev Biol 301, 478-488. 
Crawford, G. E., Davis, S., Scacheri, P. C., Renaud, G., Halawi, M. J., Erdos, M. R., 
Green, R., Meltzer, P. S., Wolfsberg, T. G., and Collins, F. S. (2006a). DNase-chip: a 
high-resolution method to identify DNase I hypersensitive sites using tiled 
microarrays. Nat Methods 3, 503-509. 
Crawford, G. E., Holt, I. E., Mullikin, J. C., Tai, D., Blakesley, R., Bouffard, G., 
Young, A., Masiello, C., Green, E. D., Wolfsberg, T. G., and Collins, F. S. (2004). 
Identifying gene regulatory elements by genome-wide recovery of DNase 
hypersensitive sites. Proc Natl Acad Sci U S A 101, 992-997. 
Crawford, G. E., Holt, I. E., Whittle, J., Webb, B. D., Tai, D., Davis, S., Margulies, E. 
H., Chen, Y., Bernat, J. A., Ginsburg, D., et al. (2006b). Genome-wide mapping of 
DNase hypersensitive sites using massively parallel signature sequencing (MPSS). 
Genome Res 16, 123-131. 
 174
Cumano, A., Dieterlen-Lievre, F., and Godin, I. (1996). Lymphoid potential, probed 
before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. 
Cell 86, 907-916. 
Cumano, A., Ferraz, J. C., Klaine, M., Di Santo, J. P., and Godin, I. (2001). 
Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, 
provide long-term multilineage reconstitution. Immunity 15, 477-485. 
Cumano, A., and Godin, I. (2007). Ontogeny of the hematopoietic system. Annu Rev 
Immunol 25, 745-785. 
Danielian, P. S., Echelard, Y., Vassileva, G., and McMahon, A. P. (1997). A 5.5-kb 
enhancer is both necessary and sufficient for regulation of Wnt-1 transcription in vivo. 
Dev Biol 192, 300-309. 
Davidson, A. J., Ernst, P., Wang, Y., Dekens, M. P., Kingsley, P. D., Palis, J., 
Korsmeyer, S. J., Daley, G. Q., and Zon, L. I. (2003). cdx4 mutants fail to specify 
blood progenitors and can be rescued by multiple hox genes. Nature 425, 300-306. 
Davidson, A. J., and Zon, L. I. (2004). The 'definitive' (and 'primitive') guide to 
zebrafish hematopoiesis. Oncogene 23, 7233-7246. 
Davidson, A. J., and Zon, L. I. (2006). The caudal-related homeobox genes cdx1a and 
cdx4 act redundantly to regulate hox gene expression and the formation of putative 
hematopoietic stem cells during zebrafish embryogenesis. Dev Biol 292, 506-518. 
de Bruijn, M. F., Speck, N. A., Peeters, M. C., and Dzierzak, E. (2000). Definitive 
hematopoietic stem cells first develop within the major arterial regions of the mouse 
embryo. Embo J 19, 2465-2474. 
Deichmann, A., Hacein-Bey-Abina, S., Schmidt, M., Garrigue, A., Brugman, M. H., 
Hu, J., Glimm, H., Gyapay, G., Prum, B., Fraser, C. C., et al. (2007). Vector 
integration is nonrandom and clustered and influences the fate of lymphopoiesis in 
SCID-X1 gene therapy. J Clin Invest 117, 2225-2232. 
DeKoter, R. P., Walsh, J. C., and Singh, H. (1998). PU.1 regulates both cytokine-
dependent proliferation and differentiation of granulocyte/macrophage progenitors. 
Embo J 17, 4456-4468. 
Delassus, S., and Cumano, A. (1996). Circulation of hematopoietic progenitors in the 
mouse embryo. Immunity 4, 97-106. 
Detrich, H. W., 3rd, Kieran, M. W., Chan, F. Y., Barone, L. M., Yee, K., Rundstadler, 
J. A., Pratt, S., Ransom, D., and Zon, L. I. (1995). Intraembryonic hematopoietic cell 
migration during vertebrate development. Proc Natl Acad Sci U S A 92, 10713-10717. 
Dieterlen-Lievre, F., and Martin, C. (1981). Diffuse intraembryonic hemopoiesis in 
normal and chimeric avian development. Dev Biol 88, 180-191. 
Dillon, N., and Sabbattini, P. (2000). Functional gene expression domains: defining 
the functional unit of eukaryotic gene regulation. Bioessays 22, 657-665. 
 175
Donaldson, I. J., Chapman, M., Kinston, S., Landry, J. R., Knezevic, K., Piltz, S., 
Buckley, N., Green, A. R., and Gottgens, B. (2005). Genome-wide identification of 
cis-regulatory sequences controlling blood and endothelial development. Hum Mol 
Genet 14, 595-601. 
Dorschner, M. O., Hawrylycz, M., Humbert, R., Wallace, J. C., Shafer, A., Kawamoto, 
J., Mack, J., Hall, R., Goldy, J., Sabo, P. J., et al. (2004). High-throughput localization 
of functional elements by quantitative chromatin profiling. Nat Methods 1, 219-225. 
Drissi, H., Luc, Q., Shakoori, R., Chuva De Sousa Lopes, S., Choi, J. Y., Terry, A., 
Hu, M., Jones, S., Neil, J. C., Lian, J. B., et al. (2000). Transcriptional autoregulation 
of the bone related CBFA1/RUNX2 gene. J Cell Physiol 184, 341-350. 
Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., Amling, M., 
and Karsenty, G. (1999). A Cbfa1-dependent genetic pathway controls bone 
formation beyond embryonic development. Genes Dev 13, 1025-1036. 
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997). 
Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89, 747-754. 
Duncan, A. W., Rattis, F. M., DiMascio, L. N., Congdon, K. L., Pazianos, G., Zhao, 
C., Yoon, K., Cook, J. M., Willert, K., Gaiano, N., and Reya, T. (2005). Integration of 
Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6, 
314-322. 
Dzierzak, E. (2002). Hematopoietic stem cells and their precursors: developmental 
diversity and lineage relationships. Immunol Rev 187, 126-138. 
Dzierzak, E., and Speck, N. A. (2008). Of lineage and legacy: the development of 
mammalian hematopoietic stem cells. Nat Immunol 9, 129-136. 
Echelard, Y., Vassileva, G., and McMahon, A. P. (1994). Cis-acting regulatory 
sequences governing Wnt-1 expression in the developing mouse CNS. Development 
120, 2213-2224. 
Egawa, T., and Littman, D. R. (2008). ThPOK acts late in specification of the helper 
T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell 
lineage. Nat Immunol 9, 1131-1139. 
Egawa, T., Tillman, R. E., Naoe, Y., Taniuchi, I., and Littman, D. R. (2007). The role 
of the Runx transcription factors in thymocyte differentiation and in homeostasis of 
naive T cells. J Exp Med 204, 1945-1957. 
Eggermont, J., and Proudfoot, N. J. (1993). Poly(A) signals and transcriptional pause 
sites combine to prevent interference between RNA polymerase II promoters. Embo J 
12, 2539-2548. 
Eggers, J. H., Stock, M., Fliegauf, M., Vonderstrass, B., and Otto, F. (2002). Genomic 
characterization of the RUNX2 gene of Fugu rubripes. Gene 291, 159-167. 
 176
Eguchi, M., Eguchi-Ishimae, M., Green, A., Enver, T., and Greaves, M. (2005). 
Directing oncogenic fusion genes into stem cells via an SCL enhancer. Proc Natl 
Acad Sci U S A 102, 1133-1138. 
Ehlers, M., Laule-Kilian, K., Petter, M., Aldrian, C. J., Grueter, B., Wurch, A., 
Yoshida, N., Watanabe, T., Satake, M., and Steimle, V. (2003). Morpholino antisense 
oligonucleotide-mediated gene knockdown during thymocyte development reveals 
role for Runx3 transcription factor in CD4 silencing during development of CD4-
/CD8+ thymocytes. J Immunol 171, 3594-3604. 
Ellingsen, S., Laplante, M. A., Konig, M., Kikuta, H., Furmanek, T., Hoivik, E. A., 
and Becker, T. S. (2005). Large-scale enhancer detection in the zebrafish genome. 
Development 132, 3799-3811. 
Euskirchen, G. M., Rozowsky, J. S., Wei, C. L., Lee, W. H., Zhang, Z. D., Hartman, 
S., Emanuelsson, O., Stolc, V., Weissman, S., Gerstein, M. B., et al. (2007). Mapping 
of transcription factor binding regions in mammalian cells by ChIP: comparison of 
array- and sequencing-based technologies. Genome Res 17, 898-909. 
Evans, K., Ott, S., Hansen, A., Koentges, G., and Wernisch, L. (2007). A comparative 
study of S/MAR prediction tools. BMC Bioinformatics 8, 71. 
Ferkowicz, M. J., Starr, M., Xie, X., Li, W., Johnson, S. A., Shelley, W. C., Morrison, 
P. R., and Yoder, M. C. (2003). CD41 expression defines the onset of primitive and 
definitive hematopoiesis in the murine embryo. Development 130, 4393-4403. 
Ferro, M. T., Hernaez, R., Sordo, M. T., Garcia-Sagredo, J. M., Garcia-Miguel, P., 
Fernandez Guijarro, M., Lopez, J., Villalon, C., Vallcorba, I., Cabello, P., and San 
Roman, C. (2004). Chromosome 21 tandem repetition and AML1 (RUNX1) gene 
amplification. Cancer Genet Cytogenet 149, 11-16. 
Follows, G. A., Dhami, P., Gottgens, B., Bruce, A. W., Campbell, P. J., Dillon, S. C., 
Smith, A. M., Koch, C., Donaldson, I. J., Scott, M. A., et al. (2006). Identifying gene 
regulatory elements by genomic microarray mapping of DNaseI hypersensitive sites. 
Genome Res 16, 1310-1319. 
Follows, G. A., Janes, M. E., Vallier, L., Green, A. R., and Gottgens, B. (2007). Real-
time PCR mapping of DNaseI-hypersensitive sites using a novel ligation-mediated 
amplification technique. Nucleic Acids Res 35, e56. 
Fondon, J. W., 3rd, and Garner, H. R. (2004). Molecular origins of rapid and 
continuous morphological evolution. Proc Natl Acad Sci U S A 101, 18058-18063. 
Fontana, L., Pelosi, E., Greco, P., Racanicchi, S., Testa, U., Liuzzi, F., Croce, C. M., 
Brunetti, E., Grignani, F., and Peschle, C. (2007). MicroRNAs 17-5p-20a-106a 
control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. 
Nat Cell Biol 9, 775-787. 
Frazer, K. A., Pachter, L., Poliakov, A., Rubin, E. M., and Dubchak, I. (2004). 
VISTA: computational tools for comparative genomics. Nucleic Acids Res 32, W273-
279. 
 177
Fujiwara, M., Tagashira, S., Harada, H., Ogawa, S., Katsumata, T., Nakatsuka, M., 
Komori, T., and Takada, H. (1999). Isolation and characterization of the distal 
promoter region of mouse Cbfa1. Biochim Biophys Acta 1446, 265-272. 
Fuks, F. (2005). DNA methylation and histone modifications: teaming up to silence 
genes. Curr Opin Genet Dev 15, 490-495. 
Furness, S. G., and McNagny, K. (2006). Beyond mere markers: functions for CD34 
family of sialomucins in hematopoiesis. Immunol Res 34, 13-32. 
Galloway, J. L., and Zon, L. I. (2003). Ontogeny of hematopoiesis: examining the 
emergence of hematopoietic cells in the vertebrate embryo. Curr Top Dev Biol 53, 
139-158. 
Gaunt, S. J., Cockley, A., and Drage, D. (2004). Additional enhancer copies, with 
intact cdx binding sites, anteriorize Hoxa-7/lacZ expression in mouse embryos: 
evidence in keeping with an instructional cdx gradient. Int J Dev Biol 48, 613-622. 
Gekas, C., Dieterlen-Lievre, F., Orkin, S. H., and Mikkola, H. K. (2005). The placenta 
is a niche for hematopoietic stem cells. Dev Cell 8, 365-375. 
Geoffroy, V., Corral, D. A., Zhou, L., Lee, B., and Karsenty, G. (1998). Genomic 
organization, expression of the human CBFA1 gene, and evidence for an alternative 
splicing event affecting protein function. Mamm Genome 9, 54-57. 
Gering, M., and Patient, R. (2005). Hedgehog signaling is required for adult blood 
stem cell formation in zebrafish embryos. Dev Cell 8, 389-400. 
Ghozi, M. C., Bernstein, Y., Negreanu, V., Levanon, D., and Groner, Y. (1996). 
Expression of the human acute myeloid leukemia gene AML1 is regulated by two 
promoter regions. Proc Natl Acad Sci U S A 93, 1935-1940. 
Glusman, G., Kaur, A., Hood, L., and Rowen, L. (2004). An enigmatic fourth runt 
domain gene in the fugu genome: ancestral gene loss versus accelerated evolution. 
BMC Evol Biol 4, 43. 
Godin, I., and Cumano, A. (2002). The hare and the tortoise: an embryonic 
haematopoietic race. Nat Rev Immunol 2, 593-604. 
Godin, I., and Cumano, A. (2005). Of birds and mice: hematopoietic stem cell 
development. Int J Dev Biol 49, 251-257. 
Goldschneider, I., Gordon, L. K., and Morris, R. J. (1978). Demonstration of Thy-1 
antigen on pluripotent hemopoietic stem cells in the rat. J Exp Med 148, 1351-1366. 
Gombart, A. F., Hofmann, W. K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S. H., 
Larsen, R. J., Asou, H., Miller, C. W., Hoelzer, D., and Koeffler, H. P. (2002). 
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding 
protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99, 
1332-1340. 
 178
Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., and Mulligan, R. C. (1996). 
Isolation and functional properties of murine hematopoietic stem cells that are 
replicating in vivo. J Exp Med 183, 1797-1806. 
Goodell, M. A., Rosenzweig, M., Kim, H., Marks, D. F., DeMaria, M., Paradis, G., 
Grupp, S. A., Sieff, C. A., Mulligan, R. C., and Johnson, R. P. (1997). Dye efflux 
studies suggest that hematopoietic stem cells expressing low or undetectable levels of 
CD34 antigen exist in multiple species. Nat Med 3, 1337-1345. 
Gothert, J. R., Gustin, S. E., Hall, M. A., Green, A. R., Gottgens, B., Izon, D. J., and 
Begley, C. G. (2005). In vivo fate-tracing studies using the Scl stem cell enhancer: 
embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. 
Blood 105, 2724-2732. 
Goyama, S., Yamaguchi, Y., Imai, Y., Kawazu, M., Nakagawa, M., Asai, T., Kumano, 
K., Mitani, K., Ogawa, S., Chiba, S., et al. (2004). The transcriptionally active form 
of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic 
para-aortic splanchnopleural (P-Sp) region. Blood 104, 3558-3564. 
Growney, J. D., Shigematsu, H., Li, Z., Lee, B. H., Adelsperger, J., Rowan, R., Curley, 
D. P., Kutok, J. L., Akashi, K., Williams, I. R., et al. (2005). Loss of Runx1 perturbs 
adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106, 
494-504. 
Grueter, B., Petter, M., Egawa, T., Laule-Kilian, K., Aldrian, C. J., Wuerch, A., 
Ludwig, Y., Fukuyama, H., Wardemann, H., Waldschuetz, R., et al. (2005). Runx3 
regulates integrin alpha E/CD103 and CD4 expression during development of CD4-
/CD8+ T cells. J Immunol 175, 1694-1705. 
Gurnett, C. A., Bowcock, A. M., Dietz, F. R., Morcuende, J. A., Murray, J. C., and 
Dobbs, M. B. (2007). Two novel point mutations in the long-range SHH enhancer in 
three families with triphalangeal thumb and preaxial polydactyly. Am J Med Genet A 
143, 27-32. 
Hacein-Bey-Abina, S., de Saint Basile, G., and Cavazzana-Calvo, M. (2003a). Gene 
therapy of X-linked severe combined immunodeficiency. Methods Mol Biol 215, 247-
259. 
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., 
Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003b). 
LMO2-associated clonal T cell proliferation in two patients after gene therapy for 
SCID-X1. Science 302, 415-419. 
Halloran, M. C., Sato-Maeda, M., Warren, J. T., Su, F., Lele, Z., Krone, P. H., 
Kuwada, J. Y., and Shoji, W. (2000). Laser-induced gene expression in specific cells 
of transgenic zebrafish. Development 127, 1953-1960. 
Harrison, D. E. (1980). Competitive repopulation: a new assay for long-term stem cell 
functional capacity. Blood 55, 77-81. 
Herbomel, P., Thisse, B., and Thisse, C. (1999). Ontogeny and behavior of early 
macrophages in the zebrafish embryo. Development 126, 3735-3745. 
 179
Hirai, H., Ogawa, M., Suzuki, N., Yamamoto, M., Breier, G., Mazda, O., Imanishi, J., 
and Nishikawa, S. (2003). Hemogenic and nonhemogenic endothelium can be 
distinguished by the activity of fetal liver kinase (Flk)-1 promoter/enhancer during 
mouse embryogenesis. Blood 101, 886-893. 
Hirai, H., Samokhvalov, I. M., Fujimoto, T., Nishikawa, S., Imanishi, J., and 
Nishikawa, S. (2005). Involvement of Runx1 in the down-regulation of fetal liver 
kinase-1 expression during transition of endothelial cells to hematopoietic cells. 
Blood 106, 1948-1955. 
Holth, L. T., Chadee, D. N., Spencer, V. A., Samuel, S. K., Safneck, J. R., and Davie, 
J. R. (1998). Chromatin, nuclear matrix and the cytoskeleton: role of cell structure in 
neoplastic transformation (review). Int J Oncol 13, 827-837. 
Horsfield, J. A., Anagnostou, S. H., Hu, J. K., Cho, K. H., Geisler, R., Lieschke, G., 
Crosier, K. E., and Crosier, P. S. (2007). Cohesin-dependent regulation of Runx genes. 
Development 134, 2639-2649. 
Hosen, N., Yamane, T., Muijtjens, M., Pham, K., Clarke, M. F., and Weissman, I. L. 
(2007). Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation 
of bmi-1 expression in normal and leukemic hematopoietic cells. Stem Cells 25, 
1635-1644. 
Houssaint, E. (1981). Differentiation of the mouse hepatic primordium. II. Extrinsic 
origin of the haemopoietic cell line. Cell Differ 10, 243-252. 
Hsia, N., and Zon, L. I. (2005). Transcriptional regulation of hematopoietic stem cell 
development in zebrafish. Exp Hematol 33, 1007-1014. 
Huang, G., Shigesada, K., Ito, K., Wee, H. J., Yokomizo, T., and Ito, Y. (2001). 
Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-
mediated degradation. Embo J 20, 723-733. 
Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Z., Koschmieder, S., Okuno, 
Y., Dayaram, T., Growney, J. D., et al. (2008). PU.1 is a major downstream target of 
AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet 40, 51-60. 
Hudson, M. E., and Snyder, M. (2006). High-throughput methods of regulatory 
element discovery. Biotechniques 41, 673, 675, 677 passim. 
Hughes, J. R., Cheng, J. F., Ventress, N., Prabhakar, S., Clark, K., Anguita, E., De 
Gobbi, M., de Jong, P., Rubin, E., and Higgs, D. R. (2005). Annotation of cis-
regulatory elements by identification, subclassification, and functional assessment of 
multispecies conserved sequences. Proc Natl Acad Sci U S A 102, 9830-9835. 
Ichikawa, M., Asai, T., Chiba, S., Kurokawa, M., and Ogawa, S. (2004a). 
Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle 3, 722-
724. 
Ichikawa, M., Asai, T., Saito, T., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., 
Chiba, S., Ogawa, S., Kurokawa, M., and Hirai, H. (2004b). AML-1 is required for 
 180
megakaryocytic maturation and lymphocytic differentiation, but not for maintenance 
of hematopoietic stem cells in adult hematopoiesis. Nat Med 10, 299-304. 
Imai, Y., Kurokawa, M., Tanaka, K., Friedman, A. D., Ogawa, S., Mitani, K., Yazaki, 
Y., and Hirai, H. (1998). TLE, the human homolog of groucho, interacts with AML1 
and acts as a repressor of AML1-induced transactivation. Biochem Biophys Res 
Commun 252, 582-589. 
Imai, Y., Kurokawa, M., Yamaguchi, Y., Izutsu, K., Nitta, E., Mitani, K., Satake, M., 
Noda, T., Ito, Y., and Hirai, H. (2004). The corepressor mSin3A regulates 
phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol 
Cell Biol 24, 1033-1043. 
Inatomi, Y., Toyama, K., Clark, S. C., Shimizu, K., and Miyauchi, J. (1994). 
Combinations of stem cell factor with other hematopoietic growth factors enhance 
growth and sensitivity to cytosine arabinoside of blast progenitors in acute 
myelogenous leukemia. Cancer Res 54, 455-462. 
Inoue, K., Ito, K., Osato, M., Lee, B., Bae, S. C., and Ito, Y. (2007). The transcription 
factor Runx3 represses the neurotrophin receptor TrkB during lineage commitment of 
dorsal root ganglion neurons. J Biol Chem 282, 24175-24184. 
Inoue, K., Ozaki, S., Ito, K., Iseda, T., Kawaguchi, S., Ogawa, M., Bae, S. C., 
Yamashita, N., Itohara, S., Kudo, N., and Ito, Y. (2003). Runx3 is essential for the 
target-specific axon pathfinding of trkc-expressing dorsal root ganglion neurons. 
Blood Cells Mol Dis 30, 157-160. 
Inoue, K., Ozaki, S., Shiga, T., Ito, K., Masuda, T., Okado, N., Iseda, T., Kawaguchi, 
S., Ogawa, M., Bae, S. C., et al. (2002). Runx3 controls the axonal projection of 
proprioceptive dorsal root ganglion neurons. Nat Neurosci 5, 946-954. 
Inoue, K., Shiga, T., and Ito, Y. (2008). Runx transcription factors in neuronal 
development. Neural Develop 3, 20. 
Ito, K., Lim, A. C., Salto-Tellez, M., Motoda, L., Osato, M., Chuang, L. S., Lee, C. 
W., Voon, D. C., Koo, J. K., Wang, H., et al. (2008). RUNX3 attenuates beta-
catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14, 226-237. 
Ito, Y. (2004). Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 
23, 4198-4208. 
Iwama, A., Zhang, P., Darlington, G. J., McKercher, S. R., Maki, R., and Tenen, D. G. 
(1998). Use of RDA analysis of knockout mice to identify myeloid genes regulated in 
vivo by PU.1 and C/EBPalpha. Nucleic Acids Res 26, 3034-3043. 
Jaffredo, T., Alais, S., Bollerot, K., Drevon, C., Gautier, R., Guezguez, B., Minko, K., 
Vigneron, P., and Dunon, D. (2003). Avian HSC emergence, migration, and 
commitment toward the T cell lineage. FEMS Immunol Med Microbiol 39, 205-212. 
Jaffredo, T., Bollerot, K., Sugiyama, D., Gautier, R., and Drevon, C. (2005a). Tracing 
the hemangioblast during embryogenesis: developmental relationships between 
endothelial and hematopoietic cells. Int J Dev Biol 49, 269-277. 
 181
Jaffredo, T., Gautier, R., Eichmann, A., and Dieterlen-Lievre, F. (1998). Intraaortic 
hemopoietic cells are derived from endothelial cells during ontogeny. Development 
125, 4575-4583. 
Jaffredo, T., Nottingham, W., Liddiard, K., Bollerot, K., Pouget, C., and de Bruijn, M. 
(2005b). From hemangioblast to hematopoietic stem cell: an endothelial connection? 
Exp Hematol 33, 1029-1040. 
Javed, A., Guo, B., Hiebert, S., Choi, J. Y., Green, J., Zhao, S. C., Osborne, M. A., 
Stifani, S., Stein, J. L., Lian, J. B., et al. (2000). Groucho/TLE/R-esp proteins 
associate with the nuclear matrix and repress RUNX 
(CBF(alpha)/AML/PEBP2(alpha)) dependent activation of tissue-specific gene 
transcription. J Cell Sci 113 ( Pt 12), 2221-2231. 
Ji, H., Vokes, S. A., and Wong, W. H. (2006). A comparative analysis of genome-
wide chromatin immunoprecipitation data for mammalian transcription factors. 
Nucleic Acids Res 34, e146. 
Jin, H., Xu, J., and Wen, Z. (2007). Migratory path of definitive hematopoietic 
stem/progenitor cells during zebrafish development. Blood 109, 5208-5214. 
Johnson, C. N., and Levy, L. S. (2005). Matrix attachment regions as targets for 
retroviral integration. Virol J 2, 68. 
Johnson, G. R., and Moore, M. A. (1975). Role of stem cell migration in initiation of 
mouse foetal liver haemopoiesis. Nature 258, 726-728. 
Jonkers, J., and Berns, A. (1996). Retroviral insertional mutagenesis as a strategy to 
identify cancer genes. Biochim Biophys Acta 1287, 29-57. 
Jotereau, F. V., Houssaint, E., and Le Douarin, N. M. (1980). Lymphoid stem cell 
homing to the early thymic primordium of the avian embryo. Eur J Immunol 10, 620-
627. 
Jotereau, F. V., and Le Douarin, N. M. (1982). Demonstration of a cyclic renewal of 
the lymphocyte precursor cells in the quail thymus during embryonic and perinatal 
life. J Immunol 129, 1869-1877. 
Kaelin, C. B., Cooper, G. M., Sidow, A., and Barsh, G. S. (2007). Mammalian 
comparative sequence analysis of the Agrp locus. PLoS ONE 2, e702. 
Kagoshima, H., Akamatsu, Y., Ito, Y., and Shigesada, K. (1996). Functional 
dissection of the alpha and beta subunits of transcription factor PEBP2 and the redox 
susceptibility of its DNA binding activity. J Biol Chem 271, 33074-33082. 
Kalev-Zylinska, M. L., Horsfield, J. A., Flores, M. V., Postlethwait, J. H., Vitas, M. 
R., Baas, A. M., Crosier, P. S., and Crosier, K. E. (2002). Runx1 is required for 
zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 
transgene advances a model for studies of leukemogenesis. Development 129, 2015-
2030. 
 182
Kanai, F., Marignani, P. A., Sarbassova, D., Yagi, R., Hall, R. A., Donowitz, M., 
Hisaminato, A., Fujiwara, T., Ito, Y., Cantley, L. C., and Yaffe, M. B. (2000). TAZ: a 
novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ 
domain proteins. Embo J 19, 6778-6791. 
Kataoka, H., Ochi, M., Enomoto, K., and Yamaguchi, A. (2000). Cloning and 
embryonic expression patterns of the zebrafish Runt domain genes, runxa and runxb. 
Mech Dev 98, 139-143. 
Keller, G., Lacaud, G., and Robertson, S. (1999). Development of the hematopoietic 
system in the mouse. Exp Hematol 27, 777-787. 
Kiel, M. J., Iwashita, T., Yilmaz, O. H., and Morrison, S. J. (2005a). Spatial 
differences in hematopoiesis but not in stem cells indicate a lack of regional 
patterning in definitive hematopoietic stem cells. Dev Biol 283, 29-39. 
Kiel, M. J., and Morrison, S. J. (2008). Uncertainty in the niches that maintain 
haematopoietic stem cells. Nat Rev Immunol 8, 290-301. 
Kiel, M. J., Yilmaz, O. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., and Morrison, S. 
J. (2005b). SLAM family receptors distinguish hematopoietic stem and progenitor 
cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121. 
Kim, I., Saunders, T. L., and Morrison, S. J. (2007). Sox17 dependence distinguishes 
the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 130, 
470-483. 
Kim, M. H., Shin, J. S., Park, S., Hur, M. W., Lee, M. O., Park, H., and Lee, C. S. 
(2002). Retinoic acid response element in HOXA-7 regulatory region affects the rate, 
not the formation of anterior boundary expression. Int J Dev Biol 46, 325-328. 
Kim, W. J., Kim, E. J., Jeong, P., Quan, C., Kim, J., Li, Q. L., Yang, J. O., Ito, Y., and 
Bae, S. C. (2005). RUNX3 inactivation by point mutations and aberrant DNA 
methylation in bladder tumors. Cancer Res 65, 9347-9354. 
Kim, W. Y., Sieweke, M., Ogawa, E., Wee, H. J., Englmeier, U., Graf, T., and Ito, Y. 
(1999). Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of 
their autoinhibitory domains. Embo J 18, 1609-1620. 
Kissa, K., Murayama, E., Zapata, A., Cortes, A., Perret, E., Machu, C., and Herbomel, 
P. (2008). Live imaging of emerging hematopoietic stem cells and early thymus 
colonization. Blood 111, 1147-1156. 
Kleinjan, D. A., and van Heyningen, V. (2005). Long-range control of gene 
expression: emerging mechanisms and disruption in disease. Am J Hum Genet 76, 8-
32. 
Knittel, T., Kessel, M., Kim, M. H., and Gruss, P. (1995). A conserved enhancer of 
the human and murine Hoxa-7 gene specifies the anterior boundary of expression 
during embryonal development. Development 121, 1077-1088. 
 183
Kobayashi-Osaki, M., Ohneda, O., Suzuki, N., Minegishi, N., Yokomizo, T., 
Takahashi, S., Lim, K. C., Engel, J. D., and Yamamoto, M. (2005). GATA motifs 
regulate early hematopoietic lineage-specific expression of the Gata2 gene. Mol Cell 
Biol 25, 7005-7020. 
Kollet, O., Dar, A., Shivtiel, S., Kalinkovich, A., Lapid, K., Sztainberg, Y., Tesio, M., 
Samstein, R. M., Goichberg, P., Spiegel, A., et al. (2006). Osteoclasts degrade 
endosteal components and promote mobilization of hematopoietic progenitor cells. 
Nat Med 12, 657-664. 
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, 
Y., Bronson, R. T., Gao, Y. H., Inada, M., et al. (1997). Targeted disruption of Cbfa1 
results in a complete lack of bone formation owing to maturational arrest of 
osteoblasts. Cell 89, 755-764. 
Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., Beilhack, G. 
F., Shizuru, J. A., and Weissman, I. L. (2003). Biology of hematopoietic stem cells 
and progenitors: implications for clinical application. Annu Rev Immunol 21, 759-806. 
Koschmieder, S., Gottgens, B., Zhang, P., Iwasaki-Arai, J., Akashi, K., Kutok, J. L., 
Dayaram, T., Geary, K., Green, A. R., Tenen, D. G., and Huettner, C. S. (2005). 
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem 
cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324-334. 
Kramer, I., Sigrist, M., de Nooij, J. C., Taniuchi, I., Jessell, T. M., and Arber, S. 
(2006). A role for Runx transcription factor signaling in dorsal root ganglion sensory 
neuron diversification. Neuron 49, 379-393. 
Lacaud, G., Gore, L., Kennedy, M., Kouskoff, V., Kingsley, P., Hogan, C., Carlsson, 
L., Speck, N., Palis, J., and Keller, G. (2002). Runx1 is essential for hematopoietic 
commitment at the hemangioblast stage of development in vitro. Blood 100, 458-466. 
Lam, E. Y., Chau, J. Y., Kalev-Zylinska, M. L., Fountaine, T. M., Mead, R. S., Hall, 
C. J., Crosier, P. S., Crosier, K. E., and Flores, M. V. (2009). Zebrafish runx1 
promoter-EGFP transgenics mark discrete sites of definitive blood progenitors. Blood 
113, 1241-1249. 
Landry, J. R., Kinston, S., Knezevic, K., de Bruijn, M. F., Wilson, N., Nottingham, W. 
T., Peitz, M., Edenhofer, F., Pimanda, J. E., Ottersbach, K., and Gottgens, B. (2008). 
Runx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver. Blood 111, 
3005-3014. 
Lapidot, T., Dar, A., and Kollet, O. (2005). How do stem cells find their way home? 
Blood 106, 1901-1910. 
Lapidot, T., and Petit, I. (2002). Current understanding of stem cell mobilization: the 
roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal 
cells. Exp Hematol 30, 973-981. 
Lau, Q. C., Raja, E., Salto-Tellez, M., Liu, Q., Ito, K., Inoue, M., Putti, T. C., Loh, M., 
Ko, T. K., Huang, C., et al. (2006). RUNX3 is frequently inactivated by dual 
 184
mechanisms of protein mislocalization and promoter hypermethylation in breast 
cancer. Cancer Res 66, 6512-6520. 
Lawson, N. D., and Weinstein, B. M. (2002). Arteries and veins: making a difference 
with zebrafish. Nat Rev Genet 3, 674-682. 
Leclercq, I., Mortreux, F., Gabet, A. S., Jonsson, C. B., and Wattel, E. (2000). Basis 
of HTLV type 1 target site selection. AIDS Res Hum Retroviruses 16, 1653-1659. 
Lele, Z., Engel, S., and Krone, P. H. (1997). hsp47 and hsp70 gene expression is 
differentially regulated in a stress- and tissue-specific manner in zebrafish embryos. 
Dev Genet 21, 123-133. 
Lemischka, I. R., Raulet, D. H., and Mulligan, R. C. (1986). Developmental potential 
and dynamic behavior of hematopoietic stem cells. Cell 45, 917-927. 
Lettice, L. A., Heaney, S. J., Purdie, L. A., Li, L., de Beer, P., Oostra, B. A., Goode, 
D., Elgar, G., Hill, R. E., and de Graaff, E. (2003). A long-range Shh enhancer 
regulates expression in the developing limb and fin and is associated with preaxial 
polydactyly. Hum Mol Genet 12, 1725-1735. 
Levanon, D., Bettoun, D., Harris-Cerruti, C., Woolf, E., Negreanu, V., Eilam, R., 
Bernstein, Y., Goldenberg, D., Xiao, C., Fliegauf, M., et al. (2002). The Runx3 
transcription factor regulates development and survival of TrkC dorsal root ganglia 
neurons. Embo J 21, 3454-3463. 
Levanon, D., Glusman, G., Bangsow, T., Ben-Asher, E., Male, D. A., Avidan, N., 
Bangsow, C., Hattori, M., Taylor, T. D., Taudien, S., et al. (2001). Architecture and 
anatomy of the genomic locus encoding the human leukemia-associated transcription 
factor RUNX1/AML1. Gene 262, 23-33. 
Levanon, D., Goldstein, R. E., Bernstein, Y., Tang, H., Goldenberg, D., Stifani, S., 
Paroush, Z., and Groner, Y. (1998). Transcriptional repression by AML1 and LEF-1 
is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A 95, 11590-
11595. 
Levanon, D., and Groner, Y. (2004). Structure and regulated expression of 
mammalian RUNX genes. Oncogene 23, 4211-4219. 
Levanon, D., Negreanu, V., Bernstein, Y., Bar-Am, I., Avivi, L., and Groner, Y. 
(1994). AML1, AML2, and AML3, the human members of the runt domain gene-
family: cDNA structure, expression, and chromosomal localization. Genomics 23, 
425-432. 
Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, 
G., Collins, F., Shinn, P., Leipzig, J., Hannenhalli, S., et al. (2006). Retroviral DNA 
integration: viral and cellular determinants of target-site selection. PLoS Pathog 2, 
e60. 
Li, C. L., and Johnson, G. R. (1992). Long-term hemopoietic repopulation by Thy-1lo, 
Lin-, Ly6A/E+ cells. Exp Hematol 20, 1309-1315. 
 185
Li, Q. L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X. Z., Lee, K. Y., 
Nomura, S., Lee, C. W., Han, S. B., et al. (2002). Causal relationship between the loss 
of RUNX3 expression and gastric cancer. Cell 109, 113-124. 
Li, Y., Okuno, Y., Zhang, P., Radomska, H. S., Chen, H., Iwasaki, H., Akashi, K., 
Klemsz, M. J., McKercher, S. R., Maki, R. A., and Tenen, D. G. (2001). Regulation 
of the PU.1 gene by distal elements. Blood 98, 2958-2965. 
Liao, E. C., Trede, N. S., Ransom, D., Zapata, A., Kieran, M., and Zon, L. I. (2002). 
Non-cell autonomous requirement for the bloodless gene in primitive hematopoiesis 
of zebrafish. Development 129, 649-659. 
Licht, J. D. (2001). AML1 and the AML1-ETO fusion protein in the pathogenesis of 
t(8;21) AML. Oncogene 20, 5660-5679. 
Ling, K. W., and Dzierzak, E. (2002). Ontogeny and genetics of the 
hemato/lymphopoietic system. Curr Opin Immunol 14, 186-191. 
Liu, J., Bramblett, D., Zhu, Q., Lozano, M., Kobayashi, R., Ross, S. R., and Dudley, J. 
P. (1997). The matrix attachment region-binding protein SATB1 participates in 
negative regulation of tissue-specific gene expression. Mol Cell Biol 17, 5275-5287. 
Liu, P., Tarle, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, 
M. J., and Collins, F. S. (1993). Fusion between transcription factor CBF beta/PEBP2 
beta and a myosin heavy chain in acute myeloid leukemia. Science 261, 1041-1044. 
Lossos, I. S., and Levy, R. (2000a). Higher-grade transformation of follicle center 
lymphoma is associated with somatic mutation of the 5' noncoding regulatory region 
of the BCL-6 gene. Blood 96, 635-639. 
Lossos, I. S., and Levy, R. (2000b). Mutation analysis of the 5' noncoding regulatory 
region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent 
mutations and intraclonal heterogeneity. Blood 95, 1400-1405. 
Mao, S., Frank, R. C., Zhang, J., Miyazaki, Y., and Nimer, S. D. (1999). Functional 
and physical interactions between AML1 proteins and an ETS protein, MEF: 
implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol 19, 
3635-3644. 
Martinez-Agosto, J. A., Mikkola, H. K., Hartenstein, V., and Banerjee, U. (2007). The 
hematopoietic stem cell and its niche: a comparative view. Genes Dev 21, 3044-3060. 
Massberg, S., Schaerli, P., Knezevic-Maramica, I., Kollnberger, M., Tubo, N., 
Moseman, E. A., Huff, I. V., Junt, T., Wagers, A. J., Mazo, I. B., and von Andrian, U. 
H. (2007). Immunosurveillance by hematopoietic progenitor cells trafficking through 
blood, lymph, and peripheral tissues. Cell 131, 994-1008. 
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., 
Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., and Maki, R. A. 
(1996). Targeted disruption of the PU.1 gene results in multiple hematopoietic 
abnormalities. Embo J 15, 5647-5658. 
 186
Medvinsky, A., and Dzierzak, E. (1996). Definitive hematopoiesis is autonomously 
initiated by the AGM region. Cell 86, 897-906. 
Michaud, J., Wu, F., Osato, M., Cottles, G. M., Yanagida, M., Asou, N., Shigesada, 
K., Ito, Y., Benson, K. F., Raskind, W. H., et al. (2002). In vitro analyses of known 
and novel RUNX1/AML1 mutations in dominant familial platelet disorder with 
predisposition to acute myelogenous leukemia: implications for mechanisms of 
pathogenesis. Blood 99, 1364-1372. 
Migliaccio, G., Migliaccio, A. R., Druzin, M. L., Giardina, P. J., Zsebo, K. M., and 
Adamson, J. W. (1991). Effects of recombinant human stem cell factor (SCF) on the 
growth of human progenitor cells in vitro. J Cell Physiol 148, 503-509. 
Mikhail, F. M., Coignet, L., Hatem, N., Mourad, Z. I., Farawela, H. M., El Kaffash, D. 
M., Farahat, N., and Nucifora, G. (2004). A novel gene, FGA7, is fused to 
RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic 
leukemia. Genes Chromosomes Cancer 39, 110-118. 
Mikkola, H. K., Fujiwara, Y., Schlaeger, T. M., Traver, D., and Orkin, S. H. (2003). 
Expression of CD41 marks the initiation of definitive hematopoiesis in the mouse 
embryo. Blood 101, 508-516. 
Mikkola, H. K., and Orkin, S. H. (2006). The journey of developing hematopoietic 
stem cells. Development 133, 3733-3744. 
Miles, C., Sanchez, M. J., Sinclair, A., and Dzierzak, E. (1997). Expression of the Ly-
6E.1 (Sca-1) transgene in adult hematopoietic stem cells and the developing mouse 
embryo. Development 124, 537-547. 
Miller, C. L., and Eaves, C. J. (1997). Expansion in vitro of adult murine 
hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability. 
Proc Natl Acad Sci U S A 94, 13648-13653. 
Min, W., Woo, H. J., Lee, C. S., Lee, K. K., Yoon, W. K., Park, H. W., and Kim, M. 
H. (1998). 307-bp fragment in HOXA7 upstream sequence is sufficient for anterior 
boundary formation. DNA Cell Biol 17, 293-299. 
Mitchell, R. S., Beitzel, B. F., Schroder, A. R., Shinn, P., Chen, H., Berry, C. C., 
Ecker, J. R., and Bushman, F. D. (2004). Retroviral DNA integration: ASLV, HIV, 
and MLV show distinct target site preferences. PLoS Biol 2, E234. 
Miyoshi, H., Ohira, M., Shimizu, K., Mitani, K., Hirai, H., Imai, T., Yokoyama, K., 
Soeda, E., and Ohki, M. (1995). Alternative splicing and genomic structure of the 
AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res 23, 2762-2769. 
Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., and Ohki, M. (1991). 
t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within 
a limited region of a single gene, AML1. Proc Natl Acad Sci U S A 88, 10431-10434. 
Mizutani, K., Yoon, K., Dang, L., Tokunaga, A., and Gaiano, N. (2007). Differential 
Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature 
449, 351-355. 
 187
Moore, K. A., and Lemischka, I. R. (2006). Stem cells and their niches. Science 311, 
1880-1885. 
Moore, M. A., and Metcalf, D. (1970). Ontogeny of the haemopoietic system: yolk 
sac origin of in vivo and in vitro colony forming cells in the developing mouse 
embryo. Br J Haematol 18, 279-296. 
Moore, M. A., and Owen, J. J. (1967). Experimental studies on the development of 
the thymus. J Exp Med 126, 715-726. 
Mooslehner, K., Karls, U., and Harbers, K. (1990). Retroviral integration sites in 
transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. J 
Virol 64, 3056-3058. 
Morrison, S. J., and Weissman, I. L. (1994). The long-term repopulating subset of 
hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1, 
661-673. 
Motoda, L., Osato, M., Yamashita, N., Jacob, B., Chen, L. Q., Yanagida, M., Ida, H., 
Wee, H. J., Sun, A. X., Taniuchi, I., et al. (2007). Runx1 protects hematopoietic 
stem/progenitor cells from oncogenic insult. Stem Cells 25, 2976-2986. 
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., 
Behre, G., Hiddemann, W., Ito, Y., and Tenen, D. G. (2002). Heterozygous PU.1 
mutations are associated with acute myeloid leukemia. Blood 100, 998-1007. 
Muller, A. M., Medvinsky, A., Strouboulis, J., Grosveld, F., and Dzierzak, E. (1994). 
Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1, 
291-301. 
Muller, F., and Tora, L. (2004). The multicoloured world of promoter recognition 
complexes. Embo J 23, 2-8. 
Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., 
Lindhout, D., Cole, W. G., Henn, W., Knoll, J. H., et al. (1997). Mutations involving 
the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89, 773-779. 
Murayama, E., Kissa, K., Zapata, A., Mordelet, E., Briolat, V., Lin, H. F., Handin, R. 
I., and Herbomel, P. (2006). Tracing hematopoietic precursor migration to successive 
hematopoietic organs during zebrafish development. Immunity 25, 963-975. 
Murphy, G. J., Gottgens, B., Vegiopoulos, A., Sanchez, M. J., Leavitt, A. D., Watson, 
S. P., Green, A. R., and Frampton, J. (2003). Manipulation of mouse hematopoietic 
progenitors by specific retroviral infection. J Biol Chem 278, 43556-43563. 
Nakagawa, M., Ichikawa, M., Kumano, K., Goyama, S., Kawazu, M., Asai, T., 
Ogawa, S., Kurokawa, M., and Chiba, S. (2006). AML1/Runx1 rescues Notch1-null 
mutation-induced deficiency of para-aortic splanchnopleural hematopoiesis. Blood 
108, 3329-3334. 
 188
Naoe, Y., Setoguchi, R., Akiyama, K., Muroi, S., Kuroda, M., Hatam, F., Littman, D. 
R., and Taniuchi, I. (2007). Repression of interleukin-4 in T helper type 1 cells by 
Runx/Cbf beta binding to the Il4 silencer. J Exp Med 204, 1749-1755. 
Narezkina, A., Taganov, K. D., Litwin, S., Stoyanova, R., Hayashi, J., Seeger, C., 
Skalka, A. M., and Katz, R. A. (2004). Genome-wide analyses of avian sarcoma virus 
integration sites. J Virol 78, 11656-11663. 
Ng, C. E., Ito, Y., and Osato, M. (2008). Retroviral integration sites (RIS) mark cis-
regulatory elements. Crit Rev Oncol Hematol. 
Ng, C. E., Osato, M., Tay, B. H., Venkatesh, B., and Ito, Y. (2007). cDNA cloning of 
Runx family genes from the pufferfish (Fugu rubripes). Gene 399, 162-173. 
Nicola, N. A. (1989). Hemopoietic cell growth factors and their receptors. Annu Rev 
Biochem 58, 45-77. 
North, T., Gu, T. L., Stacy, T., Wang, Q., Howard, L., Binder, M., Marin-Padilla, M., 
and Speck, N. A. (1999). Cbfa2 is required for the formation of intra-aortic 
hematopoietic clusters. Development 126, 2563-2575. 
North, T. E., de Bruijn, M. F., Stacy, T., Talebian, L., Lind, E., Robin, C., Binder, M., 
Dzierzak, E., and Speck, N. A. (2002). Runx1 expression marks long-term 
repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 
16, 661-672. 
North, T. E., Stacy, T., Matheny, C. J., Speck, N. A., and de Bruijn, M. F. (2004). 
Runx1 is expressed in adult mouse hematopoietic stem cells and differentiating 
myeloid and lymphoid cells, but not in maturing erythroid cells. Stem Cells 22, 158-
168. 
Nottingham, W. T., Jarratt, A., Burgess, M., Speck, C. L., Cheng, J. F., Prabhakar, S., 
Rubin, E. M., Li, P. S., Sloane-Stanley, J., Kong, A. S. J., and de Bruijn, M. F. (2007). 
Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-
regulated enhancer. Blood 110, 4188-4197. 
Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y., and 
Shigesada, K. (1993). Molecular cloning and characterization of PEBP2 beta, the 
heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 
alpha. Virology 194, 314-331. 
Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. 
Blood 81, 2844-2853. 
Ogawa, M., Tajima, F., Ito, T., Sato, T., Laver, J. H., and Deguchi, T. (2001). CD34 
expression by murine hematopoietic stem cells. Developmental changes and kinetic 
alterations. Ann N Y Acad Sci 938, 139-145. 
Ohtsuki, S., Levine, M., and Cai, H. N. (1998). Different core promoters possess 
distinct regulatory activities in the Drosophila embryo. Genes Dev 12, 547-556. 
 189
Okada, H., Watanabe, T., Niki, M., Takano, H., Chiba, N., Yanai, N., Tani, K., 
Hibino, H., Asano, S., Mucenski, M. L., et al. (1998). AML1(-/-) embryos do not 
express certain hematopoiesis-related gene transcripts including those of the PU.1 
gene. Oncogene 17, 2287-2293. 
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., and Downing, J. R. (1996). 
AML1, the target of multiple chromosomal translocations in human leukemia, is 
essential for normal fetal liver hematopoiesis. Cell 84, 321-330. 
Okuno, Y., Huang, G., Rosenbauer, F., Evans, E. K., Radomska, H. S., Iwasaki, H., 
Akashi, K., Moreau-Gachelin, F., Li, Y., Zhang, P., et al. (2005). Potential 
autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol 
Cell Biol 25, 2832-2845. 
Orkin, S. H. (2000). Diversification of haematopoietic stem cells to specific lineages. 
Nat Rev Genet 1, 57-64. 
Orkin, S. H., and Zon, L. I. (2008). Hematopoiesis: an evolving paradigm for stem 
cell biology. Cell 132, 631-644. 
Ortt, K., Raveh, E., Gat, U., and Sinha, S. (2008). A chromatin immunoprecipitation 
screen in mouse keratinocytes reveals Runx1 as a direct transcriptional target of 
DeltaNp63. J Cell Biochem 104, 1204-1219. 
Osato, M. (2004). Point mutations in the RUNX1/AML1 gene: another actor in 
RUNX leukemia. Oncogene 23, 4284-4296. 
Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, 
H., Takatsuki, K., Kanno, T., Shigesada, K., and Ito, Y. (1999). Biallelic and 
heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene 
associated with myeloblastic leukemias. Blood 93, 1817-1824. 
Osato, M., and Ito, Y. (2005). Increased dosage of the RUNX1/AML1 gene: a third 
mode of RUNX leukemia? Crit Rev Eukaryot Gene Expr 15, 217-228. 
Osato, M., Yanagida, M., Shigesada, K., and Ito, Y. (2001). Point mutations of the 
RUNx1/AML1 gene in sporadic and familial myeloid leukemias. Int J Hematol 74, 
245-251. 
Oshimo, Y., Oue, N., Mitani, Y., Nakayama, H., Kitadai, Y., Yoshida, K., Ito, Y., 
Chayama, K., and Yasui, W. (2004). Frequent loss of RUNX3 expression by promoter 
hypermethylation in gastric carcinoma. Pathobiology 71, 137-143. 
Ottersbach, K., and Dzierzak, E. (2005). The murine placenta contains hematopoietic 
stem cells within the vascular labyrinth region. Dev Cell 8, 377-387. 
Otto, F., Kanegane, H., and Mundlos, S. (2002). Mutations in the RUNX2 gene in 
patients with cleidocranial dysplasia. Hum Mutat 19, 209-216. 
Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., 
Stamp, G. W., Beddington, R. S., Mundlos, S., Olsen, B. R., et al. (1997). Cbfa1, a 
 190
candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast 
differentiation and bone development. Cell 89, 765-771. 
Owen, J. J., and Ritter, M. A. (1969). Tissue interaction in the development of thymus 
lymphocytes. J Exp Med 129, 431-442. 
Ozawa, T., Itoyama, T., Sadamori, N., Yamada, Y., Hata, T., Tomonaga, M., and 
Isobe, M. (2004). Rapid isolation of viral integration site reveals frequent integration 
of HTLV-1 into expressed loci. J Hum Genet 49, 154-165. 
Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., 
Behre, G., Hiddemann, W., and Tenen, D. G. (2001). Dominant-negative mutations of 
CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute 
myeloid leukemia. Nat Genet 27, 263-270. 
Palis, J., Robertson, S., Kennedy, M., Wall, C., and Keller, G. (1999). Development 
of erythroid and myeloid progenitors in the yolk sac and embryo proper of the mouse. 
Development 126, 5073-5084. 
Pardanaud, L., Yassine, F., and Dieterlen-Lievre, F. (1989). Relationship between 
vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 
105, 473-485. 
Paul, R., Schuetze, S., Kozak, S. L., Kozak, C. A., and Kabat, D. (1991). The Sfpi-1 
proviral integration site of Friend erythroleukemia encodes the ets-related 
transcription factor Pu.1. J Virol 65, 464-467. 
Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-
Hur, H., Many, A., Shultz, L., et al. (1999). Dependence of human stem cell 
engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848. 
Pennacchio, L. A., and Rubin, E. M. (2001). Genomic strategies to identify 
mammalian regulatory sequences. Nat Rev Genet 2, 100-109. 
Peterson, L. F., and Zhang, D. E. (2004). The 8;21 translocation in leukemogenesis. 
Oncogene 23, 4255-4262. 
Petrovick, M. S., Hiebert, S. W., Friedman, A. D., Hetherington, C. J., Tenen, D. G., 
and Zhang, D. E. (1998). Multiple functional domains of AML1: PU.1 and 
C/EBPalpha synergize with different regions of AML1. Mol Cell Biol 18, 3915-3925. 
Pimanda, J. E., Donaldson, I. J., de Bruijn, M. F., Kinston, S., Knezevic, K., Huckle, 
L., Piltz, S., Landry, J. R., Green, A. R., Tannahill, D., and Gottgens, B. (2007a). The 
SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 
activity. Proc Natl Acad Sci U S A 104, 840-845. 
Pimanda, J. E., Ottersbach, K., Knezevic, K., Kinston, S., Chan, W. Y., Wilson, N. K., 
Landry, J. R., Wood, A. D., Kolb-Kokocinski, A., Green, A. R., et al. (2007b). Gata2, 
Fli1, and Scl form a recursively wired gene-regulatory circuit during early 
hematopoietic development. Proc Natl Acad Sci U S A 104, 17692-17697. 
 191
Ploemacher, R. E., and Brons, N. H. (1988). In vivo proliferative and differential 
properties of murine bone marrow cells separated on the basis of rhodamine-123 
retention. Exp Hematol 16, 903-907. 
Potocnik, A. J. (2000). Role of beta 1 integrin for hemato-lymphopoiesis in mouse 
development. Curr Top Microbiol Immunol 251, 43-50. 
Potocnik, A. J., Brakebusch, C., and Fassler, R. (2000). Fetal and adult hematopoietic 
stem cells require beta1 integrin function for colonizing fetal liver, spleen, and bone 
marrow. Immunity 12, 653-663. 
Pozner, A., Goldenberg, D., Negreanu, V., Le, S. Y., Elroy-Stein, O., Levanon, D., 
and Groner, Y. (2000). Transcription-coupled translation control of AML1/RUNX1 is 
mediated by cap- and internal ribosome entry site-dependent mechanisms. Mol Cell 
Biol 20, 2297-2307. 
Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J. M., Tigaud, I., de Botton, S., 
Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., et al. (2002). Favorable 
prognostic significance of CEBPA mutations in patients with de novo acute myeloid 
leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100, 
2717-2723. 
Preudhomme, C., Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, 
J. L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., et al. (2000). High incidence 
of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in 
Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. 
Blood 96, 2862-2869. 
Pruss, D., Bushman, F. D., and Wolffe, A. P. (1994a). Human immunodeficiency 
virus integrase directs integration to sites of severe DNA distortion within the 
nucleosome core. Proc Natl Acad Sci U S A 91, 5913-5917. 
Pruss, D., Reeves, R., Bushman, F. D., and Wolffe, A. P. (1994b). The influence of 
DNA and nucleosome structure on integration events directed by HIV integrase. J 
Biol Chem 269, 25031-25041. 
Pryciak, P. M., and Varmus, H. E. (1992). Nucleosomes, DNA-binding proteins, and 
DNA sequence modulate retroviral integration target site selection. Cell 69, 769-780. 
Ptashne, M. (1986). Gene regulation by proteins acting nearby and at a distance. 
Nature 322, 697-701. 
Purton, L. E., Dworkin, S., Olsen, G. H., Walkley, C. R., Fabb, S. A., Collins, S. J., 
and Chambon, P. (2006). RARgamma is critical for maintaining a balance between 
hematopoietic stem cell self-renewal and differentiation. J Exp Med 203, 1283-1293. 
Purton, L. E., and Scadden, D. T. (2007). Limiting factors in murine hematopoietic 
stem cell assays. Cell Stem Cell 1, 263-270. 
Putz, G., Rosner, A., Nuesslein, I., Schmitz, N., and Buchholz, F. (2006). AML1 
deletion in adult mice causes splenomegaly and lymphomas. Oncogene 25, 929-939. 
 192
Qiao, M., Shapiro, P., Fosbrink, M., Rus, H., Kumar, R., and Passaniti, A. (2006). 
Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 
regulates endothelial cell proliferation. J Biol Chem 281, 7118-7128. 
Rennert, J., Coffman, J. A., Mushegian, A. R., and Robertson, A. J. (2003). The 
evolution of Runx genes I. A comparative study of sequences from phylogenetically 
diverse model organisms. BMC Evol Biol 3, 4. 
Rhodes, K. E., Gekas, C., Wang, Y., Lux, C. T., Francis, C. S., Chan, D. N., Conway, 
S., Orkin, S. H., Yoder, M. C., and Mikkola, H. K. (2008). The emergence of 
hematopoietic stem cells is initiated in the placental vasculature in the absence of 
circulation. Cell Stem Cell 2, 252-263. 
Rini, D., and Calabi, F. (2001). Identification and comparative analysis of a second 
runx3 promoter. Gene 273, 13-22. 
Robertson, A. G., Bilenky, M., Tam, A., Zhao, Y., Zeng, T., Thiessen, N., Cezard, T., 
Fejes, A. P., Wederell, E. D., Cullum, R., et al. (2008). Genome-wide relationship 
between histone H3 lysine 4 mono- and tri-methylation and transcription factor 
binding. Genome Res 18, 1906-1917. 
Rohdewohld, H., Weiher, H., Reik, W., Jaenisch, R., and Breindl, M. (1987). 
Retrovirus integration and chromatin structure: Moloney murine leukemia proviral 
integration sites map near DNase I-hypersensitive sites. J Virol 61, 336-343. 
Rosenbauer, F., Owens, B. M., Yu, L., Tumang, J. R., Steidl, U., Kutok, J. L., Clayton, 
L. K., Wagner, K., Scheller, M., Iwasaki, H., et al. (2006). Lymphoid cell growth and 
transformation are suppressed by a key regulatory element of the gene encoding PU.1. 
Nat Genet 38, 27-37. 
Rosenbauer, F., and Tenen, D. G. (2007). Transcription factors in myeloid 
development: balancing differentiation with transformation. Nat Rev Immunol 7, 105-
117. 
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., 
Akashi, K., Fiering, S., and Tenen, D. G. (2004). Acute myeloid leukemia induced by 
graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet 36, 624-
630. 
Rosendaal, M., Hodgson, G. S., and Bradley, T. R. (1979). Organization of 
haemopoietic stem cells: the generation-age hypothesis. Cell Tissue Kinet 12, 17-29. 
Rowitch, D. H., Echelard, Y., Danielian, P. S., Gellner, K., Brenner, S., and 
McMahon, A. P. (1998). Identification of an evolutionarily conserved 110 base-pair 
cis-acting regulatory sequence that governs Wnt-1 expression in the murine neural 
plate. Development 125, 2735-2746. 
Ruvinsky, I., and Ruvkun, G. (2003). Functional tests of enhancer conservation 
between distantly related species. Development 130, 5133-5142. 
Sabherwal, N., Bangs, F., Roth, R., Weiss, B., Jantz, K., Tiecke, E., Hinkel, G. K., 
Spaich, C., Hauffa, B. P., van der Kamp, H., et al. (2007). Long-range conserved non-
 193
coding SHOX sequences regulate expression in developing chicken limb and are 
associated with short stature phenotypes in human patients. Hum Mol Genet 16, 210-
222. 
Sabo, P. J., Humbert, R., Hawrylycz, M., Wallace, J. C., Dorschner, M. O., McArthur, 
M., and Stamatoyannopoulos, J. A. (2004). Genome-wide identification of DNaseI 
hypersensitive sites using active chromatin sequence libraries. Proc Natl Acad Sci U S 
A 101, 4537-4542. 
Sabo, P. J., Kuehn, M. S., Thurman, R., Johnson, B. E., Johnson, E. M., Cao, H., Yu, 
M., Rosenzweig, E., Goldy, J., Haydock, A., et al. (2006). Genome-scale mapping of 
DNase I sensitivity in vivo using tiling DNA microarrays. Nat Methods 3, 511-518. 
Samokhvalov, I. M., Samokhvalova, N. I., and Nishikawa, S. (2007). Cell tracing 
shows the contribution of the yolk sac to adult haematopoiesis. Nature 446, 1056-
1061. 
Sanchez, M., Gottgens, B., Sinclair, A. M., Stanley, M., Begley, C. G., Hunter, S., and 
Green, A. R. (1999). An SCL 3' enhancer targets developing endothelium together 
with embryonic and adult haematopoietic progenitors. Development 126, 3891-3904. 
Sanchez, M. J., Bockamp, E. O., Miller, J., Gambardella, L., and Green, A. R. (2001). 
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing 
Scl under the control of a stem cell enhancer. Development 128, 4815-4827. 
Sanchez, M. J., Holmes, A., Miles, C., and Dzierzak, E. (1996). Characterization of 
the first definitive hematopoietic stem cells in the AGM and liver of the mouse 
embryo. Immunity 5, 513-525. 
Satake, M., Ibaraki, T., Yamaguchi, Y., and Ito, Y. (1989). Loss of responsiveness of 
an AP1-related factor, PEBP1, to 12-O-tetradecanoylphorbol-13-acetate after 
transformation of NIH 3T3 cells by the Ha-ras oncogene. J Virol 63, 3669-3677. 
Satake, M., Nomura, S., Yamaguchi-Iwai, Y., Takahama, Y., Hashimoto, Y., Niki, M., 
Kitamura, Y., and Ito, Y. (1995). Expression of the Runt domain-encoding PEBP2 
alpha genes in T cells during thymic development. Mol Cell Biol 15, 1662-1670. 
Sauvageau, M., Miller, M., Lemieux, S., Lessard, J., Hebert, J., and Sauvageau, G. 
(2008). Quantitative expression profiling guided by common retroviral insertion sites 
reveals novel and cell type specific cancer genes in leukemia. Blood 111, 790-799. 
Schagen, F. H., Rademaker, H. J., Fallaux, F. J., and Hoeben, R. C. (2000). Insertion 
vectors for gene therapy. Gene Ther 7, 271-272. 
Scherdin, U., Rhodes, K., and Breindl, M. (1990). Transcriptionally active genome 
regions are preferred targets for retrovirus integration. J Virol 64, 907-912. 
Schirone, R. C., and Gross, L. (1968). Effect of temperature on early embryological 
development of the zebrafish, Brachydanio rerio. J Exp Zool 169, 43-52. 
Schofield, R. (1978). The relationship between the spleen colony-forming cell and the 
haemopoietic stem cell. Blood Cells 4, 7-25. 
 194
Schubeler, D., Francastel, C., Cimbora, D. M., Reik, A., Martin, D. I., and Groudine, 
M. (2000). Nuclear localization and histone acetylation: a pathway for chromatin 
opening and transcriptional activation of the human beta-globin locus. Genes Dev 14, 
940-950. 
Schwarz, B. A., and Bhandoola, A. (2006). Trafficking from the bone marrow to the 
thymus: a prerequisite for thymopoiesis. Immunol Rev 209, 47-57. 
Schwarzwaelder, K., Howe, S. J., Schmidt, M., Brugman, M. H., Deichmann, A., 
Glimm, H., Schmidt, S., Prinz, C., Wissler, M., King, D. J., et al. (2007). 
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector 
integration site distribution in vivo. J Clin Invest 117, 2241-2249. 
Scott, E. W., Simon, M. C., Anastasi, J., and Singh, H. (1994). Requirement of 
transcription factor PU.1 in the development of multiple hematopoietic lineages. 
Science 265, 1573-1577. 
Serfling, E., Jasin, M., and Schaffner, W. (1985). Enhancers and eukaryotic gene 
transcription. Trends Genet 1, 224-230. 
Setoguchi, R., Tachibana, M., Naoe, Y., Muroi, S., Akiyama, K., Tezuka, C., Okuda, 
T., and Taniuchi, I. (2008). Repression of the transcription factor Th-POK by Runx 
complexes in cytotoxic T cell development. Science 319, 822-825. 
Shivdasani, R. A., Fujiwara, Y., McDevitt, M. A., and Orkin, S. H. (1997). A lineage-
selective knockout establishes the critical role of transcription factor GATA-1 in 
megakaryocyte growth and platelet development. Embo J 16, 3965-3973. 
Shivdasani, R. A., and Orkin, S. H. (1996). The transcriptional control of 
hematopoiesis. Blood 87, 4025-4039. 
Shoji, W., and Sato-Maeda, M. (2008). Application of heat shock promoter in 
transgenic zebrafish. Dev Growth Differ 50, 401-406. 
Silberstein, L., Sanchez, M. J., Socolovsky, M., Liu, Y., Hoffman, G., Kinston, S., 
Piltz, S., Bowen, M., Gambardella, L., Green, A. R., and Gottgens, B. (2005). 
Transgenic analysis of the stem cell leukemia +19 stem cell enhancer in adult and 
embryonic hematopoietic and endothelial cells. Stem Cells 23, 1378-1388. 
Simeone, A., Daga, A., and Calabi, F. (1995). Expression of runt in the mouse 
embryo. Dev Dyn 203, 61-70. 
Slape, C., Hartung, H., Lin, Y. W., Bies, J., Wolff, L., and Aplan, P. D. (2007). 
Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-
HOXD13 during leukemic transformation. Cancer Res 67, 5148-5155. 
Song, W. J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., 
Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999). Haploinsufficiency 
of CBFA2 causes familial thrombocytopenia with propensity to develop acute 
myelogenous leukaemia. Nat Genet 23, 166-175. 
 195
Spangrude, G. J., Aihara, Y., Weissman, I. L., and Klein, J. (1988). The stem cell 
antigens Sca-1 and Sca-2 subdivide thymic and peripheral T lymphocytes into unique 
subsets. J Immunol 141, 3697-3707. 
Speck, N. A., and Gilliland, D. G. (2002). Core-binding factors in haematopoiesis and 
leukaemia. Nat Rev Cancer 2, 502-513. 
Speck, N. A., Stacy, T., Wang, Q., North, T., Gu, T. L., Miller, J., Binder, M., and 
Marin-Padilla, M. (1999). Core-binding factor: a central player in hematopoiesis and 
leukemia. Cancer Res 59, 1789s-1793s. 
Spender, L. C., Whiteman, H. J., Karstegl, C. E., and Farrell, P. J. (2005). 
Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells. Oncogene 
24, 1873-1881. 
Spilianakis, C. G., Lalioti, M. D., Town, T., Lee, G. R., and Flavell, R. A. (2005). 
Interchromosomal associations between alternatively expressed loci. Nature 435, 637-
645. 
Steidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H. J., Will, B., Rosenbauer, F., 
Becker, A., Wagner, K., Koschmieder, S., et al. (2007). A distal single nucleotide 
polymorphism alters long-range regulation of the PU.1 gene in acute myeloid 
leukemia. J Clin Invest 117, 2611-2620. 
Stewart, M., Terry, A., Hu, M., O'Hara, M., Blyth, K., Baxter, E., Cameron, E., 
Onions, D. E., and Neil, J. C. (1997). Proviral insertions induce the expression of 
bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc 
collaborating oncogene. Proc Natl Acad Sci U S A 94, 8646-8651. 
Stricker, S., Fundele, R., Vortkamp, A., and Mundlos, S. (2002). Role of Runx genes 
in chondrocyte differentiation. Dev Biol 245, 95-108. 
Subramaniam, M. M., Chan, J. Y., Soong, R., Ito, K., Ito, Y., Yeoh, K. G., Salto-
Tellez, M., and Putti, T. C. (2009). RUNX3 inactivation by frequent promoter 
hypermethylation and protein mislocalization constitute an early event in breast 
cancer progression. Breast Cancer Res Treat 113, 113-121. 
Sugiyama, T., Kohara, H., Noda, M., and Nagasawa, T. (2006). Maintenance of the 
hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone 
marrow stromal cell niches. Immunity 25, 977-988. 
Sullivan, J. C., Sher, D., Eisenstein, M., Shigesada, K., Reitzel, A. M., Marlow, H., 
Levanon, D., Groner, Y., Finnerty, J. R., and Gat, U. (2008). The evolutionary origin 
of the Runx/CBFbeta transcription factors--studies of the most basal metazoans. BMC 
Evol Biol 8, 228. 
Suzuki, T., Minehata, K., Akagi, K., Jenkins, N. A., and Copeland, N. G. (2006). 
Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-
deficient mice. Embo J 25, 3422-3431. 
 196
Suzuki, T., Shen, H., Akagi, K., Morse, H. C., Malley, J. D., Naiman, D. Q., Jenkins, 
N. A., and Copeland, N. G. (2002). New genes involved in cancer identified by 
retroviral tagging. Nat Genet 32, 166-174. 
Takahashi, H., Mitani, Y., Satoh, G., and Satoh, N. (1999). Evolutionary alterations of 
the minimal promoter for notochord-specific Brachyury expression in ascidian 
embryos. Development 126, 3725-3734. 
Takakura, N., Watanabe, T., Suenobu, S., Yamada, Y., Noda, T., Ito, Y., Satake, M., 
and Suda, T. (2000). A role for hematopoietic stem cells in promoting angiogenesis. 
Cell 102, 199-209. 
Tan, S. H., Ida, H., Goh, B. C., Hsieh, W., Loh, M., and Ito, Y. (2006). Analyses of 
promoter hypermethylation for RUNX3 and other tumor suppressor genes in 
nasopharyngeal carcinoma. Anticancer Res 26, 4287-4292. 
Tan, S. H., Ida, H., Lau, Q. C., Goh, B. C., Chieng, W. S., Loh, M., and Ito, Y. (2007). 
Detection of promoter hypermethylation in serum samples of cancer patients by 
methylation-specific polymerase chain reaction for tumour suppressor genes including 
RUNX3. Oncol Rep 18, 1225-1230. 
Tanaka, T., Kurokawa, M., Ueki, K., Tanaka, K., Imai, Y., Mitani, K., Okazaki, K., 
Sagata, N., Yazaki, Y., Shibata, Y., et al. (1996). The extracellular signal-regulated 
kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and 
potentially regulates its transactivation ability. Mol Cell Biol 16, 3967-3979. 
Taniuchi, I., Osato, M., Egawa, T., Sunshine, M. J., Bae, S. C., Komori, T., Ito, Y., 
and Littman, D. R. (2002). Differential requirements for Runx proteins in CD4 
repression and epigenetic silencing during T lymphocyte development. Cell 111, 621-
633. 
Taoudi, S., and Medvinsky, A. (2007). Functional identification of the hematopoietic 
stem cell niche in the ventral domain of the embryonic dorsal aorta. Proc Natl Acad 
Sci U S A 104, 9399-9403. 
Tavian, M., Coulombel, L., Luton, D., Clemente, H. S., Dieterlen-Lievre, F., and 
Peault, B. (1996). Aorta-associated CD34+ hematopoietic cells in the early human 
embryo. Blood 87, 67-72. 
Telfer, J. C., and Rothenberg, E. V. (2001). Expression and function of a stem cell 
promoter for the murine CBFalpha2 gene: distinct roles and regulation in natural 
killer and T cell development. Dev Biol 229, 363-382. 
Theodorou, V., Kimm, M. A., Boer, M., Wessels, L., Theelen, W., Jonkers, J., and 
Hilkens, J. (2007). MMTV insertional mutagenesis identifies genes, gene families and 
pathways involved in mammary cancer. Nat Genet 39, 759-769. 
Theriault, F. M., Roy, P., and Stifani, S. (2004). AML1/Runx1 is important for the 
development of hindbrain cholinergic branchiovisceral motor neurons and selected 
cranial sensory neurons. Proc Natl Acad Sci U S A 101, 10343-10348. 
 197
Thirunavukkarasu, K., Mahajan, M., McLarren, K. W., Stifani, S., and Karsenty, G. 
(1998). Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 
contribute to its transactivation function and its inability to heterodimerize with 
Cbfbeta. Mol Cell Biol 18, 4197-4208. 
Thompson, M. A., Ransom, D. G., Pratt, S. J., MacLennan, H., Kieran, M. W., 
Detrich, H. W., 3rd, Vail, B., Huber, T. L., Paw, B., Brownlie, A. J., et al. (1998). The 
cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. 
Dev Biol 197, 248-269. 
Till, J. E., and McCullough, C. E. (1961). A direct measurement of the radiation 
sensitivity of normal mouse bone marrow cells. Radiat Res 14, 213-222. 
Tober, J., Koniski, A., McGrath, K. E., Vemishetti, R., Emerson, R., de Mesy-Bentley, 
K. K., Waugh, R., and Palis, J. (2007). The megakaryocyte lineage originates from 
hemangioblast precursors and is an integral component both of primitive and of 
definitive hematopoiesis. Blood 109, 1433-1441. 
Toles, J. F., Chui, D. H., Belbeck, L. W., Starr, E., and Barker, J. E. (1989). 
Hemopoietic stem cells in murine embryonic yolk sac and peripheral blood. Proc Natl 
Acad Sci U S A 86, 7456-7459. 
Tracey, W. D., Jr., Pepling, M. E., Horb, M. E., Thomsen, G. H., and Gergen, J. P. 
(1998). A Xenopus homologue of aml-1 reveals unexpected patterning mechanisms 
leading to the formation of embryonic blood. Development 125, 1371-1380. 
Uchida, N., and Weissman, I. L. (1992). Searching for hematopoietic stem cells: 
evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-
1.1 bone marrow. J Exp Med 175, 175-184. 
van Wijnen, A. J., Stein, G. S., Gergen, J. P., Groner, Y., Hiebert, S. W., Ito, Y., Liu, 
P., Neil, J. C., Ohki, M., and Speck, N. (2004). Nomenclature for Runt-related 
(RUNX) proteins. Oncogene 23, 4209-4210. 
Veillette, A., and Latour, S. (2003). The SLAM family of immune-cell receptors. Curr 
Opin Immunol 15, 277-285. 
Venkatesh, B., and Yap, W. H. (2005). Comparative genomics using fugu: a tool for 
the identification of conserved vertebrate cis-regulatory elements. Bioessays 27, 100-
107. 
Vijaya, S., Steffen, D. L., and Robinson, H. L. (1986). Acceptor sites for retroviral 
integrations map near DNase I-hypersensitive sites in chromatin. J Virol 60, 683-692. 
Visser, J. W., and Bol, S. J. (1982). A two-step procedure for obtaining 80-fold 
enriched suspensions of murine pluripotent hemopoietic stem cells. Stem Cells 1, 
240-249. 
Visser, J. W., Bol, S. J., and van den Engh, G. (1981). Characterization and 
enrichment of murine hemopoietic stem cells by fluorescence activated cell sorting. 
Exp Hematol 9, 644-655. 
 198
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., and Speck, N. A. 
(1996). Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central 
nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 93, 
3444-3449. 
Wang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. R., and Speck, N. A. 
(1993). Cloning and characterization of subunits of the T-cell receptor and murine 
leukemia virus enhancer core-binding factor. Mol Cell Biol 13, 3324-3339. 
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, 
K., Roh, T. Y., Peng, W., Zhang, M. Q., and Zhao, K. (2008). Combinatorial patterns 
of histone acetylations and methylations in the human genome. Nat Genet 40, 897-
903. 
Ward, C. M., and Stern, P. L. (2002). The human cytomegalovirus immediate-early 
promoter is transcriptionally active in undifferentiated mouse embryonic stem cells. 
Stem Cells 20, 472-475. 
Waterston, R. H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J. F., Agarwal, P., 
Agarwala, R., Ainscough, R., Alexandersson, M., An, P., et al. (2002). Initial 
sequencing and comparative analysis of the mouse genome. Nature 420, 520-562. 
Wechsler, J., Greene, M., McDevitt, M. A., Anastasi, J., Karp, J. E., Le Beau, M. M., 
and Crispino, J. D. (2002). Acquired mutations in GATA1 in the megakaryoblastic 
leukemia of Down syndrome. Nat Genet 32, 148-152. 
Wee, H. J., Voon, D. C., Bae, S. C., and Ito, Y. (2008). PEBP2-beta/CBF-beta-
dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for 
leukemogenesis. Blood 112, 3777-3787. 
Weidhaas, J. B., Angelichio, E. L., Fenner, S., and Coffin, J. M. (2000). Relationship 
between retroviral DNA integration and gene expression. J Virol 74, 8382-8389. 
Weissman, I., Papaioannou, I. V., and Gardner, R. (1978). Fetal hematopoietic origins 
of the adult hematolymphoid system: Cold Spring Harbor, New York: Cold Spring 
Harbor Laboratory). 
Weksberg, D. C., Chambers, S. M., Boles, N. C., and Goodell, M. A. (2008). CD150- 
side population cells represent a functionally distinct population of long-term 
hematopoietic stem cells. Blood 111, 2444-2451. 
Willett, C. E., Cortes, A., Zuasti, A., and Zapata, A. G. (1999). Early hematopoiesis 
and developing lymphoid organs in the zebrafish. Dev Dyn 214, 323-336. 
Wilson, A., Oser, G. M., Jaworski, M., Blanco-Bose, W. E., Laurenti, E., Adolphe, C., 
Essers, M. A., Macdonald, H. R., and Trumpp, A. (2007). Dormant and self-renewing 
hematopoietic stem cells and their niches. Ann N Y Acad Sci 1106, 64-75. 
Wilson, A., and Trumpp, A. (2006). Bone-marrow haematopoietic-stem-cell niches. 
Nat Rev Immunol 6, 93-106. 
 199
Wright, D. E., Cheshier, S. H., Wagers, A. J., Randall, T. D., Christensen, J. L., and 
Weissman, I. L. (2001). Cyclophosphamide/granulocyte colony-stimulating factor 
causes selective mobilization of bone marrow hematopoietic stem cells into the blood 
after M phase of the cell cycle. Blood 97, 2278-2285. 
Wu, M., Kwon, H. Y., Rattis, F., Blum, J., Zhao, C., Ashkenazi, R., Jackson, T. L., 
Gaiano, N., Oliver, T., and Reya, T. (2007). Imaging hematopoietic precursor division 
in real time. Cell Stem Cell 1, 541-554. 
Wu, X., Li, Y., Crise, B., and Burgess, S. M. (2003). Transcription start regions in the 
human genome are favored targets for MLV integration. Science 300, 1749-1751. 
Xiao, Z. S., Liu, S. G., Hinson, T. K., and Quarles, L. D. (2001). Characterization of 
the upstream mouse Cbfa1/Runx2 promoter. J Cell Biochem 82, 647-659. 
Yagi, R., Chen, L. F., Shigesada, K., Murakami, Y., and Ito, Y. (1999). A WW 
domain-containing yes-associated protein (YAP) is a novel transcriptional co-
activator. Embo J 18, 2551-2562. 
Yamaguchi, Y., Kurokawa, M., Imai, Y., Izutsu, K., Asai, T., Ichikawa, M., 
Yamamoto, G., Nitta, E., Yamagata, T., Sasaki, K., et al. (2004). AML1 is 
functionally regulated through p300-mediated acetylation on specific lysine residues. 
J Biol Chem 279, 15630-15638. 
Yamashita, N., Osato, M., Huang, L., Yanagida, M., Kogan, S. C., Iwasaki, M., 
Nakamura, T., Shigesada, K., Asou, N., and Ito, Y. (2005). Haploinsufficiency of 
Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J 
Haematol 131, 495-507. 
Yanagida, M., Osato, M., Yamashita, N., Liqun, H., Jacob, B., Wu, F., Cao, X., 
Nakamura, T., Yokomizo, T., Takahashi, S., et al. (2005). Increased dosage of 
Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. 
Oncogene 24, 4477-4485. 
Yoder, M. C., Hiatt, K., Dutt, P., Mukherjee, P., Bodine, D. M., and Orlic, D. (1997a). 
Characterization of definitive lymphohematopoietic stem cells in the day 9 murine 
yolk sac. Immunity 7, 335-344. 
Yoder, M. C., Hiatt, K., and Mukherjee, P. (1997b). In vivo repopulating 
hematopoietic stem cells are present in the murine yolk sac at day 9.0 postcoitus. Proc 
Natl Acad Sci U S A 94, 6776-6780. 
Yokomizo, T., Hasegawa, K., Ishitobi, H., Osato, M., Ema, M., Ito, Y., Yamamoto, 
M., and Takahashi, S. (2008). Runx1 is involved in primitive erythropoiesis in the 
mouse. Blood 111, 4075-4080. 
Yokomizo, T., Ogawa, M., Osato, M., Kanno, T., Yoshida, H., Fujimoto, T., Fraser, 
S., Nishikawa, S., Okada, H., Satake, M., et al. (2001). Requirement of 
Runx1/AML1/PEBP2alphaB for the generation of haematopoietic cells from 
endothelial cells. Genes Cells 6, 13-23. 
 200
 201
Yokota, T., Huang, J., Tavian, M., Nagai, Y., Hirose, J., Zuniga-Pflucker, J. C., Peault, 
B., and Kincade, P. W. (2006). Tracing the first waves of lymphopoiesis in mice. 
Development 133, 2041-2051. 
Zambotti, A., Makhluf, H., Shen, J., and Ducy, P. (2002). Characterization of an 
osteoblast-specific enhancer element in the CBFA1 gene. J Biol Chem 277, 41497-
41506. 
Zeigler, B. M., Sugiyama, D., Chen, M., Guo, Y., Downs, K. M., and Speck, N. A. 
(2006). The allantois and chorion, when isolated before circulation or chorio-allantoic 
fusion, have hematopoietic potential. Development 133, 4183-4192. 
Zhang, D. E., Zhang, P., Wang, N. D., Hetherington, C. J., Darlington, G. J., and 
Tenen, D. G. (1997a). Absence of granulocyte colony-stimulating factor signaling and 
neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. 
Proc Natl Acad Sci U S A 94, 569-574. 
Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W. G., Ross, J., Haug, J., Johnson, 
T., Feng, J. Q., et al. (2003). Identification of the haematopoietic stem cell niche and 
control of the niche size. Nature 425, 836-841. 
Zhang, Y., Biggs, J. R., and Kraft, A. S. (2004). Phorbol ester treatment of K562 cells 
regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 
279, 53116-53125. 
Zhang, Y. W., Bae, S. C., Huang, G., Fu, Y. X., Lu, J., Ahn, M. Y., Kanno, Y., Kanno, 
T., and Ito, Y. (1997b). A novel transcript encoding an N-terminally truncated 
AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic 
differentiation of 32Dcl3 myeloid cells. Mol Cell Biol 17, 4133-4145. 
 
 
